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Abstract 
 
Dose limiting haematotoxicity has been associated with a range of therapeutic agents used for 
the treatment of a number of different conditions. Haematotoxicity is usually assessed as part 
of the preclinical safety studies in experimental animals, where changes in peripheral blood 
cell numbers and bone marrow cellularity are determined at the end of the study.  Often no 
information on the mechanism of the haematotoxicity is revealed.  This thesis demonstrates 
how in vitro bone marrow cultures can be utilized to assist in the assessment of 
haematotoxicity by two different approaches; firstly, in vitro bone marrow cultures can be 
used to assess the haematopoietic lineage specificity of vincristine sulphate, vinblastine 
sulphate, hydroxyurea and anagrelide hydrochloride using clonogenic cultures, enabling 
ranking of these compounds according to their haematotoxicity.  Secondly, using in vitro 
assays only, elucidate the mechanism(s) of the megakaryocytic lineage specific inhibition of 
anagrelide hydrochloride.  To this end both clonogenic cultures and LTBMC offer the ability 
to elucidate mechanisms of action on multipotent stem cells, lineage specific cells and effects 
on the bone marrow microenvironment following single and repeated administration. In 
addition, the combination of cell identification techniques flow cytometry and light 
microscopy was shown to provide a more detailed understanding of the different cell 
populations within the non-adherent cell layer. 
 
In vivo AN reduces platelet counts only, however, the mechanism of the megakaryocyte 
specific toxicity by AN is not understood. In these studies, the mechanism (s) of the 
megakaryocytic lineage haematotoxicity of AN was examined using the established human 
clonogenic and LTBMC. The action of AN was shown to be focused at a late stage in 
megakaryocyte (Mk) colony development. Ranking the potential mechanisms of action of AN 
by concentration at which they were noted, the inability to organize the microtubules appears 
to be secondary to 1) alteration in cell cycling, 2) surface receptor expression and 3) inhibition 
in achieving high (greater than 8N) ploidy number.  However, identification of the primary 
mechanism based solely on concentration seems to be very crude and most probably reflects a 
limitation of in vitro systems. The inhibition of platelet production by AN is most likely a 
result from a combination of mechanisms; inhibition of cell cycling, disruption in the 
expression of cell surface receptors, inhibition of the ability of the cells to increase ploidy 
number and an associated inability to organize microtubules leading to a reduction in platelet 
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release. 
This work also demonstrated the importance of the selection of the source of bone marrow 
used in the cultures.  The concentration at which 50 percent of Mk colony growth was 
inhibited (IC50) by AN for murine cells was markedly (46 fold) different (88.6μM) compared 
to the IC50 with human cord blood (hCB) (1.92μM).  This disparity is indicative of 
differences in species sensitivity possibly related to AN having a greater affinity towards the 
human c-mpl thrombopoietin (TPO) receptor than the equivalent murine receptor as suggested 
by McCarty et al (2006). 
 
This work highlights the utility of in vitro bone marrow cultures as a tool for investigating the 
lineage specific haematotoxicity by evaluating compounds used in the treatment of ET. In 
addition in vitro haematopoietic cultures can successfully be used as a tool to investigate 
potential mechanism(s) of haematotoxicity as demonstrated herein by providing an insight to 
mechanism of platelet count reduction by AN. 
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Chapter 1 
1.0 Introduction 
1.1   The Haematopoietic System 
 
All blood cells are derived from a small common pool of totipotent cells, called 
haematopoietic stem cells. The production of all the blood cells is strictly regulated by the 
haematopoietic microenvironment, which includes stromal cells, extracellular matrix 
molecules and soluble regulatory factors.  
 
Blood cells composing the haematopoietic system can be classified into two main classes, 
lymphoid (B, T and natural killer lymphocytes) and myeloid (erythrocytes, megakaryocytes, 
granulocytes and monocytes). The life -span of the fully differentiated mature forms of blood 
cells vary considerably, from several hours for some cells (granulocytes), and several weeks 
(erythrocytes) to several years (lymphocytic and monocytic memory cells) for others. The 
haematopoietic system is extraordinarily complex, since not only are huge numbers of new 
mature cells produced per day, but there is also a need for the maintenance of a pool of 
undifferentiated cells and for a rapid response to situations of acute stress (Kiel et al 2006; 
Ogawa et al, 1993). 
 
During ontogeny, there are a number of haematopoietic sites. Studies in mice and birds have 
shown that an early intra-embryonic site of haematopoiesis is found in the para-aortic 
splanchnopleura (Cumano et al, 1996) and the aorta, gonads, (Medvinsky et al, 1996).  It is 
believed that haematopoietic stem cells arise in these two structures and also in blood islands 
of the yolk sac, enter the embryonic circulation and colonize the newly formed liver rudiment. 
The fetal liver is the site of definitive haematopoiesis early during embryonic development. 
From birth onwards, and throughout adult life, the bone marrow with its intersinusoidal spaces 
is the site responsible for the generation of blood cells. The mechanisms responsible for these 
ontogenic shifts are not well known, and may involve changes in the developing 
haematopoietic cells (Houssaint and Hallet, 1988) or in the haematopoietic microenvironment 
(Slaper-Cortenbach et al, 1987;  Friedrich et al 1996; Kiel et al, 2006).  Recently, researchers 
have demonstrated that once in the bone marrow, the HSCs reside in vascular niches 
containing reticular cells that secrete CXCL12, a chemokine that promotes HSC maintenance 
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(Sugiyama et al 2006).  The consistent presence of HSCs adjacent to CXCL12-secreting 
reticular cells, irrespective of whether the HSCs were in vascular or endosteal locations, 
provides a functional link between vascular and endosteal niches. 
 
1.2   Differentiation in the Haematopoietic System 
 
As mentioned above, all different types of blood cells are derived, through a series of 
maturational cell divisions regulated by the haematopoietic microenvironment, from a small 
pool of totipotent cells called haematopoietic stem cells. The stem cell concept originated from 
the work of Till and McCulloch in 1961 showing the formation of nodules of haematopoietic 
cells in the spleens of lethally irradiated mice after reconstitution with bone marrow from 
normal syngeneic donors (Orlic and Bodine, 1994). In spite of much effort since then, stem 
cells are still elusive entities. These cells are of interest not only because of their 
developmental capacity but also because of their potential usefulness for the treatment of 
hematological disorders and as vectors for gene therapy (Scott and Gordon, 1995; Lord and 
Dexter, 1995; Kiel et al, 2006). The most widely used criterion for their identification, that of 
a multipotential cell capable of self-renewal as well as of reconstituting long-term 
haematopoiesis after marrow ablation, presents theoretical as well as practical problems 
(Lansdorp, 1995). Besides these two main characteristics, other well-established features of 
human stem cells include (Morrison et al, 1995; Zhixing and Linheng, 2006):  
 
a) They constitute a very small compartment, with estimates varying from less than 0.05% to 
up to 0.5% of cells in the bone marrow.  
b)  The majority of stem cells are normally quiescent, as shown by their resistance to 
treatment with 5-fluorouracil or 4-hydroperoxycyclophosphamide, which spare them and 
eliminate dividing cells without adversely affecting the long-term repopulating ability of 
bone marrow. Estimates of periodicity of mitosis vary widely (once a month to once in a 
few years), and the direct examination of the cell cycle of the long-term cells (quiescent 
totipotent stem cells) indicates that at any moment only 4% of them are in the S/G2/M 
phases.  
c)  The surface phenotype, which will be discussed fully later.  
d)  Stem cells cannot only be found in the bone marrow, but also in umbilical cord blood and 
in peripheral blood, particularly after "mobilization" treatments, such as Colony 
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Stimulating Factor- granulocytic/ monocytic. 
 
When stem cells divide, they may return to the G0 phase of the cell cycle generating more 
stem cells; alternatively, they may generate large numbers of committed progenitors with a 
progressively restricted differentiation potential. The mechanisms involved in the decision 
between self-renewal versus differentiation of the stem cell, at each division, are poorly 
understood. Till and colleagues proposed a model of stem cell functions in which the decision 
of the stem cell to self -renew and differentiate was depicted as stochastic process (Till et al, 
1961).  They tested the proposed stochastic model by performing a computer simulation based 
on the generation of random numbers and analyzing the colony forming units in the spleen.  
Recently, homeotic genes have been identified that appear to be of fundamental importance in 
these and other cellular processes (Moore et al, 2006).  
 
Most models assume that the self-renewal potential of stem cells is finite, as evidenced by 
serial transfer experiments (Keller et al, 1998). Stochastic and deterministic models (Nakahata 
et al, 1982) attribute different weights to the roles played by intrinsic and micro-environmental 
factors in the decision between self-renewal and differentiation. 
 
The transition from stem cells to mature haematopoietic cells occurs through several 
intermediate steps characterized by the progressive loss of the self-renewal capacity and the 
commitment to a specific cell lineage. The progenitor cell compartment which can be 
identified by the expression of surface antigens specific to each lineage has the potential to 
differentiate into any of the haematopoietic lineages (Kaushansky, 2006). 
The developmental potential of the pluripotent progenitor cells is generally limited to only one 
or two of the haematopoietic lineages and these cells progressively display the antigenic, 
biochemical, and morphological features characteristic of the mature cells of the appropriate 
lineages, losing their capacity for self-renewal. Their proliferation is normally tightly 
controlled and coupled to their maturation, so those cells leaving the bone marrow usually 
possess little or no proliferative potential. 
 
The expression of different receptors on the surface of haematopoietic progenitors permits the 
interaction with various regulatory elements present in their environment, which includes 
stromal cells, extracellular matrix molecules (EMM) and soluble regulatory factors (cytokines 
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and growth/differentiation factors). Although the role played by the microenvironment in the 
determination of the stem cell fate is still unclear, its pivotal role in the regulation of the 
amplification of the progenitor cell compartment is well established. Further differentiation of 
cells into one of several lineages critically depends on the nature of factors acting on these 
cells at a particular time and at a particular concentration.  Figure 1 .1 shows the differential 
pathway of totipotent haemopoietic stem cells. 
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Figure 1. 1 The Differential Pathway of Totipotent Haemapoietic Stem Cells 
The totipotent haemopoietic stem cells have the potential to differentiate to mature lymphocytic, erythroid, megakaryocytic, monocytic and granulocytic cell 
lineages. Proliferative potential reduces as the cells differentiate to give rise to the mature cell lineages.  Key cytokines involved in differentiation are shown.  
Abbreviations: CFC-GEMM - colony forming cells-granulocytic, erythrocytic, monocytic; CFC-MIX colony forming cells-granulocytic/ monocytic, erythrocytic; 
CFC-E Mk – colony forming cell erythroid/ megakaryocytic; CFC-E - colony forming cell-erythrocytic; CFC-Mk - colony forming cell-megakaryocytic; IL - 
Interleukin; GM-CSF- Granulocytic/monocytic Colony Stimulating Factor; M-CSF - monocytic Colony Stimulating Factor; G-CSF - Granulocytic Colony 
Stimulating Factor; Epo- erythropoietin; Tpo - thrombopoietin.  
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1.3  Megakaryopoiesis 
 
Megakaryopoiesis results in the production and release of platelets. The erythroid and 
megakaryocyte lineages are closely related. There is increasing evidence that the erythroid and 
megakaryocyte lineages are derived from a common bipotent progenitor, called the Burst 
forming units –erythroid / megakaryocyte forming units (BFU-E/MK) that gives rise to 
colonies containing a large majority of erythroblasts and a minority of MKs (Debiliet al, 
1996).  In the current scheme of hematopoietic development, the BFU-E/MK progenitors are 
considered to derive from the CFC-Mix (totipotent stem cells. However, a controversial model 
suggests that the BFU-E/MK can derive directly from HSC (Forsberg et al, 2006).  As with the 
other lineages it is a multistage process of cellular differentiation and maturation regulated by 
a variety of cytokines (George, 2004). 
 
Although megakaryopoiesis is normally confined to the bone marrow from the end of the third 
trimester of pregnancy, in all mammals, megakaryocytes (Mk) are found in large numbers in 
the lungs (Kickler, 2005).  It has been shown that pulmonary Mk originate from the bone 
marrow and are carried to the lungs via the blood supply and retained there (Debili et al, 1992; 
Kickler, 2005).  Furthermore, the contribution of the pulmonary Mk to the body platelet pool 
can be between 7 and 25 percent (Debili et al, 1992; Deutsch and Tomer, 2006). 
The development and maturation of the committed megakaryocytic stem cells is unique in that 
they develop a highly polyploid DNA content which is associated with giant multi-lobed 
nuclei.  Formation of platelets results from the projection of megakaryocytic cytoplasm 
through the sinusoidal endothelium (Deutsch and Tomer, 2006).  
1.3.1 Megakaryopoiesis and the endomitotic process 
 
The megakaryocytes are polyploid during normal differentiation.  Polyploidy enables platelet 
production as the MK cytoplasm volume increases in parallel with ploidy. MK can stop DNA 
duplication at any stage between 2 N to 64 N, and possibly until 128 N. In humans the modal 
ploidy is 16 N (about 50% of the MK). During polyploidization  and at the end of this process, 
the MK cells increase the synthesis of platelet specific proteins and of important proteins for 
platelet formation and function. This leads to an 81-fold increase in MK volume and, 
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theoretically, in the number of platelets produced. It has been suggested that only MKs with a 
ploidy over 4 N are capable of forming proplatelets. Endomitosis was originally given to the 
polyploidization mechanism because it was thought that mitosis was occurring without rupture 
of the nuclear envelope (Ravid et al, 2002). Endomitosis corresponds to a mitosis that skipped 
anaphase B and cytokinesis (Vitrat et al, 1998) An endomitosis, similarly to a mitosis, begins 
with the duplication of the centrosomes, the development of a mitotic spindle, the prophase 
with chromatin condensation, the rupture of the nuclear envelope, the alignment of the 
chromosomes on the equatorial plate during the metaphase and finally the separation of the 
sister chromatids at anaphase. However, the spindle of a polyploid MK is multipolar with the 
number of poles corresponding to the ploidy level. In MK polyploidy, the spindle remains 
short and does not elongate as in a normal mitosis. Chromatids move towards each pole and 
appear as a round mass circling each pole at anaphase, but each DNA mass remains tight as a 
consequence of the absence of spindle elongation. Nevertheless, a true midzone develops as 
during normal mitosis (Geddis et al, 2006). At the end of endomitosis, the MK contains a 
single nucleus with a single nuclear membrane. Each nuclear lobe corresponds to each pole of 
the multipolar spindle and their number is the direct reflection of the ploidy (Roy et al, 2001). 
The cell cycle during MK polyploidization is clearly composed of a succession of G1, S, G2 
and M phases, but the M phase is incomplete (Ravid et al, 2002). After M phase, MKs re-enter 
into G1 to initiate a subsequent cell cycle in order to duplicate their DNA. None of the 
molecular mechanisms suggested at the origin of the endomitotic process are involved in MK 
polyploidization. Endomitosis appears to be related to a failure in cytokinesis and thus may be 
due to an abnormal depolymerization of microtubules and/or a defect in contractile forces 
related to the actin/myosin II complex.  MK cells express very high levels of cyclin D3 and 
that an ectopic increase in cyclin D1 raises the MK ploidy level (Sun et al, 2001).   
Microtubule reorganization is considered one of the key events in the release of platelets from 
Mk cells. Tubulin –α has been shown to be associated with microtubule structures in platelets 
and interact with tubulin -β.  Tubulin-β1 has been demonstrated to be concentrated in 
specialized microtubule structures in mature megakaryocytes and platelets (Radley and 
Scurfield 1980).  Tubulin-β1 KO mice have been found to produce up to 60% less platelets 
when compared with wild type (Levin et al 1993).  An overview of megakaryocyte production 
of platelets is provided in Figure 1.2.  Similar to the development of erythrocytes, the nucleus 
is extruded.  This strongly supports a close etiology of the erythroid and megakaryocytic cell 
lineages (Tavassoli,1980).   
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Figure 1. 2 Megakaryocyte production of platelets, (Patel et al, 2005)  
Megakaryocytes transition from immature cells (A) to released platelets (E), a systematic series of 
events occurs. (B) The cells first undergo nuclear endomitosis, organelle synthesis, and a cytoplasmic 
maturation and expansion, while a microtubule array, emanating from centrosomes, is established. (C) 
Prior to the onset of proplatelet formation, centrosomes disassemble and microtubules translocate to 
the cell cortex. Proplatelet formation commences with the development of thick pseudopods. (D) 
Sliding of overlapping microtubules drives proplatelet elongation as organelles are tracked into 
proplatelet ends, where nascent platelets assemble.  Proplatelet formation continues to expand 
throughout the cell while bending and branching amplify existing proplatelet ends. (E) The entire 
megakaryocyte cytoplasm is converted into a mass of proplatelets, which are released from the cell. 
The nucleus is eventually extruded from the mass of proplatelets, and individual platelets are released 
from proplatelet ends. 
 
Mk progenitors express the CD34 antigen, but mature Mk cells do not. Additionally the 
precise stage along the Mk differentiation at which the CD34 is lost is not known. Purified 
marrow CD34+ cells give rise within 4 days in culture to rare mature Mk, suggesting that 
some Mk precursors bear the CD34 antigen (Chang et al, 2007). By flow cytometry, CD34+ 
cells bearing platelet glycoproteins (GP) could be detected, but at a low frequency (less than 
2% of the marrow CD34 positive (+) cells.  These cells gave rise within another 4 days in 
culture to numerous Mk (up to 50%), showing that these CD34+ cells were greatly enriched in 
Mk precursors. This was confirmed by ultrastructural studies that showed the presence of 
typical megakaryoblasts. By flow cytometry, three populations of small cell size can be 
defined: CD34+ CD61- (development stage I), CD34+ 61+ (development stage II) and CD34-
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CD61+ive cells(development stage III). The two CD61+ ive populations are almost pure 
immature MK. Alpha-Granules, organelles containing alkaline phosphatase, are rare in the 
CD34+ ive CD61+ ive cells, whereas they are more developed in the CD34- ive CD61+ ive 
cells, which also exhibited demarcation membranes (Erickson et al, 1993; Deutsch and Tomer, 
2006). Recent flow cytometric studies have demonstrated that VWF is strongly expressed by 
early (2 and 4 N) marrow MKs, enabling their complete resolution from the other marrow 
cells at a level superior to that achieved with GPIIb/IIIa as a lineage-specific marker (Tomer, 
2004). 
A diagrammatic representation of megakaryopoiesis is shown figure 1.3. 
 
 
  
Figure 1. 3 Diagrammatic representation of Megakaryopoiesis (Chang, et al, 2007) 
Mk colonies derive from a bi-potent BFU-E/Mk progenitor.  Stem cell factor (SCF), interleukins 3, 6 and 
11 (IL-3,IL-11, IL-6),  leukocyte inhibitory factor (LIF) thrombopoietin (Tpo) and erythropoietin (Epo) 
drive the maturation and differentiation to give rise to mature megakaryocytes (MK stage III) cells.  Also 
shown are the surface antigens expressed during megakaryopoiesis; CD34+ CD61- (development 
stage I), CD34+ 61+ (development stage II) and CD34-CD61+ive cells (development stage III).  Β-
tubulin is detectable intracellularly in all three development stages. 
 
 
CD61
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1.4   Regulation of Haematopoiesis 
 
Haematopoiesis is controlled by a number of proteins, growth factors and cytokines that define 
the lineage of the differentiating cells.   In the last decade it has become clear that homeobox 
containing genes (HOX genes) not only play a significant role in regulating body formation, 
but in addition, they are contributing to organization and regulation of haematopoiesis. The 
HOX genes are organized into four genomic clusters (A, B, C and D).   
Analysis of human and mouse haematopoietic cell lines revealed that some HOX genes were 
expressed in several haematopoietic cell lineages (HOXC8, HOXA7 and HOXB7), while 
others were limited to a single cell lineage; HOXA10 which is restricted to myelomonocytic 
cell lines.  Furthermore, expression of all HOXB genes was mainly associated with cell lines 
of the erythroid lineage (Oostveen et al, 1999). 
 
Over expression of HOXB4 in totipotent haemopoietic cells results in the increased self- 
renewal potential suggest that it involved in controlling the self-renewal versus differentiation 
decision processes (Abramovich et al, 2005; Moore et al, 2006).   
A number of growth factors and cytokines act through binding to high affinity receptor 
tyrosine kinases (RTKs).  Twenty different RTKs have been identified of which many are 
involved in the regulation of haematopoiesis.  Table 1.1 shows the key RTKs involved in 
haematopoiesis. 
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Receptor Tyrosine Kinase Role in Haematopoiesis 
RTK CLASS II (Insulin Receptor 
Family) 
Regulate the proliferation and differentiation of 
haematopoietic cells via specific receptors located on 
erythrocytes, monocytes, as well as B and T 
lymphocytes. 
RTK CLASS III (PDGF Receptor 
Family) - cKit 
Binding of c-KIT ligand, stem cell factor (SCF), results in 
c-KIT dimerization and subsequent activation of the 
JAK-STAT, PI-3 kinase and MAP kinase pathways that 
promote cell growth and differentiation 
RTK CLASS III (PDGF Receptor 
Family)- FLT3 
FLT3 (FMS-like tyrosine kinase, CD135 is expressed in 
multipotential haematopoietic stem cells and 
progenitors, suggesting a critical role in stem cell 
development and differentiation. 
RTK CLASS III (PDGF Receptor 
Family)- PDGFRα and β 
 
Expressed on myeloid lineage; over activation results in 
myeloproliferative disorder with eosinophilia, 
eosinophilic leukaemia or chronic myelomonocytic 
leukaemia 
RTK CLASS IV (FGF Receptor 
Family) 
 
Expressed on most haemopoietic cell lineages; over 
activation resulting in myeloproliferative disorder with 
eosinophilia,  
RTK CLASS V (VEGF Receptor 
Family) 
 
Clonogenic assays reveal that VEGF inhibits total 
colony formation from less mature progenitor cells and 
at the same time promotes the formation of myeloid, 
mixed and erythroid colonies from lineage-committed 
progenitors. VEGFR-1 has also been suggested as 
regulating the cell cycle and differentiation of 
haematopoietic stem cells and promoting 
haematopoietic cell mobilization. 
RTK CLASS VII (TRK Receptor 
Family) 
 
Regulate immature erythroblasts 
(TrkA), eosinophilic metamyelocytes and 
polymorphonuclear cells (TrkB), as well as 
promyelocytes, myelocytes and megakaryocytes (TrkC). 
Table 1. 1 Receptor tyrosine Kinases and their regulatory role in haematopoiesis 
The key receptor tyrosine kinases (RTKs) expressed on normal and malignant cell lineages and their 
potential role in the regulation of haematopoiesis are shown. 
 
The generation of haematopoietic colonies is absolutely dependent on the continuous presence 
of so-called colony-stimulating factors (CSF), and the in vitro haematopoietic cultures were 
the key to the original discovery and characterization of many of the haematopoietic growth 
factors. Colony formation assays, therefore, allow the study of the influences of given growth 
factors or cytokines on the determination of the lineage along which colony-forming cells 
differentiate. Growth factors are denominated according to the colonies originating under their 
influence - M-CSF or GM-CSF, for instance, for factors inducing colonies composed of 
monocytes or granulocytes and monocytes, respectively.  The cytokine families share some 
common features, for example, they are all found in the extracellular compartment, that 
interact with specific target cells to stimulate growth or differentiation.  There are very few 
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responses that are mediated by just the one cytokine and many responses can be achieved by 
several cytokines (Nicola et al, 1994; Keil et al, 2000; Kaushansky, 2006).  Many of the 
cytokines also overlap in the target population they control.  This ensures that cell production 
continues if one or more pathways are inhibited.   It has also been shown that the impact of 
combinations of cytokines can induce a greater than additive proliferative response - 
synergism.  For example, work conducted using factor dependent cell lines have demonstrated 
stimulatory synergy between granulocytic/ monocytic - colony stimulating factor (GM-CSF), 
interleukin -3 (IL-3) and erythropoietin (Epo) (Hendrie et al, 1991; Kaushansky, 2006).   A 
number of other synergies have been identified, including synergies between interleukin-6 (IL-
6) and interleukin 11.  Also synergy has been demonstrated to be important between Epo and 
thrombopoietin (Tpo) in vivo (Ogawa et al, 1993; Kaushansky, 2006). The cytokine network 
also has an inhibitory / negative feedback mechanism (Figure 1.4).  These systems ensure that 
cell proliferation and cell maturation is kept under tight control.  For example, changes in the 
oxygen potential of body organs act as a feed back loop on the production of Epo.  When 
oxygen tension is high Epo release by the kidney is reduced.  Other inhibitory mechanisms 
result from cell to cell interactions.  For example, acidic isoferritins (AIFs), found in mature 
granulocytes, monocytes, lymphocytes and erythrocytes contribute to a feedback mechanism 
affecting colony forming units - granulocytic / monocytic (CFU-GM) and burst forming units 
-erythroid (BFU-E) (Jacobs et al, 1983).  A similar inhibitory effect on CFU-GM and BFU-E 
colonies has been demonstrated by the production of increased levels of interferons (Gasner et 
al,1985; Kaushansky, 2006).  Also lactoferrin present in neutrophils has been implicated in 
controlling release of the cytokine GM-CSF.   A detailed list of cytokines grouped according 
to their known target lineages is shown in Table 1.2.  
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Figure 1. 4 Regulation of the Production of Haematopoietic Growth Factors 
(modified from Kaushansky, 2006) 
The production of growth factors by various tissues and cells (arrows) is both constitutive and inducible 
and subject to adsorption by receptor-bearing cells. Production of erythropoietin (red arrows) is 
inducible by hypoxia in the kidney and constitutive in the liver (10 percent of total body erythropoietin), 
and it is excreted in the urine. G-CSF (green arrows) is mostly inducible in tissues from fibroblasts and 
macrophages and from endothelial cells by inflammatory mediators (interleukin-1, interleukin-6, and 
tumor necrosis factor α. Thrombopoietin (blue arrows) is produced constitutively by the liver 
(accounting for approximately 50 percent of baseline thrombopoietin levels) and kidney (accounting for 
a minority of the total amount) and is inducible in the liver by inflammatory mediators (especially 
interleukin-6) and from bone marrow stromal cells by thrombocytopenia. In addition, both G-CSF and 
thrombopoietin are removed from the circulation by receptor-mediated uptake and destruction by the 
mature cells that bear the corresponding receptors on neutrophils and platelets.  Arrows indicate the 
production and secretion of haematopoietic growth factors. 
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Lineage Cytokines 
Stem cells SCF, IL-1, IL-6, IL-3, GM-CSF, G-CSF, M-CSF, IL-
12, IL-4 
Granulocytes IL-6, IL-3, GM-CSF, G-CSF, SCF, IL-11, IL-4 
Granulocyte 
subpopulations: 
 
Neutrophils IL-6, IL-3, GM-CSF, G-CSF, SCF, IL-11, IL-4 
Eosinophils IL-6, IL-3, GM-CSF, G-CSF, SCF, IL-11, IL-4, IL-5 
Basophils IL-6, IL-3, GM-CSF, G-CSF, SCF, IL-11, IL-4 
Monocytes/ Macrophages M-CSF, IL-3, GM-CSF, IL-4 
Megakaryocytes SCF, IL-3, GM-CSF, IL-6, Tpo, Epo, Oncostatin M, 
IL-6, LIF 
Erythroid cells IL-3, SCF, Epo 
T -lymphocytes IL-1, IL-2, IL-4, IL-10, IL-7 
B-lymphocytes SCF, IL-7, IL-6, IL-2 
Dendritic cells GM-CSF 
 
Table 1. 2 Haematopoietic Growth Factors  
Cytokines are grouped according to their known target lineages. Many of the cytokines also overlap in 
the target population they control.  This ensures that cell production continues if one or more pathways 
are inhibited.   The impact of combinations of cytokines can induce a greater than additive proliferative 
response – synergy  Abbreviations: SCF- Stem Cell Factor, IL - Interleukin, GM-CSF- 
Granulocytic/monocytic Colony Stimulating Factor, M-CSF - monocytic Colony Stimulating Factor, G-
CSF - Granulocytic Colony Stimulating Factor, Epo- erythropoietin, Tpo - thrombopoietin. 
1.5  Regulation of Megakaryopoiesis 
A number of transcription factors regulate the expression of genes specific for the platelet/MK 
lineages, genes involved in the polyploidization process, and genes implicated in proplatelet 
formation, have been identified.  The GATA-1 and FOG -1 proteins have been detected in 
MKs (Chang et al, 2007). The directed knock-out of these proteins in the MK lineage has 
permitted the generation of mice presenting marked abnormalities in megakaryocytopoiesis 
characterized by a profound macro-thrombocytopenia with an excess of small immature MKs 
in the marrow and combined with an increase in cell proliferation.  The bHLH transcription 
factor TAL-1 is expressed in MKs. Recent data indicate that TAL-1 plays a major role in 
platelet production during stress thrombopoiesis by regulating NF-E2 transcriptional activity. 
The ETS family of transcription factors includes more than 30 different members; four of 
them, ETS-1, PU.1/SPI-1, FLI-1 and GABPa, are expressed in the MK lineage and are able to 
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transactivate different promoters of MK genes in vitro. Furthermore, Fli-1 knock-out is lethal 
in the embryo due to a defect in vascular development and megakaryocytopoiesis, 
characterized by a marked thrombocytopenia with an excess of small immature MKs 
undergoing apoptosis (Chang et al, 2007).  
c-Mpl is a member  of the type I haematopoietic growth factor receptor family and is 
expressed by stem cells, erythroid colony forming units and megakaryocytes, their precursors, 
and their progeny. For the most part, c-Mpl is constitutively expressed in these cell types 
although receptor display is modulated by thrombopoietin binding and receptor 
internalization. In addition, co-expression of the signaling kinase JAK2 is vital for 
haematopoietic cytokine receptor expression (Saharinen, et al, 2003).  Once c-Mpl is activated 
by thrombopoietin engagement, its multiple effects on HSCs, megakaryocytes, and platelets 
are mediated by a series of biochemical signaling events. Thrombopoietin activates both JAK2 
and TYK2 in c-Mpl–bearing cell lines, although only JAK2 is essential for signaling and is the 
predominant isoform activated in primary megakaryocytes (Kaushansky, 2005c).  By 
generating a complex composed of the phosphatase SHP2, a scaffolding Gab/IRS protein, and 
the p85 regulatory subunit of PI3K, thrombopoietin stimulation of megakaryocytes and their 
precursors activates PI3K and its immediate downstream effector Akt (PKB) (Kaushansky, 
2005c).  Blocking this pathway inhibits thrombopoietin-induced cell survival and proliferation 
(Kaushansky, 2005c).  In the mature platelet, the hormone enhances α-granule secretion and 
aggregation induced by thrombin in a PI3K-dependent fashion. 
 
A number of cytokines play a pivotal role in the differentiation and proliferation of platelets.  
Stem cell factor (SCF) has been found to synergize with interleukin-3 (IL-3), interleukin-6 
(IL-6) interleukin-11 (IL-11), leukocyte inhibitory factor (LIF), erythropoietin (Epo) and 
oncostatin M to increase the number of megakaryocytic colonies (Adams,1997; Deutsch and 
Tomer 2006), in vitro. Thrombopoietin (Tpo) is a major hormonal regulator of 
megakaryocytopoiesis both in vitro and in vivo, and, thus, blood platelet production. Existing 
data show that the action, chemical nature, and immunologic properties of thrombopoietin 
from animal sources are similar, if not identical. The cloning and characterization of 
thrombopoietin, a ligand for the receptor encoded by the c-Mpl proto-oncogene, provides new 
insights into the humoral regulation of megakaryocytopoiesis and platelet production. 
Consistent with the proposed role as a major physiological regulator of megakaryocytopoiesis, 
thrombopoietin has potent effects on megakaryocytopoiesis in vitro and in vivo. Tpo initiates 
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its biologic effects by binding to the Mpl receptor, which is a member of the haemapoietic 
receptor family.   
 
In addition to the original supposition that thrombopoietin functions as a late-acting 
megakaryocyte maturation factor, recombinant thrombopoietin proves also to be a potent 
stimulator of haematopoietic progenitor cells, inducing them to undergo proliferation and 
differentiation into megakaryocytic colonies (Goncalves et al, 1997; McDonald et al, 1987; 
Kaushansky, 2005a). 
Recent studies have shown that not only does Tpo poteniate the action of megakaryocytic 
colony stimulating factor (meg-CSF), but it also has a direct effect on precursor cells to 
increase the number of megakaryocytic colonies. Other in vitro work showed that Tpo 
stimulates precursor cells directly to differentiate into megakaryocytic colonies (Ivanovic et al, 
2006). In vivo, Tpo increases megakaryocyte size and number; it causes an elevation in the 
number of precursor cells in mouse marrow and increases the maturation of megakaryocytes. 
Moreover, Tpo increases the endomitosis of megakaryocytes in the marrow of mice, along 
with elevating the number of megakaryocytic colonies in spleens of lethally irradiated bone 
marrow reconstituted mice (Broudy et al, 1997).  MK volume and ploidy attained predictable 
maximum values simultaneously; MK ploidy is an accurate measure of the Mpl-ligand 
stimulation of megakaryopoiesis (Tomer & Harker, 1996). TPO can also act in synergy with 
other haematopoietic cytokines and has been utilised effectively to expand human HSC and 
MK progenitor cells in vitro (Kaushansky, 2005b; Ivanovic et al, 2006). 
 
Platelet production is also stimulated in mice by Tpo as evidenced by elevated isotopic 
incorporation into platelets; it increases platelet sizes, and when administered in high doses 
Tpo elevates platelet counts. Full development of colonies of megakaryocytes may depend on 
two growth factors. It has been hypothesized that one factor, meg-CSF, is effective in clonal 
expansion whereas a second factor is predominately involved in the endomitotic phase of 
megakaryocyte development. Multifactoral regulation has been observed for the other cell 
lineages (Deutsch and Tomer, 2006). The Mpl receptor is not limited to the megakaryocytic 
lineage, but also includes progeny of BFU-E. The binding affinity of the Mpl receptor for Tpo 
is high, with relatively few receptors displayed per cell. These findings suggest that Tpo, can 
speed red blood cell recovery after myelosuppressive therapy, in vivo, and enhance colony-
17 
forming unit-erythroid generation, in vitro. (Goncalves et al 1997; Siticka et al , 1996; 
Williams et al, 1990; Yang et al, 1995 : Deutsch and Tomer, 2006).  
 
1.6  Surface Antigen Phenotype of Haemopoietic Stem Cells 
 
In the 1980's the identification of surface antigens - so called glycoproteins- on the surface of 
all haemopoietic cells greatly enhanced the understanding of haemopoietic cell maturation.  
Surface antigens were identified that were found exclusively on totipotent stem cells and 
others that were specific to mature cells of specific cell lineages.  The expression of these 
surface antigens was found to change during the maturation events.  As the totipotent 
haemopoietic cells matures the surface antigen specific for the totipotent potential of the cells 
is lost.  As maturation continues and lineage specific cells emerge, lineage specific surface 
antigens develop.   The lineage- or function-specific surface antigens are called Clusters of 
Differentiation (CD).  The identification and isolation of lineage-specific cells has been 
greatly enhanced by the commercial availability of monoclonal antibodies raised against such 
surface antigens.  Flow cytometric cell sorting and magnetic bead separation used in 
conjunction with the lineage-specific monoclonal antibodies has enabled pre-selection of the 
totipotent haemopoietic cells for addition to in vitro cultures. Table 1.3 summarizes the 
expression of haemopoietic surface markers by murine haemopoietic cells modified from 
Morrison et al, 1995. 
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Cell Surface Marker Major lineage of expression Multipotent progenitor 
Thy-1 T cells Low 
Sca-1 T cells High 
c-kit Pluripotent stem cells High 
Mac-1 Granulocytes and monocytes Negative or low 
CD4 T cells Negative or low 
CD3 T cells Negative 
CD5 T and B cells Negative 
CD8 T cells Negative 
B220 B cells Negative 
Gr-1 granulocytes Negative 
CD41 megakaryocytes Negative 
Ter119 Erythroid progenitor cells Negative 
CD34 Multipotent progenitor cells High 
H-2K All haemopoietic cells High 
Ly5 All haemopoietic cells High 
 
Table 1. 3 The expression of haematopoietic cell surface markers by murine cells 
(modified from Morrison et al, 1995) 
The lineage specific surface antigens expressed on pluripotent, lineage committed progenitors and 
mature murine haemopoietic cells used to identify these cell lineages by flow cytometry.  The table 
highlights the surface antigens that are expressed on progenitor cells alone, such as CKit and Sca-1 
and others that are expressed on all cell lineages such as H-2K and Ly5.  Others shown are expressed 
exclusively by committed cell lineages such as CD4, CD3 and CD8 on T cells.  CD- Clusters of 
differentiation. 
 
 
1.7   The Experimental Analysis of Haematopoietic Differentiation 
 
Although histological observations of the haematopoietic system, in vivo, continue to be the 
primary source of information on the process of differentiation (Metcalf and Moore, 1971) 
several in vitro assays have also been employed in the study of the haematopoietic system.  
 
Till and Mc Culloch established in 1961 the first quantitative assay for cells with a 
radioprotective effect, cells that are not undergoing cell replication. These non -replicating 
cells were initially considered to be the most primitive haematopoietic cells. However, it is 
now been recognised that these cells were predominantly Spleen Colony-Forming Units 
(CFU-S) and do not represent the more primitive stem cells. In vivo assays in which human 
haematopoietic cells are engrafted in immunodeficient mice, have demonstrated the existence 
of human pluripotent cells either by limiting dilution analysis or by clonal integration of a 
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retroviral marker gene (Namikawa et al , 1990; Larochelle et al 1996; Bhatia et al 1997).  The 
term marrow repopulating ability, derived from in vivo studies, refers to primitive totipotent 
haematopoietic stem cells with self-renewal capacity that are capable of repopulating the bone 
marrow of lethally irradiated mice.  Two different types of cells with marrow repopulating 
ability have been distinguished in the mouse. Initial engraftment (short-term repopulation) is 
due to CFU-S. Long-term engraftment is attributed to a different cell type but is possible only 
if the animals also receive short-term repopulating cells (Cope, 1998).   
 
However, it was the development of in vitro short- term culture systems for the study of 
haematopoiesis (Nishijima et al, 1997) that allowed the identification and quantification of 
several different types of precursor cells. The colony formation assay (Metcalf et al, 1997) 
allows the enumeration of early progenitors capable of forming colonies when cultured under 
appropriate conditions in semisolid medium. In these short- term cultures, cells are grown in 
vitro in soft agar or other highly viscous media, containing, for example, methylcellulose, 
plasma gel or fibrin clots. These semisolid media reduce cell movement and allow individual 
cells to develop into cell clones that are identified as single clusters (<50 cells) or colonies 
(>50 cells) of differentiated cells after a culture period of 7 to 14 days. These colonies are the 
progeny of single cells called Colony-Forming Units (CFU), and the composition of the 
colonies determines which CFU is being assessed. Thus, Colony-Forming Units granulocytes, 
erythrocytes, monocytes and megakaryocytes (CFU-GEMM) correspond to pluripotent 
progenitor cells identified by the production of multi-lineage colonies (granulocytes, 
erythrocytes, monocytes and megakaryocytes).  This system has also enabled the identification 
of the high proliferative potential Colony-Forming Cells (HPP-CFC), defined by their ability 
to form very large colonies containing approximately 50,000 cells and including progenitor 
and mature haematopoietic cells of the granulocyte, macrophage, erythroid lineages (Cheng et 
al, 2006). Cells that give rise to colonies smaller than 1 mm, on the other hand, are usually 
referred to as low proliferative potential colony-forming cells (LPP-CFC). These primitive 
haematopoietic stem cells are considered to comprise cell types such as Burst Forming Unit- 
erythrocyte (BFU-E) and Colony-Forming Units granulocytes, erythrocytes, monocytes (CFU-
GM). Until the availability of recombinant thrombopoietin (Tpo), the evaluation of 
megakaryopoiesis has not been very easy, in vitro. Tpo amplifies the action of colony 
stimulating factor-megakaryocyte, but it also has a direct effect on precursor cells to increase 
the number of megakaryocytic colonies. Other in vitro work showed that Tpo stimulates 
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precursor cells directly to differentiate into megakaryocytic colonies (Broudy et al, 1997; 
Kaushansky 2006). 
 
1.8  Long-term Bone Marrow Cultures 
 
As described above, differentiation into various lineages can be observed in agar-based assays. 
Sustained production or self-renewal of clonogenic cells, however, has not been possible with 
standard semisolid culture systems. The long-term bone marrow cultures (LTBMC), were 
originally described by Dexter and colleagues for murine cells (Dexter et al, 1974) and later 
adapted for human cells (Gartner and Kalpan, 1980; Coulombel et al, 1983), and make use of a 
rich culture medium containing high concentrations of horse serum and hydrocortisone.  The 
rich culture conditions enable self-renewal of stem cells over a period of several months in the 
presence of a supportive microenvironment. The long-term culture of bone marrow cells 
employs primary adherent layers of stromal cells as an important source of cytokines and low 
molecular weight substances required for the controlled differentiation and proliferation of 
haematopoietic progenitor cells (Figure 1.5). Stromal cells provide a complex functional 
EMM allowing direct cell-to-cell contacts between different cell types. These, alone or in 
synergy with defined cytokines, can conserve primitive stem cells, induce early differentiation 
of a fraction of the primitive progenitors, and prevent their terminal differentiation.  In 
addition to CFU-S and HPP-CFC, pluripotent stem cells and early precursors can be identified 
by the LTBMC as cobblestone area-forming cells (CAFC) (Weilbaecher et al, 1991).   
 
 
Work has been conducted to improve the basic LTBMC protocol by ensuring good stromal 
layer development and increasing the longevity of the progenitor cells.  The quality of the 
horse serum added to LTBMC has long been known to affect the quality of and time taken to 
establish a healthy stromal layer.  The variability in the horse serum has been identified to be 
due to the level of interleukin-6 (IL-6) present in the particular batch of horse serum in use.  
Horse serum containing high levels of IL-6 supported healthy stromal cell development.  This 
suggests that IL-6 is one of the factors that plays a role in the formation and function of 
haematopoietically active LTBMC (Hauser et al, 1997).   Addition of IL-6 to LTBMC could 
reduce horse serum batch to batch variance.  The addition of Stem Cell Factor (SCF) has been 
shown to establish haematopoietic activity more rapidly, and reduce the decline in cellularity 
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and progenitor cell content normally observed during the first few weeks of culturing (Dunlop 
et al, 1993).  Exogenous addition of other growth factors, for example, interleukin-3 result in 
only moderate expansion of progenitor cells and increase mature cells and enable healthy 
stromal layer development (Carlo-Stella and Rozzoli, 1990; Yaroslavskiy et al, 1998).   
1.9   The Haematopoietic Stroma 
 
To obtain sustained haematopoiesis, primitive haematopoietic cells must interact with an 
adequate microenvironment, which includes, as already mentioned, stromal cells, EMM 
components and soluble regulatory factors (Eaves et al, 1991; Zhixing et al, 2006). The 
experimental analysis of haematopoiesis, in vitro, has provided much of the present 
knowledge on the role played by the stroma in the process. 
The term "stromal cells" is used rather loosely and the true histogeneic origin of these 
mesenchyme-derived cells is still uncertain. Stromal cells, which mechanically support the 
differentiating haematopoietic cells, include adventitial reticular cells (adipocytes), 
macrophages, fibroblasts, and osteoclasts and are frequently defined as non-haematopoietic 
cells (Dexter et al, 1976; Derubeis and Cancedda, 2004).  The following cell types are found 
in the stroma: 
 
Adventitial reticular cells - These cells reside on the adluminal surface of venous endothelial 
cells, which branch through the medullary cavity, and appear to provide a reticular network 
that supports haematopoietic cells. Marrow adipocytes possess the mechanical function of 
controlling haematopoietic volume: impaired haematopoiesis is associated with increased 
accumulation of fat inclusions, whereas accelerated haematopoiesis is associated with loss of 
fat vacuoles and the provision of increased space for haematopoietic cells (Tavassoli et al, 
1984). Adipocytes may play an additional role in blood cell production as a reservoir for lipids 
needed in cell metabolism during proliferation.  
Macrophages, fibroblasts and osteoclasts - Macrophages, fibroblasts and osteoclasts, cells 
derived from haematopoietic precursor cells and osteoblasts, may also play important roles in 
the haematopoietic microenvironment. Macrophages are important in removing defective cells 
resulting from ineffective erythropoiesis and in the removal of the nuclear pole, produced 
during the process. Fibroblasts release cytokines, which control the proliferation and 
maturation of the totipotent progenitor cells (Derubeis and Cancedda, 2004). 
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Stromal cells represent a highly dynamic structure, which plays an active role in 
haematopoiesis by producing EMM components and both soluble and membrane-associated 
growth factors (Fernandes et al, 1996; Zhixing and Linheng, 2006).  Stromal cells are rare in 
the marrow (approximately 0.125% of the marrow cellularity).  Adherent stromal cell layers in 
LTBMC, established by growing bone marrow cells over a period of several weeks, are 
considered to mimic many characteristics of the marrow microenvironment.  However, it has 
not yet been established conclusively that these cultures encompass all types of stromal cells 
identified in vivo and that they retain all of their functional properties in vitro. 
 
Haematopoietic stromal precursors have been described, besides adult bone marrow, in fetal 
liver and fetal bone marrow, with reported differences in the anatomic and ultrastructural 
characteristics.  Although the in vivo structures of the stroma, seen in the fetal liver and fetal 
bone marrow, vary from that seen in adult bone marrow, the variations do not affect their 
ability to support haematopoiesis (Riley et al, 1987; Van Den Heuvel et al, 1991; Zhixing and 
Linheng, 2006).  
 
The ontogeny of stromal cells is currently very poorly understood. Based on the well-
established generation of multiple mesenchymal cell types from bone marrow cells, the 
existence of stromal stem cells has been proposed (Owen et al, 1988; Prockop, 1997; Zhixing 
and Linheng, 2006). Besides gaps in our knowledge of the biology of these cell populations, 
information at the molecular level is also lacking. At least 16 Hox genes and 5 genes with 
homeobox domains, that are thought to be involved in the maintenance of the stromal layer 
cellular composition, have already been identified, although their temporal expression has not 
yet been determined (Simmons et al, 1987; Abramovich et al, 2005). 
 
The transplantation capability of stromal cells is also a controversial subject. Some studies 
have indicated that the stroma of bone marrow receptors is developed from the host's precursor 
cells (Laver, et al, 1987; Tanaka et al, 1994).  Others have shown that stromal cells in LTBMC 
of transplanted patients originate from the donor marrow (Keating et al, 1982). Using an in 
vivo system, it has been reported that murine bone marrow mesenchymal precursor cells, 
expanded in culture, were detected in the bone, cartilage and lungs of recipient mice at 1 to 5 
months after transplantation.  Recently, the migration of bone marrow-derived cells to areas of 
induced muscular degeneration, followed by differentiation along the myogenic pathway and 
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participation in the regeneration of damaged fibers, has been reported in mice (Ferrari et al, 
1998). 
 
The existence of stromal precursors outside the bone marrow in adults is highly controversial, 
in that while some studies have detected their presence in peripheral blood (Sutkowski et al, 
1995; Shi et all, 1998 ; Fernandez, 1997; Abramovich et al, 2005) others have reported 
negative results ( Ojeda-Uribe et al, 1993; Lazarus et al, 1997). The existence of stromal 
precursors in cord blood under normal conditions is the subject of intense discussion ( Mayani 
et al, 1998; Ye et al, 1994; Nieda et al, 1997; Prindull et al; 1987; Hows et al, 1992). A study 
(Rios and Williams, 1990), reported a deficiency in the myeloid progenitor cell growth in 
LTBMC of umbilical cord blood, suggesting that this may be due to the impaired development 
of an adherent layer. Other researchers (Clausen et al, 2000) have described the establishment 
of an adherent layer from human umbilical cord blood capable of supporting the proliferation 
of haematopoietic clonogenic cells.  The variable results are probably based on the varying 
experimental conditions employed. 
 
The haematopoietic stroma is defined by its ability to support haematopoiesis. This functional 
characteristic is most probably a result of interactions between the adherent cells and 
haematopoietic cells. Although stromal layers can be developed by in vitro cultivation of 
different organs, only those derived from bone marrow were shown to support the 
proliferation of more primitive haematopoietic cells (Miller et al, 1998; Zhixing and Linheng, 
2006). Although stem cells adhere to stroma developed from other organs, their 
haematopoietic potential is not maintained.  
1.10 Haematotoxicity 
 
Dose limiting haematotoxicity has been associated with a range of therapeutic agents. The 
haemapoietic cell lineage that is often affected in vivo is the megakaryocyte lineage. For a 
number of years, in vitro haemapoietic cultures have been available for the evaluation of the 
potential myelotoxicity of compounds, with the emphasis on the erythroid and myeloid 
lineages. Only since the commercial availability of recombinant thrombopoietin in 1994, has it 
been possible to study megakaryopoiesis in vitro. 
 
Two mechanisms often attributed to the sensitivity of haematopoiesis to these classes of 
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therapeutic agents are the high mitotic rate within the bone marrow and the consequence of 
direct exposure via systemic administration. For example, methotrexate and docetaxel, are 
known to block cell cycling (Botta et al, 1999).  As a consequence of the blockade of cell 
cycling, haematopoietic cell differentiation and maturation is disrupted, resulting in a decrease 
in the number of mature cells released into blood circulation.  Also just as critical, self- 
renewal of the totipotent stem cells can be disrupted (Botta et al, 1999).   Although the modes 
of action of different therapeutic agents maybe similar, differences in the sensitivity of each 
specific haematopoietic cell lineages to them, have been reported both in vivo and in vitro.  
For example, granulocytic/monocytic cell lineage maturation and differentiation is disrupted at 
lower exposure concentrations than that reported to affect the erythroid cell lineage (Williams 
et al, 1990).   
 
Hence, the ability to determine the mechanism underlying the lineage specific haematotoxicity 
would be of great value, if haematopoietic cultures could be developed with a similar 
sensitivity and lineage specificity to in vivo human bone marrow.    
 
An important advantage of a liquid LTBMC system over in vitro short-term cultures is the 
ability to evaluate any potential effects on the stromal layer, which is not present in the latter 
culture system.    Additionally, stromal cells have been shown to exhibit some drug 
metabolizing activities.   Therefore, evaluation of any potential haematotoxicity of metabolites 
of the parent compound is possible.   Also any direct toxicity affecting the ability of the 
stromal layer cells to produce cytokines that direct differentiation and maturation can be 
evaluated.   For example, it has been reported that therapeutics such as doxorubicin, 
accumulate in stromal cells subsequently affecting their ability in supporting haematopoiesis 
(Pessina et al, 1999). Other agents, such as methotrexate, have been reported, in vitro, to 
increase the proliferation of the stromal macrophage cell population (Corraza et al, 2004).  The 
increase in macrophage cell population resulted in an increase in the production and release of 
colony stimulating factors.  Although an increase in the colony counts of 
granulocytic/monocytic cell lineage would be expected, no such increase was found.  
Researchers found that the granulocytic/monocytic cells were unable to utilize the cytokines 
(Williams et al, 1998; Corraza et al, 2004).  The mechanism of the cytokine blockade is 
unknown.    
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1.11 Comparison of In Vitro Haematotoxicity Using Murine, Human Adult and 
Human Cord Haematopoietic Cells 
 
The integration of in vitro bone marrow studies into the discovery process would facilitate 
early evaluation for potential haematotoxicity.  In vitro murine haematopoietic cultures have 
been shown to be predictive for human haematotoxicity associated with anti- cancer and anti-
viral therapeutics (Scheding, 1994).  Other compounds, such as lead and catechol, have been 
found to be more haematotoxic to human haematopoietic cells than murine haematopoietic 
cells (Van Den Heuvel et al, 1999).  Lead was found to be 10 to 15 times more toxic to human 
Burst Forming Units - Erythroid (BFU-E) than murine BFU-E, based on IC50 concentrations. 
Human CFU-GM cell lineage was 6 times more sensitive to Catechol than murine CFU-GM 
cell lineage.  For adryamicin, methoxy-morpholinyldoxorubicin, Flavopiridol and Taxol, no 
differences in the in vitro haematotoxicity, based on IC 50 values, have been demonstrated 
between data derived from human adult bone marrow and human cord blood derived cells 
(Corsini et al, 2000).   The use of human cord blood stem cells in the in vitro cultures would 
be advantageous for predicting human haematotoxicity potential of new chemical entities and 
thereby circumvent the issue of differences in species sensitivity. 
 
1.12 Role of Platelets 
 
Platelets are produced in the bone marrow megakaryocytes stimulated by the growth factor 
thrombopoietin (George, 2004).  Platelets are found in peripheral blood circulation at 
concentrations ranging from 150 to 450 x 109/L.   
 
Haemostasis is the complex physiologic process that leads to the arrest of bleeding. It consists 
of the following components: platelets; plasma proteins, blood vessels and endothelial cells. 
With injury to a vessel, all the components are very quickly activated. Blood vessels constrict, 
platelets aggregate to form a plug, the plug is stabilized by the formation of insoluble fibrin 
due to the action of thrombin on soluble fibrin (Kickler, 2005).  At the site of vessel damage, 
subendothelial structures come into contact with the blood, where collagen is the more 
abundant thrombogenic substance to which platelets adhere and by which they become 
activated. In the high shear arterial system, platelets slow down by reversibly interacting or 
"rolling" over collagen-bound von Willebrand Factor (VWF), mainly via the platelet 
26 
glycoprotein complex GPIb-IX-V. The platelets then directly interact with collagen via their 
collagen receptors, of which glycoprotein (GP)VI and integrin α2β1 are considered to be the 
more important ones.  Platelets bind to each other. Formation of this platelet ‘web’ is the result 
of the binding of fibrinogen to glycoprotein IIb–IIIa, an integrin molecule that only binds 
fibrinogen after the molecule undergoes a conformational change.  The activated platelet 
membrane permits the binding of clotting proteins Factor V and X complex, leading to greatly 
increased catalytic activity of these plasma factors.   
1.13 Known Mechanisms of Drug Induced Platelet Count Reduction 
 
Drug induced thrombocytopenia (reduction in peripheral blood circulating platelet cell counts 
with or without reductions in bone marrow megakaryocyte numbers) has been described with 
a wide range of compounds including anti-neoplastic agents, anti-coagulants, anti-viral agents 
(Gynn et al, 1972; Kickler, 2005).  The known primary pharmacology of such therapies 
include:  
1. Direct inhibition of cell cycling of all replicating cells, including haematopoietic cells.   
Anti retroviral therapies also specifically target cell cycling.   
2. Inhibition of the formation of microtubules resulting in cell cycle arrest at metaphase 
has been attributed to vinca alkaloid agents such as Vinblastine and Vincristine.  
Interestingly, both these two agents have been used in the treatment of essential 
thrombocythemia (discussed in more detail in chapter 3). 
3. Inhibition of dihydrofolate reductase (folate antagonist).  This mode of action is noted 
with anti-neoplastic and rheumatoid arthritis agent methotrexate (Storb et al, 1986; 
Kickler, 2005).  
The consequence of the pharmacology of these therapies results in the reduction of both 
circulating and bone marrow haematopoietic cells.   
Platelet destruction may also be caused by direct toxic effect of the drug on the platelets 
or, more commonly, through an immunological mechanism (Van Den Bemt et al, 2004).  
Three mechanisms of action have been described:  
1. Hapten-Dependent Antibodies: Although infrequent, penicillins and cephalosporins 
can cause thrombocytopenia. These betalactam antibiotics – or haptens – bind 
covalently to autologous proteins (in this case a cell membrane protein of the 
thrombocyte) to form novel antigens.  Antibodies are subsequently formed, directed 
against this hapten-protein complex and ultimately result in cell destruction (Van den 
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Bemt et al, 2004). 
2. Drug-Induced, Platelet-Reactive Auto-Antibodies: Platelet-specific auto-antibodies 
appear to be involved in the thrombocytopenia caused by gold and procainamide, and 
occasionally by quinine and quinidine.  These auto-antibodies are induced by these 
drugs but bind to platelet membrane targets without a requirement for added drugs 
(Van Den Bemt et al, 2004). 
3. Drug-Dependent Antibodies:  Although this mechanism has been recognized for some 
time, the trigger for the induction of antibody formation is unknown.  One hypothesis 
proposes the binding of the drug to the platelet glycogen protein complex.  The 
resultant complex initiates an antibody response.  The favored glycoproteins are the 
GPIb/IX/V and the GPIIB/IIa glycoprotein complexes (Van Den Bemt et al, 2004).   
 
1.14 Essential Thrombocythemia 
 
Essential Thrombocythemia (ET) shares with other myeloproliferative disorders (MPD) such 
as chronic myeloid leukemia, Polycythemia vera, myelofibrosis and myeloid metaplasia of the 
spleen, a molecular pathogenesis leading to overproduction of mature blood cells.  ET is 
defined as a disease where the platelet count of an individual is elevated above 600,000/mL 
platelets, as a direct result of over production. Essential thrombocythemia is currently defined 
as a persistent thrombocythemia state that is neither reactive nor associated with an otherwise 
defined chronic myeloid disorder (Briere, 2007). 
 
ET patients are at risk from spontaneous thrombotic events (blood clots) occurring in the 
blood circulation. The genetic causes of the most common MPD remained unknown until the 
identification of mutations that activate Janus kinase 2 (JAK2) signalling in most patients with 
myeloproliferative disorders including ET (Briere, 2007).  In 2005, several independent 
groups identified a recurrent mutation in the JAK2 tyrosine kinase in most patients with ET.  
JAK2 is a member of the Janus family of cytoplasmic non-receptor tyrosine kinases, which 
also includes JAK1, JAK3 and TYK2 (Levine, et al, 2007). The mutation is a guanine-to-
thymidine substitution, which results in a substitution of valine for phenylalanine at codon 617 
of JAK2 (JAK2V617F) (Kralovics, et al,2005),  gain -of -function mutation of JAK2 
in myeloproliferative disorders. How the JAK2V617F mutation sustains the increased 
phosphorylation of JAK2 in the presence of serum, but in the absence of interleukin-3, and the 
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factor or factors in serum that mediate this effect remain unknown. (Kralovics et al, 2005). 
The mutation is present in haematopoietic cells but not germline. DNA from ET patients 
demonstrated that JAK2V617F is a somatic mutation that is acquired in the haematopoietic 
compartment. In addition, the JAK2V617F allele can occasionally be present in different 
haematopoietic compartments including B and T lymphoid cells. These findings suggest that 
the mutation might occur in the pluripotent haematopoietic stem cell (Levine, et al, 2007).  
However, the consequence of the presence of the presence of the JAK2V617F in the B and T 
cells is unknown. 
 
Acquisition of the constitutively active Janus kinase 2 (JAK2)V617F mutation occurs in 
65–97% of patients with polycythemia vera (homozygous in 25–33%), 35–57% with 
myelofibrosis with myeloid metaplasia (MMM) (homozygous in 9–29%), and 23–57% with 
ET (homozygous in 0–7%) (James et al, 2005). JAK2V617F is a constitutively active tyrosine 
kinase that activates signal transducer and activator of transcription (Stat), mitogen activated 
protein kinase (MAPK) and phosphotidylinositol 3-kinase (PI3K) signalling pathways, and 
transforms haematopoietic progenitors.  Gain-of-function mutations in JAK2 exon 12 and in 
the thrombopoietin receptor are observed in some patients with JAK2V617F-negative 
myeloproliferative disorders, suggesting constitutive activation of JAK2 signalling is central 
to the pathogenesis of PV and ET (Levine, et al, 2007). Negative regulation of JAK2 
signalling is normally mediated by suppressor of cytokine signalling (Socs) proteins, most 
notably SOCS1 and SOCS3; recent data indicate that instead of acting as a suppressor, SOCS3 
enhanced the proliferation of cells expressing JAK2 V617F allele. Additionally, although 
SOCS1 and SOCS2 are degraded in the presence of JAK2 V617F, turnover of SOCS3 is 
inhibited by the JAK2 mutant kinase and this correlated with marked tyrosine phosphorylation 
of SOCS3 protein. These findings suggest that the JAK2 V617F has overcome normal SOCS 
regulation by hyperphosphorylating SOCS3, rendering it unable to inhibit the mutant kinase. 
Thus, JAK2 V617F may even exploit SOCS3 to potentiate its myeloproliferative capacity 
(Hookham, et al, 2007).  The mechanism of activation of JAK2 kinase activity by mutations in 
the JAK2 signalling pathway is shown in figure 1.5. 
Clinical phenotype 
Median age at diagnosis in ET is estimated at 55 years. The female to male ratio is about 2:1. 
Thrombohemorrhagic complications cap the clinical course and major thrombosis, which is 
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mostly arterial, occurs in 11–25% of patients at diagnosis and in 11–22% during follow-up 
(Tefferi, 2006).  In contrast, the incidence of major hemorrhage is only 2–5% at diagnosis and 
1–7% during follow-up.  Similarly, hemorrhage is a rare cause of death in ET whereas 
thrombosis might account for 13–27% of deaths.  Abdominal large vessel thrombosis is 
particularly prevalent in ET affecting approximately 10% of ET patients. Non-life-threatening 
complications in ET include microvascular disturbances (headaches, acral paresthesia, 
erythromelalgia) and first trimester miscarriages (Tefferi, 2006). The former are relatively 
frequent but easily managed by low-dose aspirin therapy. The miscarriages occur in 30–40% 
of pregnant women with ET and do not appear to be increased by either  a higher platelet 
count or aspirin therapy (Tefferi, 2006). 
Treatment 
 
The majority of patients with ET can have a normal life expectancy in the first 15 years of the 
disease. Thereafter, survival is shortened because of increased attrition from disease 
transformation into AML, which occurs in less than 5% and 20% of the cases in the first and 
second decades of the disease, respectively (Tefferi, 2006).  Leukemic transformation in ET is 
considered a natural progression of the disease and not a result of drug therapy. Both anti-
platelet (aspirin) and cytoreductive agents are used in ET to either alleviate microvascular 
symptoms or prevent thrombo-hemorrhagic complications, respectively (Tefferi, 2006).  
Hydroxyurea is the first line cytoreductive agent used; vincristine, vinblastine and anagrelide 
are considered second line therapies.   
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Figure 1. 5 Mechanism of activation of JAK2 kinase activity by mutations in the JAK2 
signalling pathway, Levine et al, 2007. A) Cytokine ligands normally bind cytokine receptors, which 
results in Janus kinase 2 (JAK2) phosphorylation, recruitment of signal transducer and activator of 
transcription (Stat) signalling proteins and phosphorylation and activation of downstream signalling 
pathways including Stat transcription factors, mitogen activated protein kinase (MAPK) signalling 
proteins, and the phosphotidylinositol 3-kinase (PI3K)–Akt pathway. b) The JAK2V617F and JAK2 
exon 12 mutant kinases bind cytokine receptors and are phosphorylated in the absence of ligand, and 
lead to ligand-independent activation of downstream signalling pathways. c | By contrast, 
MPLW515L/K mutant thrombopoietin receptors are able to phosphorylate wild-type JAK2 in the 
absence of thrombopoietin, and result in the activation of signalling pathways downstream of JAK2. 
Negative regulation of JAK2 signalling is normally mediated by suppressor of cytokine signalling (Socs) 
proteins, most notably SOCS1 and SOCS3; recent data indicate that the JAK2V617F allele might 
escape negative feedback by SOCS3. 
 
1.15 Anagrelide Hydrochloride 
 
Anagrelide (AN) (Figure 1.6) was initially developed in 1992, by Roberts laboratories Inc 
(Eatontown, USA) as a potential anti-thrombotic therapy by inhibiting platelet aggregation 
(Petrides, 2006).  The anti-thrombotic activity of AN was assessed in various animal models 
including the biolaser induced rabbit thrombosis model, electrically induced dog thrombosis 
model and the ellagic acid-induced rat thrombosis model.  In all thrombosis models evaluated 
AN was a potent anti-aggregation agent (SBA, 1997).  Furthermore, in vitro human platelet 
aggregation studies demonstrated that AN prevented platelet aggregation by increasing the 
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phosphorylation of platelet proteins and it also inhibited thrombin-induced increase of intra-
platelet calcium ions. 
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Figure 1. 6 Anagrelide Hydrochloride Structure 
Platelet count reduction: Mechanism of action 
 
After single, oral dose administration of up to and including a dose of 25mg, no reduction in 
peripheral blood platelet count was noted. In the initial single dose study the volunteers 
receiving single administrations were followed for 14 days following dosing.  No reduction in 
platelet counts were noted following this post treatment period (SBA, 1997).  However, initial 
repeat dose studies in healthy volunteers highlighted the ability of AN to reduce platelet 
counts.   Doses of 1mg were noted to cause a reduction in peripheral blood platelet count 
(SBA, 1997).  
 
Pre and post AN treatment bone marrow aspirates from patients with Essential 
Thrombocythemia (ET) demonstrated no alteration in the number of megakaryocytes (SBA, 
1997). Additionally, doses of AN that reduced platelet counts in the pre-clinical toxicology 
studies caused no significant reduction in megakaryocytes (SBA, 1997).  Therefore the 
reduction in circulating platelets was not a direct result of a reduction in the number of 
megakaryocytes within the bone marrow (SBA, 1997).   The metabolites of AN were not 
identified in the SBA.  Four metabolites have subsequently been identified but their structures 
and their platelet aggregation and Mk colony inhibition activities have not been reported by 
Roberts Pharmaceuticals.  It has been demonstrated, however, that all four major metabolites 
are produced in the rat, dog, monkey and humans.   
 
In vitro clonogenic cultures using human bone marrow-derived stem cells showed that 
concentrations between 32nM - 161μM inhibited megakaryocytic colony formation with an 
C10H7Cl2N3OHCl 
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IC50 concentration of 32μM (SBA, 1997).  Mazur et al (1992) demonstrated that AN at 
concentrations of 32 μM to 161μM, resulted in an increase (65%) in the percentage of 
megakaryocytes in developmental stages I and II compared to concurrent controls (41.5% in 
developmental stages I and II).  This shift in the developmental stage of cultured human 
megakaryocyte is a morphological change only, and in terms of megakaryocyte function is 
unclear.  
 
Lane et al, (2001) hypothesized that all in vitro and in vivo studies carried out with AN’s 
thrombocytopenic effects have been complicated, for a number of reasons. Firstly, the water-
insoluble nature of AN (solubility of AN in water was 2μg/mL) has, in their opinion, hindered 
in vitro studies.  Secondly, even though AN is capable of inhibiting platelet aggregation across 
species, they claimed  it only decreased platelet levels in human subjects. This obstacle has 
hindered studies related to pharmacokinetics and toxicity in monkeys, dogs, and mice. Finally, 
the extensive biotransformation of AN suggested that the anti-platelet aggregation and 
thrombocytopenia effects may not be directly mediated by intact AN, but rather through active 
metabolites. 
 
While investigating the effects of AN in other species, an AN metabolite, 2-amino-5,6-
dichloro-3,4,-dihydroquinazoline (AM) produced only in human subjects was identified, 
characterized, and synthesized.  The structure of AM, 2-amino-5,6-dichloro-3,4,-
dihydroquinazoline is provided in Figure 1.7.   
 
Lane et al (2001) demonstrated that administration of AM to BALB/c mice caused 
thrombocytopenia and altered Mk content in the BM compartment. However, no AN -parent 
compound controls were included.  In support of the in vivo data, acute administration of AM 
blocked in vitro Mk migration. Moreover, chronic administration of AM blocked in vitro 
TPO-induced maturation of human and murine bone marrow stem cells into mature polyploid 
Mks. Lane et al (2001) proposed that these data indicated that biotransformation of AN into 
active metabolite was essential for its thrombocytopenic effect in mice.  On the basis that only 
the human liver has the capacity to generate the active metabolite, AN itself can only induce 
thrombocytopenia in humans. Unlike AN, AM does not affect platelet levels and does not 
inhibit ADP-induced human platelet aggregations. However, AM seems to promote 
thrombocytopenia by inhibiting Mk migration and maturation.  
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Figure 1. 7Structure of AM (2-amino-5,6-dichloro-3,4,-dihydroquinazoline), Metabolite 
of AN 
 
In summary, Lane et al (2001) described an AN metabolite that selectively inhibits Mk 
maturation and migration, without influencing platelet aggregation. The availability of AM 
enabled, for the first time, parallel in vitro and in vivo animal studies centered on the cellular 
mechanisms by which AN decreases platelet levels.  
 
Although experiments by Lane et al (2001) did not include the parent compound as a positive 
control, they further concluded that AM was 50 times more potent than AN itself. However, 
Erusalimsky et al (2002) and Wang et al (2005) carried out work where side-by-side 
comparisons of AN and AM for their ability to inhibit Mk maturation in cultures of human 
cord blood–derived CD34+ cells.   In these experiments AM at concentrations up to 2 μM 
(~432 ng/mL) showed no evidence of activity on a number of megakaryocyte maturation 
parameters, including expression of the differentiation marker CD61 (platelet glycoprotein 
11b/111a), increase in cell size, and polyploidy.  In sharp contrast, AN was active at doses as 
low as 10 nM, with half maximal inhibition (ID50) observed at 100 nM, and a maximal effect 
seen at 1–2 μM.  Erusalimsky et al (2002) also investigated the in vivo activity of AM in 
BALB/c mice. In contrast to Lane et al (2001) AM was given intraperitoneally at 7.5mg/kg to 
BALB/c mice for 7days (directly mimicking the design of Lane et al, 2001) failed to show any 
statistically significant difference in the mean platelet count between groups. BALB/c mice 
dosed with AN demonstrated a significant decrease in circulating platelet counts (reduction of 
35-45% verses concurrent control values).   Lane et al. (2001) also suggested that AM was a 
metabolite "produced only in human subjects," thereby offering an explanation for the lack of 
thrombocytopenic effects of AN in animal species. However, an extensive review of the pre-
clinical data (preclinical studies were carried out on behalf of Roberts Pharmaceutics Co.) by 
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Erusalimsky et al (2002) showed that all animal species investigated (rats, dogs, and rabbits) 
produce significant amounts of AM. For example, in rats given AN at 5 mg/kg per day 
(dietary dosing), Cmax of AM was 38.6 nM and for AN 45nM.  As previously mentioned the 
structure of AN metabolites had not been determined by Roberts pharmaceuticals.  Therefore, 
the differences in the results obtained by the groups may be explained by structural differences 
in the AM utilized by Lane and Erusalimsky.  Furthermore, the purity of AM used by the two 
groups varies significantly.  Presence of AN in the batch of AM used by Lane et al may also 
have contributed to the difference in results. 
 
Another explanation for the species difference in the activity of AN comes from the work of 
McCarty et al (2006).  These investigators showed that TPO-stimulated growth of murine 
BaF3 megakaryocytes transfected with human c-mpl (TPO receptor) was markedly reduced 
(ranging from 40 to 80 %) in the presence of 16nM to 500μM of AN.  In contrast, the 
untransfected BaF3 megakaryocyte progenitors demonstrated no change in growth (0 to 10%) 
with AN across the same concentration range.  This suggests that AN has greater affinity 
towards the human c-mpl (TPO) receptor than the murine c-mpl (TPO) receptor.  Clearly the 
debate on the mechanism of action of AN resulting in platelet count reduction is unresolved.  
Toxicology 
 
 
A full package of toxicology studies including acute and repeat dose studies, one year repeat 
dose studies in the rat and dog and safety pharmacology, reproductive toxicology, 
carcinogenicity and genotoxicity studies were completed with AN in the dog, rat, rabbit, 
mouse and monkey (SBA, 1997) .  In all species evaluated a dose dependent inhibition of 
platelet aggregation was noted.    A decrease in platelet count was noted in the rodent species 
(10% of control) at higher doses then that required to inhibit platelet aggregation.  In ex vivo 
platelet aggregation studies in rats, dogs and monkeys, AN inhibited ADP or collagen induced 
platelet aggregation in a dose dependant manner.  The dose at which collagen induced platelet 
aggregation was inhibited (ED 50) in the rat and monkey were 1.2 and 4mg/kg of AN, 
respectively. 
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Clinical Trial Findings 
 
Repeat dose clinical studies with AN in healthy volunteers showed that doses sufficient to 
inhibit platelet aggregation were unfortunately also associated with a substantial increase in 
cardiovascular side effects.  At that time, an unexpected finding was a dose dependent 
decrease in platelet count.  The reduction in platelet count was found not to reduce platelet 
survival time or cause significant bleeding. In addition, no drug induced platelet antibodies 
were detected.  Doses ranging between 1-3mg given every 8 hours for 6 to 9 days were shown 
to cause a profound reduction in platelet count with a nadir of 20 x10 9/ l occurring within 10 
and 12 days of commencement of treatment.   This reduction in platelet count opened a new 
avenue of clinical research suggesting AN may have a role in the treatment of ET as well as 
other chronic myeloproliferative disorders, including polycythemia vera, chronic myeloid 
leukemia, and agnogenic myeloid metaplasia (Finazzi et al 1999; Petrides, 2006). A study 
conducted in 8 patients, 5 of whom were diagnosed with ET demonstrated that no anti- 
aggregating effect was detectable at concentrations which significantly reduced platelet counts 
(Balduini, 1992; Petrides, 2006). 
 
Clinical trials have shown that AN has a large volume of distribution and is extensively 
metabolised; less than 1% is recovered unchanged in the urine. Plasma half-life after a 2.0-mg 
dose is 1.3 hours, with a mean Cmax value of 734ng/mL. AN's efficacy and safety have been 
evaluated in open-label, non-comparative trials, in which the response rate (reduction in 
platelet) was 60-93% (Pescatore et al, 2000; Petrides, 2006).  The recommended starting 
dosage is 0.5 mg four times a day or 1 mg twice a day, with dosage adjustment to the lowest 
effective amount required to reduce and maintain platelet count below 600 x 109/L.  
Approximately 25% of patients treated with AN develop fluid retention (considered to be due 
to the vascular dilating pharmacology of AN), and some develop frank congestive heart failure 
(Petrides, 2006). Changes in cardiac function were noted at doses >10mg/kg in the dog. These 
changes included reduction in blood pressure and heart rate as well as elevated T waves.  The 
mechanism for the cardiac findings are not understood (SBA,1997).  Side effects resulting in 
discontinuation of treatment with AN occur in 15% of the total number of patients given AN 
(Oertel et al, 1998; Petrides, 2006).   
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1.16 Taxol 
 
Taxol is an anti-cancer therapeutic that inhibits cell cycling by anti-microtubule agent that 
promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by 
preventing depolymerization (Needleman et al, 2005). Taxol stabilizes microtubules by 
straightening the GDP protofilament and slowing down the transition of protofilaments from 
straight to a curved configuration. This stability results in the inhibition of the normal dynamic 
reorganization of the microtubule network that is essential for vital interphase and mitotic 
cellular functions. In addition, taxol induces abnormal arrays of microtubules throughout the 
cell cycle and multiple asters of microtubules during mitosis (Geard et al, 1994). The 
haematotoxicity associated with Taxol treatment is discussed in chapter 5. 
 
1.17 Background to the Project 
 
The development of new pharmaceuticals requires a tremendous investment in time (typically 
10 to 13 years) and resources (typically hundreds of millions of pounds). Part of drug 
development is preclinical and clinical safety evaluation, the assessment of potential toxicity 
of new drugs. For a variety of therapeutics, haematotoxicity is often the dose-limiting factor. 
Haematotoxicity is usually assessed as part of the preclinical studies in experimental animals. 
However, information on the mechanism of the haematotoxicity noted can not be elucidated 
from the toxicology studies. Over the last 10 years in vitro bone marrow models have been 
developed.  The integration of in vitro bone marrow studies into the discovery process may 
facilitate early evaluation for potential haematotoxicity and facilitate identification of the 
potential mechanisms of the observed haematotoxicity and could reduce drug development 
time.  The identification of the potential mechanism of the haematotoxicity would enable 
a) The determination whether the haematotoxicity is animal species specific; b) potentially 
provide clinical investigators more specific biomarkers to identify the haematotoxicity in 
clinical trials.  As with all toxicities noted in preclinical studies, potential mechanism (s) for 
the toxicities noted are required for regulatory submissions to enable the progression of 
clinical trials of new medicines and ultimately their approval. 
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1.18 Aims of the Project 
 
Megakaryocytic lineage specific toxicity has been reported in clinical trials with anagrelide 
hydrochloride (AN).  The goals of this project were to investigate the utility of in vitro bone 
marrow cultures to 1) assess the haematopoietic lineage specificity of vincristine sulphate, 
vinblastine sulphate, hydroxyurea and anagrelide hydrochloride using clonogenic cultures;  2) 
to elucidate the mechanism(s) of the megakaryocytic lineage specific inhibition of anagrelide 
hydrochloride using both clonogenic and LTBMC.  The potential mechanism(s) and target 
specificity of AN action were elucidated by determining: 
• The ability of pluripotent stem cells to maintain a consistent number of pluripotent cells, in 
LTBMC, whilst others continue to differentiate into lineage specific progenitors in the 
presence of AN. 
• The effect of AN on the development and maturation of megakaryocytic specific lineage 
by assessing cell cycling, ploidy, cell surface receptor and tubulin expression 
To achieve these aims the following initial steps were necessary; the establishment and 
validation of: (i) a robust murine haematopoietic clonogenic assay to assess the ability of 
haematopoietic stem cells to differentiate into Colony Forming Units of the megakaryocytic 
cell lineage, (ii) murine clonogenic assays to evaluate haematopoietic stem cell differentiation 
into the granulocytic/ monocytic and erythroid cell lineages were established prior to the 
commencement of this programme of work (assay validation data Chapter 2). (iii) human cord 
blood haematopoietic clonogenic cultures to evaluate haematopoietic stem cell differentiation 
into the granulocytic/ monocytic, erythroid and megakaryocytic cell lineages (iv) long-term 
murine and human cord blood liquid culture system and assessment of:  a) The developing 
stromal layer by light microscopy; b) The morphological identification of cells present in the 
non-adherent layer; c) The assessment of the ability of a fully established LTBMC to produce 
lineage committed colonies (by plating non adherent cells into clonogenic cultures); d) 
Determination of the phenotype of the haematopoietic cells differentiating in the LTBMC 
using flow cytometry techniques and immunohistochemical techniques. 
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Chapter 2 
2.0 Materials and General Methods 
2.1 Materials 
 
The details of the source of the murine and human cord blood haematopoietic cells used in the 
clonogenic and LTBMC are provided below.  In addition, the ET reference compounds used in 
this thesis, the antibodies used to identify haematopoietic lineages in the non-adherent layers 
of LTBMC (murine and hCB) and the tublin –α and tubulin –β antibodies used are also 
provided.  Details of all other reagents utilized and culture plates, flasks, culturing media, flow 
cytometry reagents (for surface and intracellular antigen detection and cell cycle analysis,) and 
APAAP staining (for the identification of CFU-Mk colonies) are provided in Appendix A 
(pages 194 to 198). 
Haematopoietic Cell Source  
Supplier Catalogue Number 
Human umbilical cord and placental 
blood 
Poietic Technologies, USA 88364 
Balb/C mouse BM Charles River, UK - 
Essential Thrombocythemia Reference Compounds 
The reference compounds used for the evaluation of clonogenic cultures is provided below 
 
Essential Thrombocythemia reference 
compounds  
Supplier Catalogue 
Number 
Vincristine Sulfate Sigma, UK V8388  
Vinblastine Sulfate Sigma, UK V1377-10MG 
Hydroxyurea Sigma, UK S647268 
Anagrelide Hydrochloride Shire 
Pharmaceuticals,UK 
- 
DMSO Sigma, UK D4540-100ML 
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Antibodies for Identification of Murine Haematopoietic Cells 
Antibodies used for the identification on cell lineages of cells collected from murine LTBMC 
(non-adherent cells) is provided below 
 
Antibody Supplier Catalogue 
Number 
Rat-Anti mouse CD117 PE Serotec, Oxford, UK 76599 
Rat-Anti mouse Mono/Macro(F4/80) Serotec, Oxford, UK 65321 
Rat-Anti mouse Erythroid (ter119) Serotec, Oxford, UK 97539 
Rat-Anti mouse Granulocyte precursor Serotec, Oxford, UK 63181 
 
Human Mk-CFU Cell Surface and Intracellular Tubulin Markers 
Antibodies used for the identification of Human Mk-CFU colonies and intracellular Tubulin 
are provided below 
 
Antibody  
Supplier Catalogue 
Number 
Mouse-Anti human CD34 Becton Dickinson, USA 555821 
Mouse-Anti human CD61 Becton Dickinson, USA 553346 
Mouse-Anti human CD42 Becton Dickinson, USA 559458 
Mouse Anti human Tubulin α MP Biomedicals, USA 69125 
Mouse Anti- human Tubulin β MP Biomedicals, USA 69126 
 
2.2 General Methods 
 
2.2.1 Murine and hCB BFU-E and CFU-GM Clonogenic cultures 
 
The GM/E clonogenic assay was based upon the cultures described by Metcalf et al (1997).   
0.3 ml of murine bone marrow cells (following positive selection of CKit positive cells) or 
hCB cells (104cells /ml) were added to 3 mL Methocult media (Metachem Diagnostic, UK). 
The cell count was adjusted for cell viability and the cell count was determined using the 
Advia 12 analyser (Bayer, USA).   Details of the positive selection of murine CD117 positive 
cells, the thawing process of hCB cells and composition the murine and hCB clonogenic 
culture media are provided in Appendix A.  The tubes were then vortexed and allowed to 
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stand (5 minutes),  at 37oC in a water bath before 3.3 mL were dispensed into Falcon (Becton 
Dickinson, USA) cell culture six-well plates.  The plates were incubated in a CO2 incubator. 
Burst Forming Units -Erythroid (BFU-E) were counted after 10 days (murine BFU-E and 
CFU-GM colonies) and 12 days (hCB BFU-E and CFU-GM colonies) incubation and the 
Colony Forming Units-Granulocyte, Monocytic (CFU-GM) were counted after 12 days 
incubation.    The basic murine and hCB clonogenic culture method is outlined in Figure 2.1.  
Descriptions of the murine and hCB BFU-E and CFU-GM colonies are provided in Appendix 
A. 
The murine clonogenic cultures were established prior to the commencement of this thesis, the 
murine BFU-E and CFU-GM colony counts, with and without pre-selection of CKit positive 
murine HSC, obtained during the validation are provided in tables 2.1 to 2.4.   
 
Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 43 38 47 43 5 
2 51 37 40 43 6 
3 33 39 47 40 6 
4 30 51 40 40 9 
5 32 39 47 39 6 
6 27 56 34 39 12 
 
Table 2.1Murine BFU-E Clonogenic Cultures, Without Pre Selection: Assay Validation  
Mononuclear cells, prepared using lymphoprepR were added to murine granulocytic/ monocytic and 
erythroid clonogenic culture media (Methocult M3434).  The cultures were incubated in a CO2 incubator 
at 37oC, for 10 days.  The BFU-E colonies per well was determined using an inverted microscope.  
Murine BFU-E clonogenic culture validation was carried out in triplicate on 6 separate occasions. 
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Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 27 39 22 29 9 
2 29 12 19 20 9 
3 13 22 26 20 7 
4 15 47 26 29 16 
5 26 17 33 25 8 
6 41 19 27 29 11 
 
Table 2.2Murine CFU-GM Clonogenic Cultures, Without Pre Selection: Assay Validation  
Mononuclear cells, prepared using lymphoprepR were added to murine granulocytic/ monocytic and 
erythroid clonogenic culture media (Methocult M3434).  The cultures were incubated in a CO2 incubator 
at 37oC, for 10 days.  The CFU-GM colonies per well was determined using an inverted microscope.  
Murine CFU-GM clonogenic culture validation was carried out in triplicate on 6 separate occasions. 
 
 
 
 
 
Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 80 77 91 83 7 
2 82 71 87 80 8 
3 67 90 88 82 13 
4 71 68 79 73 6 
5 62 77 84 74 11 
6 85 77 72 78 7 
 
Table 2.3Murine BFU-E Clonogenic Cultures, With CKit Pre-Selection: Assay Validation  
C-Kit positive cells prepared using Lymphoprep followed by C-Kit  positive selection using Dynal beads  
murine stem cells were added to murine granulocytic/ monocytic and erythroid clonogenic culture 
media (Methocult M3434) .  The cultures were incubated in a CO2 incubator at 37oC, for 10 days.  The 
BFU-E colonies per well was determined using an inverted microscope.  Murine BFU-E clonogenic 
culture validation was carried out in triplicate on 6 separate occasions. 
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Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 41 53 57 50 7 
2 47 55 60 48 6 
3 48 57 62 56 6 
4 45 59 63 56 8 
5 46 43 50 46 3 
6 48 59 51 51 5 
 
Table 2.4Murine CFU-GM Clonogenic Cultures, With CKit Pre-Selection: Assay 
Validation  
C-Kit positive cells prepared using Lymphoprep followed by C-Kit  positive selection using Dynal beads  
were added to murine granulocytic/ monocytic and erythroid clonogenic culture media (Methocult 
M3434) .  The cultures were incubated in a CO2 incubator at 37oC, for 10 days.  The CFU-GM colonies 
per well was determined using an inverted microscope.  Murine CFU-GM clonogenic culture validation 
was carried out in triplicate on 6 separate occasions. 
 
2.2.2 Murine Megakaryocytic (Mk) Clonogenic Cultures - Standard Culture 
Conditions 
 
1.7 mL of HCC-4900 media (Metachem Diagnostics, Northampton, UK) was placed in a 
sterile tube. The suppliers (Metachem Diagnostics, Northampton, UK) suggested the cytokine 
concentrations and other components used; 1.1mg/mL collagen, 0.9% Methylcellulose based 
media (HCC-4900), 1% bovine serum albumin, 10 μg/mL bovine pancreatic insulin, 200 
μg/mL human transferring, 10 ng/mL rm. IL-3 and 50 ng/mL rm. thrombopoietin. 
 
0.1 mL of CKit positive cells (1x106cells) were added to 1.7 mL Megacult-C media.  Cell 
count was determined using an automated cell counter (Advia 120, Bayer, USA).  The cell 
count was adjusted for cell viability.  The tubes were then vortexed and allowed to stand for 5 
minutes at 37oC in a water bath.  1.2 mL of 1.1 mg/mL collagen, stored on ice prior to the 
procedure, was added to the tubes. The tubes were then vortexed and allowed to stand for 5 
minutes at 37oC in a water bath.  3.2 mL of the final culture mixture was dispensed into each 
well of a six well culture plate.   The colonies were identified morphologically using an 
inverted microscope, following 10 days incubation as described by Gribaldo et al, 1996 and 
Dobo et al 1999.  The basic CFU-Mk murine clonogenic method is outlined in Figure 2.1. 
2.2.3 Murine Megakaryocytic (Mk) Clonogenic Cultures -Modified Culture 
Conditions 
 
In a series of experiments 0.1mL of rm IL-6 (10ng/mL) (Metachem Diagnostics, 
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Northampton, UK) was added to the HCC-4900 media (Metachem Diagnostics, Northampton, 
UK) media mix. The remaining procedure was the same as described in section 2.2.2  
2.2.4 hCB CFU-Mk Clonogenic Cultures 
 
0.1mL of viable hCB cells (1x105cells/mL), were added to 2mL of warm MegaCultTM –C 
(Methachem Diagnostics, UK) and 1.2mL of collagen (details of the MegaCult-C media 
composition is provided in Appendix A). The cell count was adjusted for cell viability.  The 
viability count was determined by flow cytometry.  The tube was mixed well and plated at a 
plating concentration of 1 x 104cells/mL.  The plates were then incubated at 5% CO2, 95% 
relative humidity at 35oC.  The colonies were identified morphologically using an inverted 
microscope, following 12 days incubation, as previously described by Gribaldo et al, 1996 and 
Dobo et al 1999  The basic method is outlined in Figure 2.1.  The hCB clonogenic cultures 
were established by a year in industry student whilst this work was on-going.  The hCB BFU-
E and CFU-GM colony counts, obtained during the validation are provided in tables 2.5 to 2.7.   
 
 
Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 145 157 169 157 12 
2 148 139 185 157 20 
3 164 157 184 168 11 
4 173 163 195 177 13 
5 173 167 194 178 12 
6 146 153 170 156 10 
 
Table 2.5 hCB BFU-E Clonogenic Cultures: Assay Validation 
hCB cells  were added to human granulocytic/ monocytic and erythroid clonogenic culture media 
(Methocult -GF) .  The cultures were incubated in a CO2 incubator at 37oC, for 12 days.  The BFU-E 
colonies per well was determined using an inverted microscope.  hCB BFU-E clonogenic culture 
validation was carried out in triplicate on 6 separate occasions. 
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Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 62 74 77 71 8 
2 81 50 63 65 13 
3 59 68 75 67 7 
4 71 55 78 68 10 
5 63 68 71 67 3 
6 72 77 63 71 6 
 
Table 2.6 hCB CFU-GM Clonogenic Cultures: Assay Validation 
hCB cells  were added to human granulocytic/ monocytic and erythroid clonogenic culture media 
(Methocult -GF) .  The cultures were incubated in a CO2 incubator at 37oC, for 12 days.  The CFU-GM 
colonies per well was determined using an inverted microscope.  hCB CFU-GM clonogenic culture 
validation was carried out in triplicate on 6 separate occasions. 
 
 
 
Experiment No Culture 1 Culture 2 Culture 3 
Mean colony count per 
well 
Standard 
Error of 
Mean 
1 84 71 73 76 7 
2 69 87 74 77 8 
3 63 88 75 75 10 
4 83 71 77 77 5 
5 89 65 76 77 10 
6 87 72 68 76 8 
 
Table 2.7 hCB CFU-Mk Clonogenic Cultures: Assay Validation 
hCB cells  were added to human CFU-Mk clonogenic culture media (Megacult-C) .  The cultures were 
incubated in a CO2 incubator at 37oC, for 12 days.  The CFU-Mk colonies were stained and the number 
of CFU-Mk colonies per well determined using an inverted microscope.  hCB CFU-Mk clonogenic 
culture validation was carried out in triplicate on 6 separate occasions. 
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Compound Concentration BFU-E colonies / well CFU-GM colonies per well CFU-Mk colonies /well 
 
 
1 2 3 1 2 3 1 2 3 
Vincristine Sulphate 0 186 185 195 82 77 78 82 88 87 
 0.001 176 180 165 71 73 71 71 68 63 
 0.1
 
147 135 133 51 48 44 28 31 36 
 0.01 166 167 152 64 61 55 47 41 38 
 1 83 96 77 21 27 31 20 18 14 
 10  55 47 69 14 16 11 7 9 11 
Chloramphenicol Succinate 0 186 172 185 79 88 71 82 80 73 
 0.001 177 165 160 61 57 54 77 75 80 
 0.01 127 111 124 45 41 52 59 61 66 
 0.1
 
79 68 70 36 33 39 47 52 56 
 1 35 41 36 21 18 26 31 29 35 
 10  12 11 15 11 9 17 20 18 27 
Diazipam 0 178 168 196 83 81 84 90 82 85 
 0.001 167 180 173 71 88 79 88 81 74 
 0.01 158 164 152 68 77 70 77 61 66 
 0.1
 
138 133 141 62 71 74 58 63 65 
 1 93 108 92 44 48 38 37 26 41 
 10  54 46 66 32 48 31 15 35 22 
 0 167 190 172 80 71 83 83 88 74 
Methotrexate 0.001 128 151 168 66 59 61 78 75 66 
 0.01 93 104 84 60 44 47 68 62 57 
 0.1
 
63 72 69 41 41 46 56 50 48 
 1 43 36 22 25 39 22 43 40 35 
 10  17 23 11 15 4 16 30 25 19 
Table 2.8 Evaluation of hCB Clonogenic Cultures with Known Haematotoxic and Non-haematotoxic Compounds 
hCB cells  were added to human CFU-GM/BFU-E and CFU-Mk clonogenic culture media.  The cultures were incubated in a CO2 incubator at 37oC, for 10 and 
12 days.  The CFU-GM, BFU-E and CFU-Mk colonies per well was determined using an inverted microscope.  A concentration related decrease in colony count 
was noted with all compounds. 
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Figure 2. 1 Diagrammatic Representation of Clonogenic Cultures Using Murine or hCB Stem 
Cells   
CKit positive murine or hCB stem cells (104cells/mL) were added to murine or hCB clonogenic cultures 
(Chapter 3 and 5).  Test compound or vehicle control was added to the clonogenic cultures at 
clonogenic culture initiation, and remained within the cultures throughout the culturing period.  The 
cultures were incubated in CO2 incubator. At the end of the incubation time number colonies (BFU-E, 
CFU-GM and CFU-Mk) was determined using an inverted microscope and /or flow cytometry analysis 
(CFU-Mk colonies only) was conducted (chapters 3 and 5).  Flow cytometry analysis included cell cycle 
analysis, surface antigen expression and tubulin expression, following AN treatment (chapter 5).  
2.2.5 Murine and hCB LTBMC 
 
The method initially used was based upon the cultures described by (Dexter et al 1978), a 
liquid culture system that contains an established layer of stromal cells (support cells) and 
Stem cells (murine 
BM derived or hCB 
cells 
 hCB cells or  Murine CKit positive 
cells  (selected using Dynal beads) 
 
Addition of vehicle control or 
test compound  Compound addition step used in direct clonogenic assay 
assessment (chapter 3 and 5) 
Cell count determined using Advia 120
analyser. 
Cell viability determined using flow 
cytometry 
Colony counts
Set-up cultures
1 
Stem cells added to: 
1) CFU-GM media 
2) CFU-MK media 
2 
Incubation of cultures in 
CO2 incubator 
CFU-Mk cells were collected from hCB 
clonogenic cultures and flow cytometry 
analysis conducted (cell cycle analysis, 
surface antigen and tubulin expression 
analyses (chapter 5) 
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non-adherent cells. The stromal layer is developed from fresh bone marrow in tissue culture 
flasks or plates where the stromal cells attach to the culture surface. The cultures are given 
fresh medium weekly, and after 5 to 6 weeks the stromal layer is usually developed.  Once the 
stromal layer is developed, freshly harvested, pre-selected progenitor cells from primary bone 
marrow can be added to the cultures.  It is the proliferation and development of these freshly 
harvested cells that are supported by the already established stromal layer. 
Stromal Layer Development: Culture Initiation:  100 μL of murine bone marrow or hCB 
cells (1 x106 cells/mL) was added to 9.90mL of Myelocult media (Methachem Diagnostics, 
UK) containing penicillin / Steptomycin (Sigma, UK) 833μl , 20μL hydrocortisone (Sigma, 
UK) (10-6M)  into a 25mL culture flask. The cell count was determined using an automated 
cell counter (Advia 120, Bayer, USA).  The flasks were then placed into a 5% CO2 incubator 
at 37o C. 
Stromal Layer Development: Weekly Feeding:  Once a week the flasks containing the 
developing stromal layers were removed from the incubator, taking care not to shake the 
cultures, and as much of culture media as possible (9.5-9.7 mL), containing non- stromal cells 
(maturing granulocytes, monocytes and megakaryocytes) was removed.  9.5 mL of fresh 
media, containing antibiotics, was then added to the cultures. The stromal layer reached 95-
97% confluency by the end of 5 weeks. 
Inoculation of Ckit murine Positive Cells or hCB cells to Developed Stromal Layer: Once 
a confluent stromal layer was established, the stromal layer was inoculated with CKit positive 
murine cells (mLTBMC) or hCB cells (human LTBMC).    At weekly intervals, 9.0 -9.5 mL 
of the media was removed and replaced with fresh culture medium.  A diagrammatic 
representation of LTBMC is provided in Figure 2.2. 
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Figure 2. 2 Diagrammatic Representation of LTBMC, Using Murine or hCB Stem Cells  
Murine mononuclear cells or hCB cells (106cells/mL) were added to the LTBMC media and the 
flasks incubated in a CO2 incubator.  Weekly collections of non-adherent cells were made when 
culturing media was replaced.  Non adherent cells were identified by morphology and surface 
antigen expression by flow cytometry (chapter 4). When stromal layer was confluent fresh 
murine or hCB cells were added (106cells/mL). Anagrelide or vehicle control was added to the 
hCB LTBMC when confluent stromal layer was inoculated with fresh hCB cells (chapter 5). Non-
adherent cells collected weekly from the established LTBMC were added to murine or hCB 
clonogenic assays and the number of CFU-GM, BFU-E and CFU-Mk colonies determined 
(chapter 4 and 5). In addition, following anagrelide treatment, cell cycle analysis, surface 
receptor expression and tubulin-α and tubulin- β expression and mean fluorescence intensity 
was determined by flow cytometry (chapter 5). 
 Inoculation with 
fresh bone marrow or hCB
derived 
mononuclear cells 
All media replaced weekly 
Non-adherent cell count determined
Non adherent cell identification
Flow cytometry Morphology
Media removed weekly from cultures
Re-inoculation with murine CKit positive 
or hCB stem cells  
Media replaced weekly 
Cell count of non-adherent cells, using Advia 120
Flow cytometry: 
Cell cycle analysis 
Stromal layer 
developed after 6 
weeks 
Chapter 4 and 5: Short-
term cultures (BFU-E, 
CFU-GM and CFU-Mk). 
Addition of vehicle 
control or Anagrelide 
(chapter 5) 
Cells cytospun onto microscope 
slides, stained with May Grunwald-
Giemsa  prior to cell identification 
by morphology   
Cell count 
determined using 
Advia 120 analyser 
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2.2.6 Flow Cytometry Analysis 
Surface Membrane Staining 
The recommended quantity of the Flurescein isothiocyanate (FITC)-conjugated and 
Phycoerythrin (PE)-conjugated monoclonal antibodies were added to a set of tubes (two tubes 
per sample to be analyzed).  100μL of non-adherent cells, from human or murine LTBMC or 
cells collected from clonogenic cultures were added to all the tubes.  The tubes were gently 
mixed and incubated for 15 minutes at room temperature (18-23oC) in the dark and then 
centrifuged for 3 minutes at 600g.   Supernatant was decanted, leaving behind approx. 50μl of 
fluid and 2 mL of Cell Wash (Becton Dickinson, CA, USA) added to each tube and then 
lightly mixed to re-suspend the cells.  The tubes were again centrifuged for 3 minutes at 600g.  
The supernatant was removed so that approx. 50μL of fluid is left behind.  The cells (1x104 
cells /mL) were re-suspended in 0.5 mL of Cellfix (Becton Dickinson, CA, USA).   
10 000 cells were analyzed from each sample using a FACScan flow cytometer (Becton 
Dickinson, CA, USA) using CellQuest software. Two dimensional dot plots (TDDP) were 
used to distinguish the different cell phenotypes as well as the relative size and relative 
complexity of the cells. The four sub-populations of the FITDDP are shown in Appendix A. 
Intracellular Staining 
 
The method employed has previously been described by Jung et al, 1993. 50µL of cells 
collected from clonogenic cultures or non adherent layers from LTBMC suspension sample 
was placed into a falcon tube.  100µL of reagent A (IC-FixTM Cell Fixation Buffer) of the Fix 
and Perm cell permeabilsation kit was added to each tube.  The tubes were incubated at room 
temperature (18-22°C) and then 2mL of Cell Wash (Becton Dickinson, CA, USA) was added 
to all the tubes.  The tubes were centrifuged for 15 minutes at 400g.  Supernatant was 
decanted, leaving behind approx. 50µL of fluid.  100µL of Reagent B (IC-PermTM Cell 
Permeabilization Buffer) of the Fix and Perm cell permeabilsation kit was added to each tube 
and the recommended quantity of the FITC conjugated monoclonal antibody was added.  The 
antibodies to be used are specific for the intracellular antigen that is being measured and for 
the species being tested and incubated at room temperature (18-22°C) for fifteen minutes. 
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At the end of the incubation period 2mL of Cell Wash (Becton Dickinson, CA, USA) was 
added to all the tubes.  The tubes were centrifuged for 15 minutes at 400g.  Supernatant was 
decanted, leaving behind approx. 50µL of fluid.  The cells (1x104 cells /mL) were re-
suspended in 0.5mL of Cellfix (Becton Dickinson, CA, USA).  The cells were analysed using 
the CellQuest program, using the FACSCalibur. 
2.2.7 Cytospin Technique 
 
In order to identify the non-adherent cells from LTBMC morphologically, the cells (1x104 
cells /mL) were aspirated from the cultures and transferred to a centrifuge tube. Cell count was 
determined using an automated cell counter (Advia 120, Bayer, USA).   0.5 mL of PBS was 
added to the tubes, which were then centrifuged at 400g, 5 minutes.  The supernatant was 
removed and cells resuspended in 400µL methanol, to fix the cells.  200µL of fixed cell 
suspension attached to duplicate microscope slides using a cytospin (100g, 2 minutes).  The 
cytospin preparations were stained with May-Grunwald staining. 
 
2.2.8 Viability Count 
 
100 μl (1x105cells/mL) of stem cells was placed into falcon flow cytometry tubes to which 20 
μl of Via-Probe (7-AAD) was added to the cells. Cell count was determined using an 
automated cell counter (Advia 120, Bayer, USA).    The cells were incubated for 10 minutes 
before analysis.  Analysis was conducted using the Cell Quest programme.  10 000 cells were 
analysed from each sample using a FACScan flow cytometer (Becton Dickinson, CA, USA) 
using CellQuest software.  Histogram analysis was used to distinguish viable cells; the viable 
(7-AAD negative) cells were expressed as a percentage of the total population counted. 
2.2.9 Cell Cycle Analysis 
 
1 mL (1x105 cells/mL) of the non-adherent cells (collected from LTBMC) or cells collected 
from Clonogenic cultures were placed into a falcon flow cytometry tube and centrifuge for 5 
minutes at 300g at room temperature (20 -25o C); the cell count was determined using an 
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automated cell counter (Advia 120, Bayer, USA).    The supernatant was aspirated off the 
cells, leaving approximately 50 μL of residual fluid in the tube.  1 mL of Buffer Solution 
(Becton Dickinson, CA, USA) was added to the cell pellet and the cells were vortexed to re-
suspend and then centrifuged for 5 minutes at 300g at room temperature (20 -25o C).  The 
supernatant was aspirated off the cells, and 1 mL of 70 % ethanol was added to the cell pellet 
and the cells.  The 70% ethanol was aspirated off the cells, taking care not to disturb the cells 
in the base of the test tube.  The cells (approx.1 x105 cells/mL) were resuspended in 1mL of 
the buffer solution (Becton Dickinson, CA, USA).  The cells were centrifuged at 600g for 2 
minutes.  The buffer solution was poured off the pellet of cells.   250 μL of Solution A (trypsin 
in a spermine tetrahydrochloride detergent buffer) was added to each tube and gently mixed 
and incubated at room temperature for 10 minutes.  200 μL of Solution B (trypsin inhibitor 
and ribonuclease A in citrate stabilizing buffer with spermine) was added to each tube and 
gently mixed and  incubated at room temperature for 10 minutes. 200 μL of cold Solution C 
(propidium iodide (PI) and spermine tetrahydrochloride in citrate stabilizing buffer) was added 
to each tube and gently mixed, incubated in the fridge for 10 minutes prior to analysis.  
Analysis was conducted on the Becton Dickinson FACScan using CellQuest programme.  
Data analysis conducted using Becton Dickinson ModFit (Becton Dickinson, CA, USA). 
 
2.2.10 May Grunwald-Giemsa Staining for Light Microscopy 
 
May-Grunwald stain (Dako, Cambridgeshire, UK) was diluted 1 in two using pH 6.4 buffered 
water. The cytospin preparations thermanox cover slips were placed in May-Grunwald 
staining solution for 3 minutes.  The cover slips were then placed in the Giemsa staining 
solution for 3 minutes.  The cover slips were rinsed, and the stain was developed in pH 6.4 
buffered distilled water, then rinsed in distilled water and finally allowed to air dry. 
 
2.2.11 Evaluation Essential Thrombocythemia Reference Compounds Using 
Colony Forming Cultures 
Sigma-Aldrich Company Ltd (UK) supplied vincristine, vinblastine, hydroxyurea and 
chloramphenicol. The three compounds were bought in their dessicate state and were diluted 
to the required concentrations by reconstitution with sterile PBS on the day of culture. 
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Anagrelide was supplied by Shire Pharmaceutical.  The compounds were dissolved using neat 
dimethylsulfoxide (DMSO), with a 2% (v/v) final concentration of DMSO (using PBS).   10µl 
of control or each compound concentration was added to the GM/E and Mk clonogenic culture 
mixtures (previously described) prior to dispensing into wells of six- well plates.  Culture 
incubation conditions, incubation time and method of colony counting were the same as 
previously described.   
2.2.12 Data Analysis 
 
For each cell lineage the concentration, at which 50% inhibition of colony growth (IC50) 
occurred was calculated using ROBOSAGE software package (an automated curve fitting 
software package; version 7.30). Robosage is a Microsoft EXCEL (Redmond, Wash.) add-in 
program developed at GlaxoSmithKline (M. W. Lutz, personal communication). The 
nonlinear optimization function in Robosage is based on the Marquardt-Levenberg algorithm.   
The Marquardt-Levenberg algorithm enables the determination of the steepest descent of a 
non-linear curve.  It dynamically mixes Gauss-Newton and gradient-descent iterations. 
The formula used was:    
 y=(a-d)/(1+(x/c)^b)+d 
 
This model describes a sigmoidal curve with an adjustable baseline, a. The equation can be 
used to best fit curves where response is either increasing or decreasing with respect to the 
independent variable, X.  X is a concentration of drug under test (agonist or antagonist). Y is 
the response. A is the limiting response as X approaches zero. As X increases without bound, 
Y tends toward its lower limit, d. C is the inflection point (EC50 or IC50) for the curve that is, 
Y is halfway between the lower and upper asymptotes when X=C. B is the slope-factor or Hill 
coefficient. The sign of b is positive when the response increases with increasing dose, and is 
negative when the response decreases with increasing dose (inhibition).  
Two Sided Students t analysis (testing the null hypothesis that means of treated and control 
groups are equal) and Dunnett’s test (comparing each treatment group mean with the control 
group mean) was conducted to determine any statistical significance of the lineage specific 
toxicity noted.  
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Chapter 3 
3.1 Experimental Part 1: Megakaryocytic Clonogenic Cultures 
3.1.1 Megakaryopoiesis: Overview 
 
Megakaryopoiesis concludes with the release of platelets. As with the other lineages it is a 
multistage process of cellular differentiation and maturation regulated by a variety of 
cytokines (George, 2004). As discussed in Chapter 1, the development and maturation of the 
committed megakaryocytic stem cells is unique in that they develop a highly polyploid DNA 
content and the formation of platelets results from the projection of megakaryocytic cytoplasm 
through the sinusoidal endothelium (Deutsch and Tomer, 2006). 
3.1.2 Essential Thrombocythemia 
 
As discussed in Chapter 1, ET is an acquired MPD characterized by a sustained elevation of 
platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general 
population is approximately 30/100,000. The median age at diagnosis is 55 to 70 years, but the 
disease may occur at any age.  The clinical picture is dominated by a predisposition to 
vascular occlusive events and hemorrhages. Thromboses of large arteries represent a major 
cause of mortality associated with ET or can induce severe neurological, cardiac or peripheral 
artery manifestations. The molecular pathogenesis of ET, is associated with the JAK2 V617F 
mutation. Therapeutic interventions in ET are limited to decisions concerning the introduction 
of anti-aggregation therapy and/or starting platelet cytoreduction. The cytoreduction therapies 
used include hydroxyurea, vincristine, vinblastine and anagrelide.  
 
3.1.3 Aims of the Investigation 
 
For a number of decades, in vitro haemapoietic cultures have been available for the evaluation 
of the potential myelotoxicity of compounds.  Although anti-cancer and anti-viral therapies are 
known to cause myelotoxicity, the first cell lineage most often affected in vivo is the 
megakaryocytopoietic.  Until the availability of recombinant thrombopoietin, this aspect of 
haematopoiesis has not been possible to evaluate easily in vitro.  The initial aim of this 
investigation was  
• To establish a robust murine megakaryocytic culture system (a robust short-term culture 
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system for the erythroid and granulocytic/monocytic cell lineages had been established 
prior to the initiation of this work).  
• The second aim of the investigation was to determine if murine short-term in vitro assays 
could identify lineage specific haematopoietic effects, using compounds that are used in 
the treatment of ET, and therefore target megakaryocytes specifically. The four reference 
compounds evaluated were Vincristine (VC), Vinblastine (VB), Hydroxyurea (HU), and 
Anagrelide (AN).   Part of this work formed an industrial placement student project, where 
the student, D. Puvanendrampillai, conducted the analysis of megakaryocytic cultures 
only.  The effect of the 4 compounds on granulocyte/ monocyte, erythrocyte and 
megakaryocyte maturation was assessed in short-term cultures, and data was expressed as 
IC50 values (the concentrations at which in vitro colony growth was inhibited by 50%). 
The molecular targets of the four reference compounds are varied: DNA damage, or 
inhibition of DNA synthesis or inhibition of the formation of microtubules.  The 
characteristics of the reference compounds are shown in Table 3.1. 
 
Compound Class Pharmacology Reference 
Vincristine  Vinca alkaloid Inhibits formation of 
microtubules resulting in cell 
cycle arrest at metaphase 
Gibbs and Sorensen 2000 
Vinblastine Vinca alkaloid Inhibits formation of 
microtubules resulting in cell 
cycle arrest at metaphase 
Moss et al 1999 and Stubbs 
and Swaney 1996) 
Hydroxyurea Alkylating agent Quenches the tyrosyl free 
radical at the active site of the 
M2 protein subunit of 
ribonucleotide reductase, 
inactivating the enzyme. 
Causes cell death in S phase 
and synchronization of the 
fraction of cells that survive 
Gibbs and Sorensen 2000: 
Tefferi, 2006 
Anagrelide Quinazolin derivative Inhibits cyclic nucleotide 
phosphodiesterase and the 
release of arachindonic acid 
from phospholipase, possibly by 
inhibiting phospholipase A2. 
Mechanism of platelet count 
reduction unknown 
(Petrides, 2006) 
 
Table 3. 1  Pharmacology of Reference Compounds 
The pharmacology of the 4 ET treatment reference compounds to be used in the determination of the 
lineage specificity of each treatment using murine clonogenic cultures is provided. 
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3.2 Methods 
3.2.1 Murine BM Preparation 
 
The methods employed for the aspiration of bone marrow from Balb/C mice, pre-selection of 
mononuclear BM cells and the isolation of CKit positive murine BM cells is described in 
Appendix A.  
3.2.2 Murine Megakaryocytic (Mk) Clonogenic Cultures - Standard Culture 
Conditions 
 
Megakaryocytic clonogenic as described in Chapter 2 were utilized in these experiments 
(section 2.2). 
 
For APAAP staining, 1.5 mL of the final culture mixture was dispensed into each well of a 
double chamber culture slide.  The plates were incubated in a CO2 incubator. Colony Forming 
Units-Megakaryocytic (CFU-Mk) were counted after 5, 6, 7 and 8 days incubation.  The 
colonies were identified morphologically using an inverted microscope.   
 
3.2.3 Murine Megakaryocytic (Mk) Clonogenic Cultures -Modified Culture 
Conditions 
 
Modified megakaryocytic clonogenic as described in Chapter 2 were utilized in these 
experiments (section 2.3). 
3.2.4 Murine Granulocytic /Monocytic and Erythroid Clonogenic Assay (GM/E)  
  
GM/E clonogenic assays as described in Chapter 2 were utilized in these experiments (section 
2.1). 
 
3.2.5 Alkaline Phosphotase Anti- Alkaline Phosphotase (APAAP) Staining For 
the Identification of Murine CFU-Mk Colonies 
 
The method was based up on the technique described by Mason (1985).  The chamber slides 
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were removed from the incubator and the outer plastic was removed from the chamber. A pre-
cut polypropylene separator was placed onto the chamber slide and a filter card placed on top 
of the slide to soak up the culture liquid.  The filter card was removed, once excess liquid had 
been collected, leaving the separator in place.  The slide was then placed into a container of 
acetone maintained on ice for 5 minutes.  After the incubation time the slides were removed 
from the acetone and allowed to dry at room temperature.  0.5 ml (5μg/mL) of the Rat Anti-
Mouse CD41 monoclonal antibody (diluted 1 in 500 in phosphate buffer prior to use) was 
placed onto the slide.  The slides were incubated at room temperature for 30 minutes.  At the 
end of the incubation period the anti-CD41 antibody was poured off the slides. The slides were 
rinsed with 1.0 ml of phosphate buffer.  
0.5 ml (5μg/mL) of Rabbit anti-Rat immunoglobulin, diluted 1 in 100 in phosphate buffer) 
was placed on each slide. The slides were incubated at room temperature for 30 minutes. At 
the end of the incubation period the rabbit anti-rat immunoglobulin was poured off the slides. 
The slides were rinsed with 1.0 ml of phosphate buffer.   
 
0.5 ml (10μg/mL) of Rat APAAP antibody (diluted 1:25 as recommended by the 
manufacturer) was placed on each slide.  The slides were incubated for 30 minutes at room 
temperature. At the end of the incubation period the Rat APAAP antibody was poured off the 
slides. The slides were rinsed with 1.0 ml of phosphate buffer.  0.5 ml of 1% Fast Red solution 
was placed onto each slide. The slides were incubated for 20 minutes at room temperature. At 
the end of the incubation period the Fast Red solution was poured off the slides. The slides 
were rinsed with 1.0 ml of phosphate buffer. The positively stained colonies were identified 
and counted using a light microscope. 
Controls for APAAP staining: 
Two negative controls were used to determine the amount of background staining on every 
staining run.   
Negative control 1: The addition of CD41 was omitted.  
Negative control 2:  0.5 ml (5μg/mL) of an isotype control antibody was added in place of 
CD41.  
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3.2.6 Evaluation Essential Thrombocythemia Reference Compounds Using 
Colony Forming Cultures 
 
The source of the reference compounds and preparation of the stock solutions of the 
compounds is described in Chapter 2 (section 2.2.11).  The final concentrations used in this 
thesis ranged from 0.1 to 1000μM.  However, for the evaluation of AN only this range was 
extended.  Concentrations evaluated for AN ranged from 0.0001 to 10000μM.  10µl of control 
or each compound concentration was added to the GM/E and Mk clonogenic culture mixtures 
(previously described) prior to dispensing into wells of six- well plates.  Culture incubation 
conditions, incubation time and method of colony counting were the same as previously 
described.  All reference compound concentrations were evaluated in triplicate on three 
separate occasions. 
3.2.7 Data Analysis 
 
Determination of IC50 concentrations was carried out as described in Chapter 2 (section 
2.2.12).   
 
3.3 Results 
3.3.1 Mk Clonogenic Cultures Using Standard Conditions 
 
In this investigation, the preliminary short -term megakaryocytic cultures were established, 
using pooled bone marrow, from BALB/c mice, in three separate experiments, with the assays 
conducted in triplicate on each occasion. To determine the day at which the maximum colony 
counts were achieved counts were conducted on days 5, 6, 7 and 8 (Figure 3.2). The colony 
counts are shown in Table 3.2.  CFU-Mk colony counts increased from day 5 and reach their 
peak on day 7 and then declined on day 8.   
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Figure 3. 1  Optimum Incubation time for Murine CFU-Mk Colonies Using Megacult-C 
Culture Medium with cytokines IL-3 and Tpo.  
 The CFU-Mk colony counts per well following 5, 6, 7 and 8 days incubation in a CO2  incubator. CFU-
Mk colony counts increased from day 5 and reach their peak on day 7 and then declined on day 8. 
Mean colony counts from 3 separate experiments, evaluated in triplicate in each experiment.  Data 
shown is Mean +/- SEM. 
 
Culture Plate Number Experiment No 
Day 5 Day 6 Day 7 Day 8 
Culture  1 2 3 1 2 3 1 2 3 1 2 3 
1 3 6 4 10 7 4 17 24 27 18 15 20 
2 5 3 6 13 14 8 17 19 18 14 20 15 
3 4 8 9 10 12 16 22 27 29 14 18 16 
Mean 5 10 18 16 
SEM 2 5 4 7 
Table 3. 2  Optimum Incubation time for Murine CFU-Mk Colonies Using Megacult-C 
Culture Medium with cytokines IL-3 and Tpo. 
The CFU-Mk colony counts per well following 5, 6, 7 and 8 days incubation in a CO2  incubator. CFU-
Mk colony counts increased from day 5 and reach their peak on day 7 and then declined on day 8.  
 
As shown in the figure 3.1, the optimal day for counting CFU-Mk colonies was Day 7.  
Furthermore the number of CFU-Mk colonies present on Day 7 ranged from 14 to 21, giving a 
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mean CFU-Mk colony count of 18. As the variation in colony counts between occasions was 
not (> +/- 2SD), the standard deviation of the triplicate counts on each occasion was 
considered acceptable.  Additionally, the number of colonies that were grown in this culture 
system was quite low compared to the number of colonies observed in similar cultures by 
other researchers (Berthier, 1993). The assay system required further work to try to increase 
the number of colonies. 
3.3.2 Alkaline Phosphatase Anti Alkaline Phosphatase (APAAP) Staining For 
the Identification of CFU-Mk Colonies 
 
APAAP staining was conducted on CFU-Mk colonies to confirm their cell lineage, using 
CD41 as the lineage specific colony marker. The CFU-Mk colonies were identified by the 
presence of dark red reaction product at the CD41 (gpIIb/IIIa) antigen site (Figure 3.2).    
Additionally negative controls were set up on each occasion.  No APAAP reaction products 
were seen when either anti-mouse CD41 antibody was omitted (Figure 3.3) or when an isotype 
control antibody was substituted for the anti-mouse CD41 antibody (Figure 3.4). 
 
 
 
Figure 3. 2 (a, b and c) CFU-Mk Colonies Identified by the Presence of Dark Red 
Reaction Product at the CD41 (GpIIb/IIIa) Antigen Site. 
APAAP dark red staining indicating CD41 expression on CFU-MK colonies (x 100 
objective), following 7 days culturing in CFU-Mk clonogenic cultures. 
 
a 
b c 
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Figure 3. 3  Negative Control: Anti-CD41 Replaced with Isotype Control 
Antibody 
APAAP staining of CFU-Mk colonies no dark red granules present (x100 objective), 
following 7 days culturing in CFU-Mk clonogenic cultures. 
  
 
 
Figure 3. 4  Negative Control: Anti-CD41 Omitted 
APAAP staining of CFU-Mk colonies no dark red granules present (x100 objective) 
following 7 days culturing in CFU-Mk clonogenic cultures. 
 
 
3.3.3 Pre-Selection of Pluripotent Stem Cells 
 
The mononuclear cell separation removes mature erythrocytes and granulocytes from the bone 
marrow sample.  The mononuclear layer is a heterogeneous cell population of pluripotent 
progenitor cells; lineage committed cells as well as mature monocytes and macrophages.   Pre-
selection of pluripotent stem cells would ensure that all lineage-committed stem cells were not 
added to the culture system. The effect of pre- selection of pluripotent stem cells (identified by 
the cell surface phenotype Sca –1 +, CKit + and cell lineage specific –low), from the 
mononuclear cell population prior to addition to the CFU-Mk assay system was investigated. 
61 
The number of CFU-Mk colonies grown in this series of experiments ranged between 28 and 
34 colonies (Figure 3.5) and the CFU-Mk colony counts are shown in table3.3. Paired t test 
statistical analysis was performed to elucidate the significance of any difference in number of 
megakaryocytic colonies resulting from the pre-selection. The statistical analysis indicated 
that the increase in colony numbers with the introduction of pre-selection of pluripotent 
progenitor cells was significant at p<0.01.  Furthermore, the intra and inter assay variation was 
within +/-2SD.   
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Figure 3. 5 Effect of Pre- Selection of Pluripotent Progenitor on CFU-Mk Colony 
Numbers 
The CFU-Mk colony counts per well following pre- selection of pluripotent stem cells (identified by the 
cell surface phenotype Sca –1 +, CKit + and cell lineage specific –low), from the mononuclear cell 
population prior to addition to the CFU-Mk clonogenic media. The number of CFU-Mk colonies grown 
ranged between 28 and 34 colonies. Mean colony counts from 3 separate experiments, evaluated in 
triplicate in each experiment are provided. Data shown are mean +/- SEM 
 
Culture Plate Number Experiment No 
1 2 3 Mean CFU-Mk 
Colony count / well 
for each 
experiment 
1 30 36 39 35 
2 25 34 26 28 
3 33 30 27 30 
Table 3. 3 Effect of Pre- Selection of Pluripotent Progenitor on CFU-Mk Colony 
Numbers 
The CFU-Mk colony counts per well following pre- selection of pluripotent stem cells (identified by the 
cell surface phenotype Sca –1 +, CKit + and cell lineage specific –low), from the mononuclear cell 
population prior to addition to the CFU-Mk clonogenic media. The number of CFU-Mk colonies grown 
ranged between 28 and 34 colonies.  
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3.3.4 Effect of Recombinant Murine Interleukin-6 (rmIL-6) on Colony Numbers 
 
In this investigation, an evaluation of the effect of adding 0.1mL of rm IL-6 (10ng/mL) on 
megakaryocytic colony numbers was determined. In vitro murine Megakaryocyte cultures 
were conducted with and without rmIL-6.  Additionally, pre-selection of pluripotent stem cells 
and staining of CFU-Mk colonies, using APAAP, to aid in the morphological identification of 
CFU-Mk was conducted as previously described. 
The addition of rmIL-6 resulted in a statistically significant increase in the number of CFU-
Mk colonies from 29 (without IL-6) to 41 (Figure 3.6). The CFU-Mk colony counts with and 
without the addition of IL-6 are shown in Table 3.4. 
 
 Mean CFU-Mk Colony count per well 
Culture I.D. 1 2 3 4 5 6 
Without mIL-6 
Addition 26 31 25 31 32 29 
With mIL-6 Addition 40 45 41 43 38 39 
Table 3. 4  Comparison of Colony Forming Units-Megakaryocytic Counts with and Without 
Murine IL-6 Addition   
The CFU-Mk colony number achieved with and without the addition of rmIL-6.  0.1mL of rm IL-6 at a 
concentration of 10ng/mL was added. Addition of mIL-6 resulted in an increase in CFU-Mk colony 
counts.    
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Figure 3. 6 Comparison of Colony Forming Units-Megakaryocytic Counts with and 
Without Murine IL-6 Addition   
The effect on CFU-Mk colony number achieved with and without the addition of mLI-6.  0.1mL of rm IL-
6 at a concentration of 10ng/mL was added. Addition of mIL-6 resulted in an increase in CFU-Mk 
colony counts.   * Indicates p<0.01 of with IL-6 cultures compared with without IL-6 addition cultures.  
Mean colony counts from 3 separate experiments, evaluated in triplicate in each experiment are 
shown.  Data shown are mean +/- SEM. 
3.3.5 Identification of Lineage Specific Haematopoietic Effects, using 
Essential Thrombocythemia (ET) Treatment Compounds  
 
The effect of the 4 compounds, (Vincristine (VC), Vinblastine (VB), Hydroxyurea (HU), and 
Anagrelide (A)) on granulocyte/ monocyte, erythrocyte and megakaryocyte maturation was 
assessed in short-term cultures, and data was expressed as IC50 values (the concentrations at 
which in vitro colony growth was inhibited by 50%).  The change in colony counts for the 
granulocyte/ monocyte, erythrocyte and megakaryocyte cell lineages are shown in Figures 3.7 
– 3.9, respectively.  Moreover, the CFU-GM, BFU-E and CFU-MK colony counts at each 
concentration of each ET compound evaluated are shown in tables 3.6 to 3.10. 
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Experiment 
No. 
Concentration  
(uM) 
CFU-GM Colony counts /well 
following treatment with 
vincristine 
CFU-GM Colony counts /well 
following treatment with 
vinblastine 
1 Culture  No. 1 2 3 1 2 3 
 0 53 48 55 58 48 52 
 0.1 32 43 35 41 35 45 
 1 39 27 29 29 21 28 
 10 19 24 25 20 16 19 
 100 11 17 9 10 5 7 
 1000 5 2 1 2 0 3 
2 0 52 55 50 60 48 51 
 0.0001 N/T N/T N/T N/T N/T N/T 
 0.001 N/T N/T N/T N/T N/T N/T 
 0.1 45 30 37 49 32 37 
 1 35 28 30 31 21 27 
 10 20 19 26 24 14 18 
 100 9 11 13 10 5 6 
 1000 1 2 5 0 2 3 
3 0 56 47 53 53 59 50 
 0.1 43 36 31 37 38 42 
 1 39 29 26 22 25 30 
 10 28 19 16 13 18 22 
 100 17 10 11 4 5 10 
 1000 5 2 2 0 1 3 
 
Table 3. 5 Change in Granulocytic/Monocytic Colony Number after Treatment with Vincristine 
and Vinblastine 
The CFU-GM colony counts following treatment with 0.1 mL of vehicle control (2% (v/v) DMSO), or 
vincristine or vinblastine at concentrations 0.1 to 1000μM.  The cultures were incubated for 10 days 
and the number of CFU-GM colonies determined using an inverted microscope. A reduction in the 
colony counts with an increase in compound concentration was noted 
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Experime
nt No. 
Concentration 
(uM) 
CFU-GM Colony counts /well 
following treatment with 
Hydroxyurea 
CFU-GM Colony counts /well 
following treatment with 
Anagrelide 
1 Culture No 1 2 3 1 2 3 
 0 48 52 55 50 56 47 
 0.0001 N/T N/T N/T 43 45 38 
 0.001 N/T N/T N/T 38 37 33 
 0.1 40 38 43 41 36 35 
 1 32 29 36 31 29 27 
 10 25 22 27 27 22 22 
 100 14 16 17 23 15 14 
 1000 3 0 5 15 10 11 
 10000 N/T N/T N/T 1 2 2 
2 0 52 51 47 44 49 56 
 0.0001 N/T N/T N/T 38 41 43 
 0.001 N/T N/T N/T 38 40 40 
 0.1 44 47 33 34 37 40 
 1 37 35 27 29 30 33 
 10 28 26 23 20 25 27 
 100 15 13 14 19 22 22 
 1000 1 5 4 11 13 15 
 10000 N/T N/T N/T 1 2 3 
3 0 50 53 48 50 47 56 
 0.0001 N/T N/T N/T 47 40 40 
 0.001 N/T N/T N/T 42 41 38 
 0.1 43 39 40 37 36 35 
 1 31 34 36 29 34 30 
 10 24 21 28 22 26 25 
 100 11 17 14 16 20 18 
 1000 2 2 5 11 14 14 
 10000 N/T N/T N/T 1 5 1 
Table 3. 6 Change in Granulocytic/Monocytic Colony Number after Treatment with Hydroxyurea 
and Anagrelide  
The CFU-GM colony counts following treatment with 0.1 mL of vehicle control (2% (v/v) DMSO), or 
anagrelide or hydroxyurea at concentrations 0.0001 to 1000μM.  The cultures were incubated for 10 
days and the number of CFU-GM colonies determined using an inverted microscope; Not tested (NT).  
A reduction in the colony counts with an increase in compound concentration was noted. 
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Experiment 
No. 
Concentration 
(uM) 
CFU-E Colony counts /well 
following treatment with 
Vincristine 
CFU-E Colony counts /well 
following treatment with 
Vinblastine 
1 Culture No 1 2 3 1 2 3 
 0 77 75 80 71 85 75 
 0.1 80 85 83 65 61 60 
 1 72 75 71 50 55 48 
 10 57 55 61 36 33 39 
 100 37 34 38 16 11 14 
 1000 15 11 15 1 0 0 
2 0 74 79 75 71 78 74 
 0.0001 N/T N/T N/T N/T N/T N/T 
 0.001 N/T N/T N/T N/T N/T N/T 
 0.1 80 83 79 62 64 60 
 1 72 76 69 51 55 50 
 10 58 55 51 31 34 30 
 100 38 33 37 15 12 14 
 1000 15 18 12 0 0 0 
3 0 76 81 72 75 70 73 
 0.0001 N/T N/T N/T N/T N/T N/T 
 0.001 N/T N/T N/T N/T N/T N/T 
 0.1 81 85 79 62 63 60 
 1 70 72 74 50 54 51 
 10 53 59 56 29 36 34 
 100 37 33 36 13 17 13 
 1000 17 15 13 0 1 0 
 
Table 3. 7 Change in Erythroid Colony Number after Treatment with Vincristine and Vinblastine  
The BFU-E colony counts following treatment with 0.1 mL of vehicle control (2% (v/v) DMSO) or 
vincristine or vinblastine (0.1 to 1000μM).  The cultures were incubated for 10 days and the number of 
BFU-E colonies determined using an inverted microscope. A reduction in the colony counts with an 
increase in compound concentration was noted. 
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Experiment 
No. 
Concentration 
(uM) 
CFU-E Colony counts /well 
following treatment with 
Hydroxyurea 
CFU-E Colony counts /well 
following treatment with 
Anagrelide 
1 Culture No 1 2 3 1 2 3 
 0 73 71 74 72 77 71 
 0.0001 N/T N/T N/T 71 70 71 
 0.001 N/T N/T N/T 71 71 73 
 0.1 60 65 62 64 66 59 
 1 47 41 44 58 57 51 
 10 31 28 32 50 51 51 
 100 7 30 7 44 44 43 
 1000 0 0 0 35 36 39 
 10000 N/T N/T N/T 16 18 18 
2 0 73 75 71 72 77 69 
 0.0001 N/T N/T N/T 71 71 70 
 0.001 N/T N/T N/T 74 71 71 
 0.1 62 61 65 63 61 64 
 1 44 48 40 53 58 56 
 10 29 31 32 50 49 53 
 100 3 9 5 44 46 45 
 1000 0 1 0 39 36 36 
 10000 N/T N/T N/T 17 14 19 
3 0 74 74 71 71 76 70 
 0.0001 N/T N/T N/T 71 68 74 
 0.001 N/T N/T N/T 71 70 71 
 0.1 61 63 65 66 61 60 
 1 47 40 45 56 55 53 
 10 32 29 33 50 48 52 
 100 5 4 9 44 48 45 
 1000 0 0 0 38 38 37 
 10000 N/T N/T N/T 18 15 19 
Table 3. 8 Change in erythroid colony number after treatment with Hydroxyurea and Anagrelide 
The BFU-E colony counts following murine clonogenic culture treatment with vehicle control (2% (v/v) 
DMSO) and with vehicle control (2% (v/v) DMSO), or hydroxyurea or anagrelide (0.0001 to 1000μM).  .  
The cultures were incubated for 10 days and the number of BFU-E colonies determined using an 
inverted microscope. . A reduction in the colony counts with an increase in compound concentration 
was noted; Not tested (NT). 
 
 
 
 
 
 
 
 
 
 
68 
 
Experiment 
No. 
Concentration 
(uM) 
CFU-Mk Colony counts 
/well following treatment 
with Vincristine 
CFU-Mk Colony counts 
/well following treatment 
with Vinblastine 
1 Culture No 1 2 3 1 2 3 
 0 46 44 48 44 47 40 
 0.1 45 47 46 46 43 48 
 1 46 41 41 38 35 40 
 10 31 28 27 30 26 33 
 100 22 19 27 15 17 15 
 1000 5 7 7 4 9 4 
2 0 45 48 40 44 47 47 
 0.1 44 43 47 44 49 41 
 1 40 44 43 39 37 43 
 10 29 27 31 28 32 29 
 100 19 22 25 17 17 15 
 1000 4 8 5 5 6 6 
3 0 44 43 46 47 48 41 
 0.1 46 43 44 44 48 39 
 1 40 45 44 39 37 40 
 10 31 29 29 26 30 29 
 100 20 24 25 14 17 18 
 1000 7 4 9 4 8 6 
Table 3. 9 Change in Megakaryocytic Colony Number after Treatment with Vincristine and 
Vinblastine 
The CFU-Mk colony counts following treatment with 0.1mL of vehicle control (2% (v/v) DMSO), or 
vincristine or vinblastine (0.1 to 1000μM). The cultures were incubated for 10 days and the number of 
CFU-Mk colonies determined using an inverted microscope. A reduction in the colony counts with an 
increase in compound concentration was noted 
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Experiment 
No. 
Concentration 
(uM) 
CFU-Mk Colony counts /well 
following treatment with 
Hydroxyurea 
CFU-Mk Colony counts /well 
following treatment with 
Anagrelide 
1 Culture No. 1 2 3 1 2 3 
 0 45 40 47 44 49 41 
 0.0001 N/T N/T N/T 45 48 46 
 0.001 N/T N/T N/T 45 47 49 
 0.1 50 59 53 38 45 44 
 1 47 49 44 30 31 18 
 10 39 37 39 16 12 10 
 100 27 33 32 11 8 19 
 1000 17 14 17 9 7 11 
 10000 N/T N/T N/T 0 2 0 
2 0 41 49 46 44 48 48 
 0.0001 N/T N/T N/T 40 48 45 
 0.001 N/T N/T N/T 50 40 49 
 0.1 51 59 52 40 44 41 
 1 44 49 47 20 20 25 
 10 36 39 39 13 18 16 
 100 27 33 34 10 14 8 
 1000 18 19 10 8 8 14 
 10000 N/T N/T N/T 1 0 1 
3 0 46 43 49 48 40 41 
 0.0001 N/T N/T N/T 44 48 45 
 0.001 N/T N/T N/T 46 46 42 
 0.1 59 51 56 40 41 47 
 1 50 44 49 26 22 20 
 10 39 33 40 14 17 10 
 100 35 26 25 10 11 14 
 1000 19 14 12 9 10 11 
 10000 N/T N/T N/T 1 1 1 
Table 3. 10 Change in Megakaryocytic Colony Number after Treatment with Hydroxyurea and 
Anagrelide 
The CFU-Mk colony counts following murine clonogenic culture treatment with 0.1 mL of vehicle 
control (2% (v/v) DMSO), or hydroxyurea or Anagrelide(0.1 to 1000μM). Not tested (NT). The cultures 
were incubated for 10 days and the number of CFU-Mk colonies determined using an inverted 
microscope; NT-not tested. A reduction in the colony counts with an increase in compound 
concentration was noted 
 
 
Examples of granulocytic/ monocytic, erythroid and megakaryocytic colonies are shown in 
Figures 3.10 – 3.12.    A reduction in the colony counts with an increase in compound 
concentration was noted in all the cell lineages with all the compounds evaluated. 
Interestingly, different IC50 values were obtained for the granulocyte/ monocyte, erythrocyte 
and megakaryocyte cell lineages with the same reference compound (Table 3.11). Differences 
in the sensitivities of the cell lineages towards the other reference compounds, evaluated based 
on their IC50 values is also shown in table 3.3. For example, 50% inhibition of 
megakaryocytic colonies was achieved at a concentration of 88.6μM with anagrelide, whereas 
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greater than 10-fold higher concentration of anagrelide was required to inhibit the granulocyte/ 
monocyte (1210μM) and erythrocyte (3540μM) colony counts by 50%. Furthermore, the data 
also shows that some compounds demonstrated no difference in sensitivity towards specific 
cell lineages.  For example, IC50 concentrations for vincristine are similar for the granulocytic 
/ monocytic and erythroid lineages. 
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Figure 3. 7 Change in granulocytic/monocytic colony number after treatment 
with reference compounds 
The change in the mean colony counts following CFU-GM culture treatment with vehicle 
control (2% (v/v) DMSO), Vincristine (VC), Vinblastine (VB), Hydroxyurea (HU), and 
Anagrelide (A).  A concentration dependant decrease in CFU-GM colony count was noted.  VB 
and VC demonstrated specificity towards the granulocytic/monocytic lineage with AN 
demonstrating the least specificity to the granulocytic/monocytic lineage. CFU-GM colony 
counts from 3 separate experiments, with each concentration evaluated in triplicate are shown. 
Data shown as Mean +/- SEM.  Mean vehicle CFU-GM (for all reference compounds) control 
colony counts 51 (+/- 12). 
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Figure 3. 8 Change in erythroid colony number after treatment with reference 
compounds 
The change in the mean colony counts following BFU-E culture treatment with vehicle control (2% (v/v) 
DMSO), Vincristine (VC), Vinblastine (VB), Hydroxyurea (HU), and Anagrelide (A). A concentration 
dependant decrease in BFU-E colony count was noted. VB and VC demonstrated specificity towards 
the erythrocytic lineage with AN demonstrating the least specificity to the erythrocytic lineage. Mean 
colony counts from 3 separate experiments, with each concentration evaluated in triplicate. Data 
shown as Mean +/- SEM. Mean vehicle control (for all reference compounds) BFU-E colony counts 76 
(+/- 18) 
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Figure 3. 9 Change in megakaryocytic colony number after treatment with reference 
compounds 
The change in the mean colony counts following CFU-Mk culture treatment with vehicle control (2% 
(v/v) DMSO), Vincristine (VC), Vinblastine (VB), Hydroxyurea (HU), and Anagrelide (A) A concentration 
dependant decrease in CFU-Mk colony count was noted. AN, VB and VC demonstrated specificity 
towards the megakaryocytic lineage with HU demonstrating the least specificity to the megakaryocytic 
lineage. Mean colony counts from 3 separate experiments, with each concentration evaluated in 
triplicate. Data shown as Mean +/- SEM. Mean vehicle control (for all reference compounds) CFU-Mk 
colony count 44 (+/- 19). 
 
 
Figure 3. 10 Murine Granulocytic/ Monocytic Colony  
A phase contrast of methylcellulose based culture-showing star shaped CFU-GM 
colony (objective x 100) 
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Figure 3. 11 Murine Erythroid Colony 
A phase contrast of methylcellulose based culture showing spherical BFU-E colony of 
cells with slight red pigmentation (objective x 100)  
 
 
Figure 3. 12 Murine Megakaryocytic Colony  
A phase contrast of collagen based culture showing CFU-Mk colony (objective x 100)  
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Compound IC50 in μM  
Growth Inhibition of cell lineages  
 
Vincristine     34.3                         28                        3.05 
     E                 =               GM            <                Mk  
 
Vinblastine     13.6                       12.2                        4.34 
     GM               =               Mk           <                  E 
 
Hydroxyurea      632                        489                       270                        
     Mk               <               E            <                 GM 
 
Anagrelide     3540                      1210                       88.6   
       E              <               GM              <               Mk 
 
 
Table 3. 11 Growth Inhibition of the Different Cell Lineages towards the 4 Reference 
Compounds  
The IC50 growth inhibition concentrations of each compound tested and the relative haemopoietic cell 
lineage sensitivity towards each compound.  Mk = Megakaryocytes, GM = Granulocytic/Monocytic E = 
Erythroid = similar lineage specificity to compound, based on IC 50 concentration < reduced lineage 
specificity to compound, based on IC 50 concentration.  IC50 concentration determined using 
Robosage (automated curve fitting Microsoft add-in program). 
 
 
3.4 Discussion 
3.4.1 Use of Recombinant Human Thrombopoietin 
 
Culture media containing recombinant human thrombopoietin had been described to support 
the development of murine BALB/c megakaryocytic colonies by several researchers. Indeed 
the initial investigations demonstrated that the combination of cytokines IL-3 and Tpo together 
with the addition of collagen encouraged maturation and differentiation of the haemapoietic 
stem cells into megakaryocytic lineage.  The identity of the colonies seen was confirmed using 
APAAP staining, with an antibody raised against glycoproteins IIIa/ IIb.    Also the use of 
APAAP negative controls ensure that the positive staining seen was not due to non-specific 
rather than specific binding to the target antigen.  However, the number of colonies grown was 
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disappointing.  Furthermore due to the low colony numbers and the high inter assay variability 
the evaluation of potential megakaryocytic toxicity would be impossible.  Further work was 
required to increase the number of colonies grown.  
 
3.4.2 The Effect of Purifying the Cell Population and Using Recombinant 
Murine Thrombopoietin 
 
In this series of experiments a change to the culture protocol was made to try and improve the 
CFU-Mk colony growth.  Additionally, pre-selection of haematopoietic stem cells was 
introduced to ensure that only totipotent stem cells were added to the culture system.  This was 
achieved by the introduction of positive selection of haematopoietic stem cells (Ckit +) from 
the mononuclear cell population.  More importantly the pre-selection of haematopoietic stem 
cells standardised the number of progenitor cells added to the cultures on each occasion. The 
introduction of this change increased the number of colonies from a maximum of 18 in the 
initial experiments to 31 CFU-Mk colonies, a 1.7-fold increase.  Also the inter assay variation 
of colony counts per well was reduced to within +/- 2SD.  Once again, the APAAP staining 
enabled confirmation of the identity of the cell lineage. 
3.4.3 The Effect of Murine Interleukin-6 
 
Murine interleukin-3 (mIL-3) and murine interleukin-6 (mIL-6) are reported to work in 
synergy to increase the number of megakaryocytic colonies (Drayer et al, 2000).  This series 
of experiments showed that the addition of mIL-6 leads to a further statistically significant 
increase in the number of CFU-Mk colonies.  
 
To achieve a robust culture system with optimal maturation and differentiation of the 
haematopoietic stem cell into the megakaryocytopoietic cell lineage, pre-selection of 
haematopoietic stem cells for addition to the cultures, use of murine thrombopoietin and 
murine IL-6 and IL-3 were demonstrated to be essential.  
 
The work carried out on CFU-Mk clonogenic culture method prior to its use in the evaluation 
of ET reference compounds demonstrates the importance of ensuring that the method 
irrespective of the manufacturers’ reassurances is fully validated prior to use.  A similar 
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validation exercise was carried out on the murine CFU –GM and BFU-E clonogenic method, 
prior to the initiation of this thesis.   
 
3.4.4 Lineage Specific Haematopoietic Effects, using Essential 
Thrombocythemia (ET) Treatment Compounds  
 
The GM/E and Mk clonogenic haematopoietic cultures enabled the evaluation of the 
haematotoxicity of compounds towards the granulocytic/monocytic, erythroid and 
megakaryocytic cell lineages.  The IC50 data and the ranking order demonstrated that some of 
the compounds evaluated had shown selective toxicity towards specific cell lineages.  
Anagrelide was most specific (in terms of inhibiting colony numbers) towards the 
megakaryocytic lineage and the least towards the granulocytic/monocytic and erythroid 
(myeloid) cell lineage.  The reduction in colony count of CFU-GM and BFU-E was not very 
marked and in order to determine the IC50 concentrations for these lineages the concentration 
range used was extended. Vincristine also demonstrated a specificity (in terms of inhibiting 
colony numbers) towards the megakaryocytic lineage, whereas vinblastine and hydroxyurea 
showed specificity (in terms of inhibiting colony numbers) towards the granulocytic 
/monocytic and erythroid cell lineages, respectively.   The difference in lineage specificity 
between vincristine and vinblastine is surprising, particularly as both are routinely used in the 
treatment of ET.  Further work would be required to determine the reasons for this difference.    
 
In addition, to fully validate the murine CFU-Mk clonogenic assay it would have been of 
value to include compounds that are not used in the treatment of ET, but have, in vivo, been 
shown to cause reduction in platelet counts as well as compounds that are generally known not 
to cause haematotoxicity.  A further validation of the CFU-Mk clonogenic assay was carried 
out by a sandwich student.  In this validation, a further 7 compounds were evaluated including 
AZT, chloramphenicol, methotrexate as well as vincristine and vinblastine (data not shown in 
the thesis).  The fuller validation demonstrated chloramphenicol was the least specific towards 
the megakaryocytic lineage followed by methotrexate.  Vincristine once again demonstrated 
the greatest sensitivity towards the megakaryocytic lineage. 
 
77 
Limited in vitro GM/E and MK clonogenic human culture data is available with any 
haematotoxic compounds let alone compounds used for the treatment of ET. A similar lineage 
specificity to that demonstrated in the in vitro short -term murine haematopoietic cultures is 
found, although the culture conditions and compound exposure times varied (Oertel MD 
1998). 
 
All of the compounds tested are known to decrease megakaryocyte and myeloid cell lineages 
in vivo in man (Gibbs and Sorensen 2000; Moss et al 1999; Stubbs and Swaney 1996; Tefferi, 
2006; Petrides, 2006). Both anagrelide and vincristine have been shown to possess the most 
potent megakaryocyte inhibiting properties clinically. Clinical trial data demonstrated that AN 
doses ranging between 1-3mg given every 8 hours for 6 to 9 days was caused a profound 
reduction in platelet count with a nadir of 20 x10 9/ l occurring within 10 and 12 days of 
commencement of treatment (SBA, 1997).   The mean Cmax at 2mg/kg (once daily) was 
23.6nM (734ng/mL). The murine CFU-Mk colony IC50 concentration 88.6μM was 3,754 
times higher than the human in vivo concentration at a dose of 1mg/kg.  This disparity is 
indicative of AN having a greater affinity towards the human c-mpl (TPO) receptor than the 
murine c-mpl (TPO) receptor as suggested by McCarty et al (2006).   
 
Hydroxyurea and vinblastine although used to treat ET, are known to show greater specificity 
to the myeloid cell lineages (Gibbs and Sorensen 2000: Tefferi, 2006).  Therefore, the current 
results from in vitro assays agree with the lineage specificity noted in humans in vivo.   
 
The mean Cmax concentration of HU at a clinical dose of 50mg (total human dose) is 8.42mM 
(3.1mg/mL) (Nicholas et al, 1998).  This concentration is 13 fold greater than the murine 
megakaryocytic IC50 concentration. In this case greater sensitivity to inhibition of Mk colony 
growth was demonstrated by the murine haematopoietic cells, suggesting that murine 
haematopoietic cells are more sensitive to HU.   Unfortunately, exposure data following in 
vivo dosing in ET patients with vinblastine and vincristine is not available for comparison 
with the in vitro data generated in this thesis.  
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The cultures may be capable of some metabolism primarily through the action of 
macrophages, although there number would be very low following positive selection for 
pluripotent stem cells prior to addition to clonogenic cultures. However, media from the 
treated cultures were not collected for the determination of concentration of the ET reference 
compounds at the end culturing period.  Therefore a clear understanding the dynamics of the 
test compound in the cultures is not known.   It is important to note that the semi-solid methyl 
cellulose based media used in the clonogenic cultures would also make treatment 
concentration checks at the end of the culturing period difficult as well as affect the 
homogeneity of the compound concentrations.  
In summary, the current results indicate that in vitro murine GM/E clonogenic cultures could 
potentially aid in the ranking of new drug candidates and may facilitate compound safety 
evaluation.   
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Chapter 4 
4.1 Experimental Part 2: Long Term Bone Marrow Cultures 
(LTBMC) 
 
In LTBMC most components of haematopoiesis are reproduced in vitro. In fact the unique 
feature of these cultures is that sustained haematopoiesis occurs in the absence of added 
growth factors but is absolutely dependent upon the establishment of an adherent layer of bone 
marrow derived stromal cells. The stromal cells provide the appropriate environment to 
promote the survival, self-renewal, proliferation, and differentiation of the haematopoietic 
progenitor cells (Keil et al, 2000).  
 
The formation of the multi- adherent cell layer takes place in four to six weeks of culture. 
Primitive haematopoietic cells added to the developed stromal layer migrate beneath and 
between the stromal cells where, in intimate association with the stromal cells, haematopoiesis 
is established (Daniel, 1989). Furthermore the most immature cells remain within the adherent 
layer and as these cells divide and mature some of the progeny are released into the growth 
medium. Once the stromal layer is developed, freshly harvested, pre-selected progenitor cells 
from primary bone marrow can be added to the cultures.  It is the proliferation and 
development of these freshly harvested cells that are supported by the already established 
stromal layer. Weekly collection of non-stromal cells enables the determination of their cell 
lineage by GM/ E and Mk clonogenic cultures and / or flow cytometry analysis. 
 
Thus, LTBMC provides a unique system with which to investigate effects on several aspects 
of haematopoiesis that can not be achieved using just clonogenic assays.  For example, cell 
adhesion interactions that bind progenitor cells and their progeny to specific stromal elements 
as well as the synthesis, secretion, and presentation of growth-stimulatory and growth-
inhibitory factors by stromal cells can be studied (Daniel et al, 1989). 
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4.1.1 In Vitro Characterization of Cord Blood Cells 
 
Cord blood has been found to contain high concentrations of haematopoietic stem cells, higher 
than that found in adult bone marrow (Broxmeyer et al, 1992).  It has also been demonstrated 
that both term and pre-term umbilical cord contain a significantly higher number of early and 
lineage committed progenitor cells than in adult peripheral blood (Broxmeyer et al, 1990). In 
vitro assays conducted with human cord blood derived haematopoietic stem cells give rise to 
all the cell lineages, when exposed to the appropriate cytokine cocktails (Huss, 1993). 
Comparison of cord blood and bone marrow in vitro cell lineages demonstrated that most 
colonies were monocyte/macrophage colonies (60.0 +/- 4.6%) in cord blood derived cultures, 
whereas those from bone marrow were largely granulocyte colonies (88.3 +/- 6.2%). The 
differences in growth curve, colony size, and turnover state of CFUs between cord blood and 
bone marrow seemed, in part, to result from the dominance of monocyte/macrophage colony-
forming cells in cord blood. The cell cycling rate of CFUs in cord blood was remarkably lower 
than that in bone marrow (De Bruyn et al, 1995; Hofmeister et al, 2007). From these results, it 
seems clear that CFUs in cord blood may differ in some aspects from those of bone marrow 
derived haematopoietic cells.  Overall, however, the cord blood derived stem cells are 
considered to be representative of bone marrow derived stem cells.  
 
Comparison of the capacity to differentiate in vitro into various cell lineages derived from 
frozen (cryopreserved) and fresh cord blood cells have also been conducted.  The results 
suggest that morphologically and phenotypically (surface cell antigen expression) the colonies 
from fresh and cryopreserved cord blood stem cells are identical (Kobylka, et al, 1998; 
Hofmeister et al, 2007). 
 
4.1.2 Haematopoietic cell phenotype determination by flow cytometry 
 
In the early 1980's surface antigens, were identified on the outer and inner surface of all 
leukocytes.  Furthermore some of these surface antigens were specific for specific cell 
populations.  Monoclonal antibodies to the surface antigens are commercially produced and 
assigned a so-called ‘cluster of differentiation’ (CD) specific for the cell type and /or function 
of the antigen (Bernard, 1984).  The antibodies are conjugated to fluorescent molecules such 
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as Fluorescein isothiocyanate (FITC).  These fluorescent molecules have the ability to absorb 
light of specific wavelengths and simultaneously emit light of longer wavelength.    
Furthermore the emission wavelengths are specific for the fluorescent probes.  Flow cytometry 
exploits the light absorption and emission properties of the conjugated antibodies to enable 
rapid analysis of the surface characteristics of a large number of cells.  Additionally the use of 
a cell fixative at the end of the procedure stabilizes the binding. 
 
Flow cytometry enables the simultaneous measurement of several characteristics of cells in 
suspension, as they flow through a fluidic stream.  Cells are aspirated into the cytometer at a 
set rate (60µl /minute) and hydrodynamically focused so that each single cell passes through 
an argon laser beam, sensing point (Delude, 2005).  Light that is reflected and refracted by the 
cell enables determination of the relative size and relative complexity of the cell.  Additionally 
light spontaneously emitted by the attached fluorochrome (conjugated antibody) is detected by 
wavelength band specific detectors.  The data from these detectors enables the determination 
of the percentage of cells expressing the specific surface antigen.   
 
4.1.3 Aims of the Investigation 
 
The aim of this investigation was to characterize the cells in the human cord blood (hCB) and 
murine LTBMC during the stromal development phase and after the confluent stromal layer 
was inoculated with haematopoietic stem cells (CD117 positive cells). Furthermore, both the 
adherent (stromal) cells and the non-adherent cells from the LTBMC were characterized, 
using light microscopy and flow cytometry.  
4.2 Methods  
 
4.2.1 Murine Long Term Bone Marrow Cultures-Standard Conditions 
The method employed is described in chapter 2 (section 2.2.5) and the aspiration of murine 
bone marrow, pre-selection of mononuclear  BM cells and the selection of CKit positice cells 
are described in Appendix A. 
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4.2.3 Murine LTBMC  
 
The method employed  is described in chapter 2 (section 2.2.5) 
 
4.2.4 Cytospin Technique 
 
The non-adherent cells were cytospun onto microscope slides as described in Chapter 2 
(section 2.7).    
4.2.5 May Grunwald-Giemsa Staining For Light Microscopy 
 
The cytospun slides were stained with May-Grunwald-Giemsa as described in Chapter 2 
(section 2.2.10).  
4.2.6 Murine Long Term Bone Marrow Cultures - Modified Conditions 
 
In a series of experiments 10μL of IL-6 (5ng/mL) and 100μL of SCF (25ng/mL) were added 
to the Myelocult media.  The remaining procedure was the same as described above. The 
addition of the cytokines was to reduce the variability of these cytokines present in the 
Myelocult media. Both these cytokines have been identified to promote healthy stromal cell 
development (Hauser et al, 1997).  Additionally SCF has been shown to aid in the rapid 
establishment of the stromal layer, and reduce the decline in progenitor cell content (Dunlop et 
al, 1993).  
 
4.2.7 Flow Cytometry Analysis    
 
The antibodies (markers) were selected to enable identification of the lineage specificity of the 
non-adherent murine and hCB derived cells, as shown in Table 4.1. and 4.2, respectively.  
Two markers conjugated to different fluorescent tags were analyzed in the same preparation 
(Table 4.1). The method employed for the cell surface antigen staining is described in Chapter 
2 (section 2.6) 
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Antibodies Target Fluorescent 
tag 
Quantity 
Added 
(Conc) 
Tube 
Rat anti- mouse 
CD117 PE 
Totipotent Stem cell FITC/Green 10μL 
(5μg/mL) 
1, 2 
and 3 
Rat anti- mouse 
Mono/Macro(F4/80)
/FITC 
Early mono/macro 
precursor 
PE/Orange 10μL 
(5μg/mL) 
1 
Rat anti- mouse 
Erythroid 
(ter119)/FITC 
Early erythroid 
precursor 
FITC/Green 10μL 
(5μg/mL) 
2 
Rat anti- mouse 
Granulocyte 
precursor/FITC 
Early granulocyte 
precursor 
PE/Orange 10μL 
(5μg/mL) 
3 
 
Table 4. 1 Lineage specific markers  
The antibodies used to identify the murine cell lineages present within the non-adherent layer of murine 
LTBMC are listed.  In addition the lineage specificity, fluorescent tag, quantity of antibody added to 
each tube is shown. 
 
 
Antibody Tube Concentration of 
Antibody 
(μg/mL) 
Expression/Target 
CD34/FITC 1 ,2 and 
3 
5 Stem cell 
CD33/PE 2 5 Mk Glycoprotein IIIb Part of 
GPIIa/IIIb complex 
CD Cmpl/PE 3  5 GP1 receptor 
CD erythroid 
/PE 
4 5 Erythroid receptor 
 
Table 4. 2 Antibodies for Receptor Expression 
The antibodies used to identify the hCB cell lineages present within the non-adherent layer of hCB 
LTBMC are listed.  In addition the lineage specificity, fluorescent tag, quantity of antibody added to 
each tube is provided.  
 
 
 
4.2.8 Murine GM/E and Mk clonogenic cultures 
 
A series of murine GM/E/ Mk clonogenic assays were used to evaluate the clonogenic ability 
of the non-adherent cells collected weekly after the inoculation of the confluent stromal layers 
with C117 positive cells.  The culture preparations and conditions employed are those 
previously outlined in chapter 2. (section 2.2.1).  0.3mL (1 x105/mL) of non-adherent cells 
was added to the Methocult medium (for the evaluation of erythroid and granulocytic cell 
lineages) and 0.3mL (1 x105/mL) of non-adherent cells was added to murine Megacult media 
84 
(for the evaluation of megakaryocytic cell lineage) as described in Chapter 2 (section 2.2.4).  
Cell count was determined using an automated cell counter (Advia 120, Bayer, USA).   
4.2.9 Preparation of cryoperserved mononuclear hCB 
 
The method employed is described in Appendix A. 
4.2.10 Viability Cell Count 
 
Cord cell viability was determined using the method described in Chapter 2 (section 2.2.8).  
 
4.2.11 Human LTBMC Medium 
 
Human cord blood cultures were utilised as described in chapter 2 (section 2.2.5). 
4.2.12 Inoculation of Confluent Stromal Layer with Fresh hCB Stem Cells (CD34 
Positive)  
 
Once a confluent stromal layer was established, the stromal layer was 'seeded' with fresh hCB 
cells. The method employed is described in Chapter 2 (section 2.2.5).   
4.2.13 hCB Clonogenic Cultures 
 
hCB clonogenic cultures as described in Chapter 2 were utilized in these experiments (section 
2.2.5). 
4.2.14 Collection of hCB Derived CFU-Mk Colonies 
 
Once the CFU-Mk cultures had been incubated for 12 days (culturing method and treatment 
with AN as described above), the culure medium was placed into BD 25mL culture tubes.  10 
mL of fresh media was added and the tubes were centrifuged for 20 minutes at 400g.  After 
centrifugation, the cells were removed washed once more as already described before carrying 
out cell counts, cell cycle analyses, ploidy analyses, cell surface receptor evaluation and 
microtubule analyses. 
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4.3  Results 
4.3.1 Murine LTBMC Using Standard and Modified Culture Conditions (Falcon 
Flasks) 
 
Freshly aspirated mouse bone marrow-derived mononuclear cells were cultured under 
standard and modified conditions.  All the cultures were set-up in Falcon T25 culture flasks, as 
recommended in the original method published by Dexter et al (1978).  Examination of the 
developing stromal layers using an inverted microscope at weekly interval revealed that the 
cells did not adhere to the Falcon flasks and by the end of six weeks a confluent stromal layer 
had not been achieved, regardless of whether standard or modified culture conditions had been 
followed.  The cells in the Falcon flasks were spherical in shape, with an occasional cluster of 
cells floating in the liquid culture media (Figures 4.1 and 4.2).  Additionally the spindle-
shaped cells (fibroblast-like cells) and flattened cells (macrophages) described by Dexter 
(1974) as being predominant components of the developing stromal layer were not observed.   
 
To ensure that the mononuclear bone marrow cells added to the LTBMC contained fibroblast-
like cells and macrophages the standard GM/E clonogenic culture was set-up.  Within four 
days of culturing spindle -shaped cells and flattened cells were observed (Figure 4.3).     
 
 
 
Figure 4. 1 Murine LTBMC 
A Hofmann modulation contrast of a murine LTBMC taken on day 21 after the addition 
of BM derived mouse mononuclear cells, using the standard LTBMC conditions 
(objective x 400) 
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Figure 4. 2 Murine LTBMC 
A Hofmann modulation contrast of a murine LTBMC taken on day 21 after the addition 
of BM derived mouse mononuclear cells using the modified LTBMC conditions 
(objective x 400) 
 
 
 
Figure 4. 3 Murine GM/E Clonogenic Assay 
A phase contrast of Fibroblast-like and flattened cells were visible after 14 days of 
culturing (objective x200) 
 
 
4.3.2 Visualization of Murine LTBMC (Standard Method), Using Nunc Culture 
Flasks 
 
In this series of experiments, the stromal layer did not firmly attach to the Falcon flask surface 
using the culture conditions and identical flask manufacturer as described by Dexter et al 
(1976).  Confluent stromal layer formation is dependent upon good adhesion between the 
adherent cells and the plastic culture vessel surface.  In this series of experiments, several 
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components of LTBMC techniques were evaluated: 
• Murine LTBMC were established using the standard culture conditions, but the media 
mixture was placed into Nunc T25 flasks.  The change in flask manufacturer was to 
evaluate if stromal development could be achieved by changing the plastic source. 
Photographs were taken weekly of the developing stromal layer, until a confluent stromal 
layer was obtained. 
• During the stromal layer development phase, between 9.0 and 9.5 mL of culture media 
was changed at weekly intervals.  The cells present in the media (non-adherent cells) 
removed from the cultures were counted.  The cells were also cytospun onto glass slides, 
fixed and stained with May Grunwald Giemsa, in order to morphologically identify the 
cells.  Photographs of the stained cells were also taken.  
 
• Once a confluent murine stromal layer was established, the stromal layer was 'seeded' with 
fresh enriched pluripotent stem cells (CD117 positive) and maintained for a period of 4 
weeks.    At weekly intervals, 9.0 -9.5 mL of the media was removed and replaced with 
fresh culture medium. The non -adherent cells, present in the media removed from the 
cultures, were counted and plated into semisolid culture medium (cell concentration 1x 104 
/ ml per plate), to evaluate differentiation into the granulocytic / monocytic and erythroid 
(myeloid) and megakaryocytic colonies after 10-12 days (short-term cultures). 
On each occasion 3 murine LTBMC were set up and the evaluation conducted on three 
separate occasions.  
 
4.3.3 Examination of Developing Murine Stromal Layer Using an Inverted 
Microscope 
 
The developing murine stromal layers were examined weekly, by phase contrast, using an 
inverted microscope. By the end of the first week, all the flasks were found to contain islands 
of cells.  Also, spindle-shaped cells (probably fibroblast-like cells) and flattened cells 
(probably macrophages) were observed in addition to round cells (probably progenitor cells), 
which were closely associated with the adherent cells. 
Small and well-haemoglobinized clusters of erythroid cells that were loosely attached to 
adherent cells were also seen. However, after the first two weeks in culture, these erythroid 
clusters were no longer found. 
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At the end of week two, the number of cells attached to the bottom of the flask seemed to have 
increased.  Moreover, by the end of the fifth week, a confluent adherent layer with persistence 
of islands of small round cells, resembling  'cobble stones',  were found in association with 
adherent cells. Also, by the fourth week, a small number of the spindle-shaped cells began to 
accumulate small droplets of lipid and were located in different regions of the culture flasks. 
 
The stromal layers achieved between 90 to 95% confluency in all cultures studied, and areas 
of active haematopoiesis and fat cells were also found irregularly distributed in the culture 
flasks. Figures 4.4 to 4.9 show the weekly development of the stromal layer. 
 
 
 
 
Figure 4. 4 Murine LTBMC: Week 1 of Stromal Layer Development   
 A phase contrast of murine LTBMC stromal layer fibroblast-like and flattened cells, 1 week 
after initiating the culture, using the standard murine LTBMC method (objective x200)  
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Figure 4. 5 Murine LTBMC: Week 2 of Stromal Layer Development                          
A phase contrast of murine LTBMC stromal layer fibroblast-like and flattened cells, on week 2, 
using the standard murine LTBMC method 
 
 
 
 
Figure 4. 6 Murine LTBMC: Week 3 of Stromal Layer Development 
   
A phase contrast of murine LTBMC stromal layer showing an increase in stromal layer 
confluency on week 3, using the standard murine LTBMC method (objective x100)  
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Figure 4. 7 Murine LTBMC: Week 4 of Stromal Layer Development 
A phase contrast of murine LTBMC stromal development at week 4; Islands of 
progenitor cells can be noted in the stromal layer (objective x400) 
 
  
 
 
Figure 4. 8 Murine LTBMC: Week 5 of Layer Stromal Development 
           
A phase contrast of a murine LTBMC stromal development, following 5 weeks of 
culturing.  A confluent stromal layer is shown. (objective x200) 
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Figure 4. 9 Murine LTBMC: Week 6 of Stromal Layer Development 
A phase contrast of murine LTBMC stromal development at week 6 of culturing.  Large 
'cobblestone' area care clearly visible (objective x100) 
 
 
4.3.4 Characterization of the Murine Non-Adherent Layer During Stromal Layer 
Development 
 
The weekly total cell counts of non -adherent murine cells declined steadily during the stromal 
layer development phase (Figure 4.10). As almost all non-adherent cells were removed each 
week, the data show that the cultures still produce non-adherent cells, but at a declining rate, 
reaching a plateau of 2.6x104 cells per week. The weekly non-adherent cell counts are shown 
in Table 4.3. 
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Figure 4. 10 Murine Stromal Layer Development: Mean Total Cell Counts Of Non-
Adherent Cells Collected  
The weekly total cell counts of non -adherent cells, during murine LTBM culture stromal cell 
development.  A steady decline in non-adherent cell numbers is noted over time.  Mean data from 
three separate experiments with each concentration evaluated in triplicate. Data shown as Mean +/- 
SEM.  SEM bars shown for each experiment, however, the bars are too small to be shown clearly in 
figure 
 
 
 
Exp. No Culture 
No. Cell count of non-adherent Cells in murine LTBMC (x103/L) 
  Day 0 Day 7 Day 14 Day 21 Day29 Day36 Day 42 
1 1 500 173 85 31.4 1.0 3.0 3.1 
 2 500 141 63 21.4 4.7 2.1 1.1 
 3 500 192 51 12.5 4.9 4.4 2.3 
2 1 500 201 63.7 35.4 6.2 3.1 3.1 
 2 500 147 49.8 24.9 4.9 2.1 1.2 
 3 500 271 88.7 17.4 3.9 2.5 3.1 
3 1 500 264 68.2 14.6 2.9 3.2 2.6 
 2 500 198 51.9 11.3 3.6 2.2 3.1 
 3 500 213 65.3 26.3 3.6 1.6 3.4 
Table 4. 3  Murine Stromal Layer Development: Mean Total Cell Counts Of Non-Adherent Cells 
Collected 
The weekly total cell counts of non -adherent cells, during murine LTBM culture stromal cell 
development.  A steady decline in non-adherent cell numbers is noted over the 42 day period. 
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4.3.5 Morphological Identification of Murine Non-Adherent Cells During 
Stromal Layer Development 
 
The non-adherent cells collected during the stromal layer development, were cyto-spun, fixed 
and then stained with May Grunwald Giemsa, in order to morphologically identify the cells.   
 
The numbers of each of the individual cell types identified declined with time in culture, but at 
different rates (Figure 4.11).  The percentage and absolute cell counts of the different lineages 
collected are shown in tables 4.4 and 4.5.  The steepest decline of the nucleated cells was 
observed for the mononuclear cell population.  This term is used to describe cells that were 
difficult to distinguish morphologically into any of the specific cell types.  Also the shallowest 
decline was noted for the monocyte/macrophage cell populations.  Erythrocytes were observed 
at day 7 only. The numbers of all the other cell types (promyelocytes, pro-monocytes, 
metamyelocytes and mono/macrophages) plateaued by day 35.  This differential decline leads 
to a change in percentages of the different cell types, as shown in Figure 4.12, with the 
monocytes/macrophages being by far the most prevalent cell type after Day 28 in culture.  
Photographs taken of the cyto- spin preparations confirm the cell types counted and examples 
are shown in Figures 4.13 and 4.14.  
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Figure 4. 11 Murine Stromal Layer Development: The Absolute Count of Different Cell 
Types Collected in the Non-Adherent Layer 
The mean absolute counts of the different cell types within the non-adherent cells identified by 
cytospinning the cells onto microscope slides and staining with May Grunwald Giemsa are shown. The 
numbers of each of the individual cell types identified declined with time in culture, but at different 
rates.  The steepest decline of the nucleated cells was observed for the mononuclear cell population.  
The shallowest decline was noted for the monocyte/macrophage cell populations.  Erythrocytes were 
observed at day 7 only. The numbers of all the other cell types (promyelocytes, pro-monocytes, 
metamyelocytes and mono/macrophages) plateaued by day 35. Mean data from three separate 
experiments.  Data shown as Mean +/- SEM.  SEM bars shown for each experiment, however, the bars 
are too small to be shown clearly in figure 
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Figure 4. 12 Murine Stromal Layer Development: The Percentage of Different Cell 
Types Collected in the Non-Adherent Layer, Stained with May Grunwald Giemsa  
The mean percentage counts of the different cell types within the non-adherent cells identified by cyto-
spinning the cells onto microscope slides and staining with May Grunwald Giemsa are shown. The 
numbers of each of the individual cell types identified declined with time in culture, but at different 
rates.  The steepest decline of the nucleated cells was observed for the mononuclear cell population.  
The shallowest decline was noted for the monocyte/macrophage cell populations.  Erythrocytes were 
observed at day 7 only. The numbers of all the other cell types (promyelocytes, pro-monocytes, 
metamyelocytes and mono/macrophages) plateaued by day 35. Mean data from three separate 
experiments.  Data shown as Mean +/- SEM. 
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Exp. No Culture day 
non-adherent 
cells collected 
Mononuclear cells 
(%) 
Promyelocytes 
(%) 
Metamyelocytes 
(%) 
Erythrocytes 
(%) 
Promonocytes 
(%) 
Monocytes 
/macrophages 
(%) 
Culture ID  1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
1 0 92 83 86 0 0 0 0 0 0 0 0 0 0 0 0 8 17 14 
2  86 95 77 0 0 0 0 0 0 0 0 0 0 0 0 14 5 23 
3  88 81 74 0 0 0 0 0 0 0 0 0 0 0 0 12 19 26 
                    
1 7 22 26 24 28 40 47 2 2 2 32 22 17 1 5 2 15 5 8 
2  27 30 29 31 44 43 2 4 0 27 17 15 4 2 3 9 3 10 
3  33 27 24 33 29 42 3 4 2 24 23 17 7 4 9 0 13 6 
                    
1 14 18 31 21 41 45 37 10 13 21 19 0 0 1 0 0 11 11 21 
2  22 14 19 36 46 44 14 18 19 16 7 2 0 2 0 12 13 16 
3  16 24 18 50 38 48 16 15 15 4 18 12 0 1 0 14 4 7 
                    
1 21 22 26 18 48 40 37 18 15 25 0 1 6 0 0 0 12 18 14 
2  20 14 13 44 50 49 15 12 17 0 2 0 0 0 0 21 22 21 
3  15 20 10 49 43 43 11 19 24 0 0 0 0 0 0 25 18 23 
                    
1 28 3 9 11 18 10 21 11 9 17 0 1 0 0 0 0 68 71 51 
2  11 4 8 16 13 24 7 15 21 2 0 0 1 0 0 63 56 47 
3  13 6 4 11 11 15 11 15 16 0 1 0 0 0 0 65 67 65 
                    
1 35 1 2 0 7 10 16 7 11 5 0 1 0 0 0 0 85 76 79 
2  1 1 0 12 18 13 6 10 6 0 0 0 0 0 0 81 71 81 
3  0 1 1 13 5 10 7 10 9 0 2 0 0 0 0 80 82 80 
                    
1 42 1 1 0 16 20 2 9 3 7 0 0 0 0 0 0 74 76 91 
2  1 2 0 14 14 11 5 3 6 1 0 0 0 0 0 79 81 83 
3  1 1 0 14 7 7 8 4 3 0 0 0 0 0 0 77 88 90 
 
Table 4. 4  Murine Stromal Layer Development: The Percentage of Different Cell Types Collected in the Non-Adherent Layer, Stained 
with May Grunwald Giemsa 
The percentage counts of the different cell types within the non-adherent cells identified by cytospinning the cells onto microscope slides and staining with May 
Grunwald Giemsa are provided. The numbers of each of the individual cell types identified declined with time in culture, but at different rates.  The steepest 
decline of the nucleated cells was observed for the mononuclear cell population.  The shallowest decline was noted for the monocyte/macrophage cell 
populations.  Erythrocytes were observed at day 7 and only very occasionally thereafter. The numbers of all the other cell types (promyelocytes, pro-monocytes, 
metamyelocytes and mono/macrophages) plateaued by day 35. 
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Exp. No Culture day 
non-adherent 
cells collected 
Mononuclear 
cells 
(x103/l) 
Promyelocytes  
(x103/l) 
Metamyelocytes  
(x103/l) 
Erythrocytes  
(x103/l) 
Promonocytes  
(x103/l) 
Monocytes 
/macrophages 
(x103/l) 
1 0 3750 0 0 0 0 0 
2  3619 0 0 0 0 0 
3  3851 0 0 0 0 0 
        
1 7 593 660 400 507 80 120 
2  632 713 415 415 61 143 
3  551 632 392 616 102 95 
        
1 14 134 321 115 0 72 77 
2  129 410 127 0 51 85 
3  145 356 116 0 89 67 
        
1 21 31 124 33 0 68 22 
2  27 93 25 0 43 30 
3  25 87 23 0 38 44 
        
1 28 1.7 5.1 4.8 0 3.1 15.1 
2  2.4 3.8 2.5 0 8.0 34.1 
3  3.1 6.0 5.5 0 6.1 21.7 
        
1 35 0.4 2.7 1.3 0 3.1 12.9 
2  0.3 3.9 2.0 0 5.3 17.8 
3  0.2 4.8 3.5 0 0.1 20.0 
        
1 42 0.3 3.7 1.1 0 8.1 18.4 
2  0.3 8.0 3.9 0 3.9 11.4 
3  0.3 4.4 2.6 0 5.0 14.8 
 
Table 4. 5  Murine Stromal Layer Development: The Absolute Count of Different Cell Types Collected in the Non-Adherent Layer  
The mean absolute counts of the different cell types within the non-adherent cells identified by cytospinning the cells onto microscope slides and staining with May Grunwald 
Giemsa are provided.  The numbers of each of the individual cell types identified declined with time in culture, but at different rates.  The steepest decline of the nucleated cells 
was observed for the mononuclear cell population.  The shallowest decline was noted for the monocyte/macrophage cell populations.  Erythrocytes were observed at day 7 only. 
The numbers of all the other cell types (promyelocytes, pro-monocytes, metamyelocytes and mono/macrophages) plateaued by day 3.
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Figure 4. 13 Non-Adherent Cells From Murine Nunc LTBMC: Week 0 
   
May Grunwald Giemsa stained  murine bone  marrow mononuclear cells on the day of harvest, 
prior to addition to LTBMC flasks.   (Objective x100) 
 
 
   
 
 
Figure 4. 14 Non-Adherent Cells From Nunc Murine LTBMC: Week 4 
May Grunwald Giemsa stained marrow mononuclear cells and monocytes non-adherent cells 
identified within the non adherent layer at week 4 during stromal layer development (objective 
x400) 
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4.3.6 Confluent Murine Stromal Layer Inoculated with Mouse CD117 Positive 
Cells 
 
At weekly intervals, murine non- adherent cells were collected, counted and plated into in vitro 
short- term cultures to evaluate differentiation into the myeloid and megakaryocytic cell 
lineages.  In all three experiments carried out, the cell count increased from the initial 
inoculation density of 4.13x 104 to about 7.28x 106 cells (Figure 4.15).   The cell counts are 
shown in table 4.6. As almost all murine non-adherent cells were removed in the weekly 
collection process, the data show that the stromal layer is now capable of consistent production 
of non-adherent cells at a slightly increasing rate.   Figure 4.16 shows the cell density in the 
non-adherent compartment throughout the entire culturing period in the murine LTBMC 
described here.   
  
 
Exp. 
No 
Culture 
No. 
Cell count of non-adherent Cells in murine 
LTBMC (x103/L) 
  Day 49 Day 56 Day 63 Day 70 
1 1 5.8 6.8 55.1 751 
 2 4.6 7.2 66.2 629 
 3 3.6 5.1 71.0 471 
      
2 1 2.7 8.2 47.9 458 
 2 4.8 4.9 66.8 761 
 3 5.9 5.1 71.6 515 
      
3 1 2.1 7.8 50.2 546 
 2 5.1 9.1 55.3 457 
 3 4.7 43.9 80.3 813 
 
Table 4. 6 The Non-Adherent Weekly Cell Count from Murine LTBMC after 
Established Stromal Layer was Inoculated with CD117+ Cells 
The total non-adherent cell count from murine LTBMC throughout the culturing period is shown. The 
non adherent cell count decrease during stromal cell development (Day 7 to day 42).  Following 
inoculation with fresh CD117 positive cells the mean total non-adherent cell count increased on day 49 
and the number of non-adherent cells was maintained for the rest of the culturing period. 
4.3.7 Inverted Microscope Examination of Murine LTBMC 
 
Haemapoietic cells actively involved in maturation and differentiation were seen on top of the 
stromal cells and appeared as small round cells with a phase-bright appearance and often 
occurred as large tightly packed foci.  
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Figure 4. 15 The Non-Adherent Weekly Cell Count From Murine LTBMC After 
Established Stromal Layer was Inoculated with CD117+ Cells 
The total cell count following inoculation with CD117 positive cells onto a confluent stromal layer.  The 
total cell count increase over the 4 week period.  Mean data from three separate experiments.  Each 
experiment was carried out in triplicate. Data shown as Mean +/- SEM.  
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Figure 4. 16 The Mean Non-Adherent Cell Count Of The Murine LTBMC, Throughout 
The Entire Culturing Period (Day 7-70) 
The total non-adherent cell count from murine LTBMC throughout the culturing period is shown. The 
non adherent cell count decrease during stromal cell development (Day 7 to day 42).  Following 
inoculation with fresh CD117 positive cells the mean total non-adherent cell count increased on day 49 
and the number of non-adherent cells was maintained for the rest of the culturing period. Mean data 
from three separate experiments.  Data shown as Mean +/- SEM. SEM bars shown for each 
experiment, however, the bars are too small to be shown clearly in figure 
Inoculation with CD117 positive cells 
 
4.3.8 Murine GM/E and Mk Clonogenic Cultures of Non -Adherent Cells after 
Inoculation with CD117 Positive Cells 
 
On a weekly basis, the murine non -adherent cells, present in the LTBMC media removed from 
cultures inoculated with CD117 positive cells, were counted and plated into short- term 
cultures, and the ability of these cells to differentiate into the granulocytic / monocytic and 
erythroid and megakaryocytic cell lineages determined.  Figures 4.17 to 4.19, show the number 
of colonies of each lineage grown.  
 
The cells were added to GM/E and Mk clonogenic cultures differentiated into colonies of the 
erythroid, mono/granulocytic and megakaryocytic lineages, (Figures 4.17 to 4.19).  The colony 
counts are shown in table 4.7.  Also all cell lineages showed an increase in colony number with 
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time with colony numbers reaching a plateau at weeks three and four, with the exception of one 
megakaryocytic culture at week 3. 
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Figure 4. 17 Number of Burst Forming Units-Erythroid (BFU-E) Colonies Grown From 
Murine Non-Adherent Cells Collected Weekly; After Established Stromal Layer Was 
Inoculated With CD117+ Cells 
The mean number of BFU-E colonies from weekly collections of non-adherent cells from murine 
LTBMC.  An increase in BFU-E colony counts with time is noted, with the colony counts reaching a 
plateau at week 3.  Mean data from three separate experiments (sets 1, 2 and 3) are shown.  Data 
shown as Mean +/- SEM. 
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Figure 4. 18 Number of Colony Forming Units-Granulocytic/ Monocytic (CFU-GM) 
Colonies Grown From Murine Non-Adherent Cells Collected Weekly, After Established 
Stromal Layer as Inoculated With CD117+ Cells 
The mean number of CFU-GM colonies from weekly collections of non-adherent cells from murine 
LTBMC.  An increase in CFU-GM colony counts with time is noted, with the colony counts reaching a 
plateau at week 3.  Mean data from three separate experiments (sets 1, 2 and 3) are shown. Data 
shown as Mean +/- SEM. 
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Figure 4. 19 Number of Colony Forming Units-Megakaryocyte (CFU-Mk) Colonies 
Grown From Murine Non-Adherent Cells Collected Weekly, After Established Stromal 
Layer Was Inoculated with CD117+ Cells 
The mean number of CFU-Mk colonies from weekly collections of non-adherent cells from murine 
LTBMC.  An increase in CFU-Mk colony counts with time is noted, with the colony counts reaching a 
plateau at week 3 in two out of the 3 experiments.  In experiment 2 a reduction in CFU-Mk colony 
counts is noted on week 3.  At week 4 the colony count increases. Mean data from three separate 
experiments (sets 1, 2 and 3) are shown.  Data shown as Mean +/- SEM. 
 
 
Mean No BFU-E 
colonies /well 
Mean No CFU-GM colonies /well Mean No CFU-Mk colonies 
/well 
Week of 
collection 
Plate No Plate No Plate No 
 1 2 3 1 2 3 1 2 3 
1 74 70 73 36 39 38 62 70 71 
2 84 81 85 42 45 47 71 81 83 
3 90 85 88 45 46 50 77 61 85 
4 89 83 80 51 45 44 72 72 87 
 
Table 4. 7  Number of BFU-E, CFU-GM and CFU-Mk Colonies Grown From Murine Non-
Adherent Cells Collected Weekly; After Established Stromal Layer Was Inoculated With 
CD117+ Cells 
The BFU-E, CFU-GM and CFU-Mk colony counts achieved following harvesting non-adherent cells 
from murine LTBMC that had been inoculated with fresh CD117 positive cells on week 0.  All cell 
lineages showed an increase in colony number with time with colony numbers reaching a plateau at 
weeks three and four, with the exception of one megakaryocytic culture at week 3. 
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4.3.9 Murine LTBMC: Adherence of Stromal Cells During the Stromal Layer 
Development Period, Using T25 Culture Flasks From Several Manufacturers 
 
As discussed previously, the original LTBMC described by Dexter et al (1976), recommended 
the use of Falcon flasks.  However, one of the problems encountered during the initial part of 
this project, was the stromal layer did not firmly attached to the Falcon flask surface. This 
made changing the medium and the separation of the non-adherent cells from the stromal layer 
impossible. Light microscopy examination of the developing stromal layers, from these initial 
studies, showed the cultures to be devoid of any fibroblasts.  Fibroblasts are an important 
component of the stromal layer, helping the layer to adhere to the culture flask thus their 
absence would affect the quality of the resultant stromal layer.  
In this current investigation, tissue culture plastic from different suppliers was used in a series 
of murine LTBMC to elucidate whether different properties of the plastics, both in materials 
used in the manufacture and method employed to sterilize the flasks, results in differences in 
the adherence of the developing stromal layer. 
 
Murine LTBMC cultures were initiated in T25 plastic culture flasks from Nunc, Falcon and 
Costar.   The development of stromal layer in the T25 flasks was monitored using light 
microscopy. Photographs were taken of the developing stromal layer.  The non-adherent cells 
collected during the weekly feeds during the stromal development period from Nunc flasks 
only, were counted and the cell lineage phenotype of the cells determined, by flow cytometry.  
On week 6, the confluent stromal layers, in the Nunc flasks, were inoculated with fresh bone 
marrow.  Thereafter for 4 weeks, the cell lineage phenotype of the non-adherent cells collected 
at weekly intervals was determined by flow cytometry. 
4.3.10 Examination of Murine LTBMC Stromal Layer Development in T25 Flasks 
using an Inverted Microscope. 
 
The developing stromal layers were examined weekly, by phase contrast, using an inverted 
microscope.  
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Nunc flasks 
 
The development of the murine stromal layer was similar to that described previously.  By the 
end of the first week, all the flasks were found to contain islands of cells.  Also, spindle-shaped 
cells (probably fibroblast-like cells) and flattened cells (probably macrophages) were observed 
in addition to round cells (probably progenitor cells), which were closely associated with the 
adherent cells. 
 
Small and well-haemoglobinized clusters of erythroid cells that were loosely attached to 
adherent cells were also seen. However, after the first two weeks in culture, these erythroid 
clusters were no longer found. 
 
At the end of week two, the number of cells attached to the bottom of the flask seemed to have 
increased.  Moreover, by the end of the fifth week, a confluent adherent layer with persistence 
of islands of small round cells, resembling  'cobble stones', by light microscopy, were found in 
association with adherent cells. Also, by the fourth week, a small number of the spindle-shaped 
cells began to accumulate small droplets of lipid and were located in different regions of the 
culture flasks. 
 
The stromal layers achieved between 90 to 95% confluency in all cultures studied, and areas of 
active haematopoiesis and fat cells were also found irregularly distributed in the culture flasks.  
Figures 4.20 to 4.24 show the cell types described, using Nunc flasks. 
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Figure 4. 20 Nunc Flask - Murine Stromal Layer Development: Week 1         
A Phase contrast of murine stromal layer development at the end of one week incubation, in a 
Nunc T25 flask.  Large number of cells can be seen adhering to the flask bottom surface.  
(Objective x100)    
 
 
 
Figure 4. 21 Nunc Flask Murine Stromal Layer Development: Week 3  
Hofmann Modulation contrast of murine stromal cell layer development following 3 
weeks incubation in a Nunc T25 flask.  Fibroblast-like cells can be noted forming a 
stromal net work. (Objective x200) 
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Figure 4. 22 Nunc Flask- Murine Stromal Layer Development: Week 4 
Hofmann Modulation contrast of murine stromal layer development following 4 weeks 
incubation in a Nunc T25 flask.  Cells are shown adhering to the surface of the flask.  
(Objective x200) 
 
 
 
Figure 4. 23 Nunc Flask - Murine Stromal Layer Development: Week 6 
Hofmann Modulation contrast of murine stromal layer development following 4 weeks 
incubation in a Nunc T25 flask.  A confluent stromal layer is noted.  (Objective x200) 
 
Falcon flasks 
Very few cells were found to adhere to the Falcon flask.  The cells appeared round and flat 
with very few fibroblastic cells present.  Also the number of cells and their appearance did not 
change throughout the stromal development period.  A confluent layer did not develop by the 
end of the sixth week. Figures 4.24 to 4.28 show the cells described, using Falcon flasks. 
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Figure 4. 24 Falcon Flask- Murine Stromal Layer Development: Week 1 
         
A Phase contrast of murine stromal layer development following one week‘s incubation, in a 
Falcon T25 flask.  The cells are round and flat and appear to be floating within the culture 
medium.  (Objective x100)  
 
     
 
 
Figure 4. 25 Falcon Flask - Murine Stromal Layer Development: Week 2 
A Phase contrast of murine stromal layer development following 2 week of incubation, in a 
Falcon T25 flask.  The cells appear are round and have not formed a fibroblast-like net work.  
(Objective x100) 
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Figure 4. 26 Falcon Flask- Murine Stromal Layer Development: Week 3  
A Phase contrast of murine stromal layer development following 3 week incubation, in a 
Falcon T25 flask.  The cells appear to be as round flat cells.  No network of cells is 
noted. (Objective x100) 
 
 
 
 
Figure 4. 27 Falcon Flask- Murine Stromal Layer Development: Week 4 
A Hofmann Modulation contrast of murine stromal layer development following 4 week 
incubation, in a Falcon T25 flask.  The cells appear to be as round flat cells.  No 
network of cells is noted (Objective x100) 
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Figure 4. 28 Falcon Flask- Murine Stromal Layer Development: Week 6 
A Hofmann Modulation contrast of murine stromal layer development following 6 week 
incubation, in a Falcon T25 flask.  The cells appear to be as round flat cells.  No 
network of cells is noted (Objective x100) 
 
Costar flasks  
 
By the end of the first week, all the flasks were found to contain small round cells with a few 
fibroblasts adhering to the flask.  The number of cells adhering to the flask appeared to be 
greater than that observed in the Falcon flasks but not as high as that observed in the Nunc 
flasks. By the end of the second week, all the flasks were found to contain islands of cells.  
Also, spindle-shaped cells and flattened cells (as described above) were observed in addition to 
round cells (probably progenitor cells), which were closely associated with the adherent cells. 
 
At the end of week three, the number of cells attached to the bottom of the flask seemed to 
have increased.  Additionally, by the end of the sixth week, a near confluent adherent layer 
with persistence of islands of small round cells, resembling  'cobble stones', by light 
microscopy, were found in association with adherent cells. Also, a few spindle-shaped cells 
began to accumulate small droplets of lipid and were located in different regions of the culture 
flasks, by the sixth week. The stromal layers achieved between 60-65% confluency in all 
cultures studied, and areas of active haematopoiesis and fat cells were also found irregularly 
distributed in the culture flasks. Figures 4.29 to 4.32 show the cells described, using Costar 
flasks. 
 
 
111 
 
Figure 4. 29 Costar Flask- Murine Stromal Layer Development: Week 2 
A Hofmann Modulation contrast of murine stromal layer development following 1 week 
incubation, in a Costar T25 flask.  The cells appear to be as round flat cells (Objective 
x100) 
 
 
 
 
Figure 4. 30 Costar Flask- Murine Stromal Layer Development: Week 3  
A Phase contrast Hofmann Modulation contrast of murine stromal layer development 
following 3 week incubation, in a costar T25 flask.  The cells appear to be adhering to 
the bottom of the flask.  Fibroblast-like cells can be seen.  (Objective x100) 
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Figure 4. 31 Costar Flask- Murine Stromal Layer Development: Week 4 
A Phase contrast of murine stromal layer development after 4 week incubation, in a 
costar T25 flask.  The cells appear to be adhering to the bottom of the flask.  
Fibroblast-like cells can be seen (Objective x100)  
 
 
 
Figure 4. 32 Costar Flask- Murine Stromal Layer Development: Week 6 
A Phase contrast of murine stromal layer development after 6 weeks incubation, in a 
costar T25 flask.  The cells appear to be adhering to the bottom of the flask.  
Fibroblast-like cells can be seen forming a network.  (Objective x100) 
4.3.11 Examination of Developed Murine Stromal Layer on Thermanox 
Coverslips 
 
The Thermanox coverslips were examined at the end of the six-week period, using an inverted 
microscope.  A 95-98% confluent stromal layer was observed with persistence of islands of 
small round cells, resembling 'cobble stones' at the end of the stromal development period.  
Also areas of active haematopoiesis and fat cells were also found irregularly distributed in the 
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culture.  Subsequently the same coverslips were fixed and stained with May Grunwald Giemsa.   
The May Grunwald Giemsa staining revealed greater detail of the fibroblast -like cells forming 
an interconnecting network.  Associated within and between the cells were numerous round 
cells probably those described as 'cobble stones' by inverted microscope.  Also interspersed 
within the fibroblast- like cells were large mononuclear cells with vast cytoplasm, the identity 
of these cells in unknown (Figures 4.33 and 4.34).  The areas of active haematopoiesis 
appeared as clusters of tightly packed cells. 
Light Microscopy of Thermanox Cover Slips 
 
 
 
Figure 4. 33 Week 3 Murine Stromal Layer Development 
May Grunwald Giemsa Staining shows fibroblast-like cells and  
flattened cells after 3 weeks of stromal layer development (Objective x100) 
 
 
 
Figure 4. 34 Week 3 Murine Stromal Layer Development 
May Grunwald Giemsa staining shows fibroblast-like cells and  
flattened cells after 3 weeks of murine stromal layer development. 
(Objective x400) 
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4.3.12  Cell Count of the Murine Non-Adherent Layer During Stromal Layer 
Development  
 
The weekly total cell counts of murine non -adherent cells declined steadily during the stromal 
layer development phase, from 5x106 to 2.97 x104, (Figure 4.35).  Furthermore, between days 
35 and 43 the non-adherent cell numbers plateaued.The total cell counts of non-adherent cells 
collected weekly during stromal layer development are shown in table 4.8.   
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Figure 4. 35 Murine Stromal Layer Development: Mean Total Cell Counts Of Non-
Adherent Cells  
The weekly total cell counts of murine non -adherent cells declined steadily during the stromal layer 
development phase, from 5x106 to 2.97 x104.  Between days 35 and 43 the non-adherent cell numbers 
plateaued.  Mean data from three separate experiments. Each experiment was carried out in triplicate.  
Data shown as Mean +/- SEM. SEM bars shown for each experiment, however, the bars are too small 
to be shown clearly in figure 
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Exp. No Culture 
No. Cell count of non-adherent Cells in murine LTBMC (x103/L) 
  Day 0 Day 7 Day 14 Day 21 Day29 Day35 Day 42 
1 1 500 153 82.1 38.2 5.2 2.9 2.0 
 2 500 147 85.1 40.1 4.6 3.0 1.9 
 3 500 169 76.2 44.0 3.2 2.9 2.6 
         
2 1 500 214 68.2 30.2 4.9 2.9 2.9 
 2 500 225 56.8 34.2 4.0 3.1 2.5 
 3 500 153 84.2 27.3 5.1 2.9 2.4 
         
3 1 500 236 65.3 29.6 6.2 2.2 2.1 
 2 500 241 89.2 33.6 4.2 1.9 1.0 
 3 500 189 77.0 35.0 4.9 3.0 1.9 
 
Table 4. 8  Murine Stromal Layer Development: Mean Total Cell Counts Of Non-
Adherent Cells 
The non-adherent cell counts collected weekly during murine stromal layer development. The weekly 
total cell counts of murine non -adherent cells declined steadily during the stromal layer development 
phase, from 5x106 to 2.97 x104.  Furthermore, between days 35 and 43 the non-adherent cell numbers 
plateaued. 
 
4.3.13 Identification of Murine Non-Adherent Cells, By Cell Surface Antigens 
(Phenotype) During Stromal Layer Development 
 
Flow cytometric analysis was conducted on murine non -adherent cells collected weekly, 
during the stromal development period, in order to identify the populations of cells present.   
By using antibodies to cell lineage -specific cell surface antigens it was possible to identify 
cells of the erythroid, granulocytic /monocytic, lineages as well as the primitive pluripotent 
progenitor cells. The cell counts of all four populations of cells (Table 4.9) decrease during the 
first four weeks and then plateau during the last two weeks of the stromal development period.  
Additionally, a dramatic reduction in erythroid numbers was noted during the development 
period (Figure 4.36).  The monocytic/ macrophage cell population was found to be the 
predominant cell lineage in the non-adherent layer.  Furthermore, the granulocyte precursors 
and progenitor cells were more prominent than erythroid precursors. Also the four populations 
identified using the lineage specific markers were found to identify 98.93% of all the cells 
present. 
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Figure 4. 36 Murine Stromal Development: Absolute Count of the Non-Adherent Cell 
Populations, Identified By Surface Antigen Detection per Culture 
The mean absolute count of the different cell populations the non-adherent cells collected weekly for 6 
weeks is shown.  The different cell populations were identified using flow cytometry to identify lineage 
specific surface antigens. The cell counts of all four populations of cells decrease during the first four 
weeks and then plateau during the last two weeks of the stromal development period.  A reduction in 
erythroid numbers was noted during the development period.  The monocytic/ macrophage cell 
population was found to be the predominant cell lineage in the non-adherent layer.  Data from three 
separate experiments Data shown as Mean +/- SEM. SEM bars shown for each experiment, however, 
the bars are too small to be shown clearly in figure 
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Exp No Day of 
collection 
of non-
adherent 
cells 
Progeniter cells 
CD117 
(x103/L) 
Mono/Macro 
(F4/80) 
(x103/L) 
Erythroid 
(ter119) 
(x103/L) 
Granulocyte 
precursor 
(x103/L) 
1 0 4.9 73.2 4.1 17.8 
 7 2.2 76.1 0.2 16.5 
 14 1.3 87.2 0.8 12.3 
 21 1.1 88.2 0.2 10.0 
 28 1.9 88.6 0.1 9.3 
 35 1.0 89.0 0.1 10.0 
 42 0.8 88.3 0.1 10.4 
      
2 0 2.2 79.2 2.1 18.2 
 7 2.6 72.5 0.7 22.6 
 14 4.7 80.9 0.3 13.5 
 21 1.9 79.9 0.2 17.3 
 28 2.4 89.1 0.1 8.2 
 35 3.4 86.4 0.2 10.1 
 42 4.1 89.3 0.2 7.2 
      
3 0 5.6 78.1 4.1 12.6 
 7 3.1 78.4 0.2 19.3 
 14 4.7 74.6 0.7 20.1 
 21 2.2 75.1 0.1 23.2 
 28 2.7 86.1 0.2 11.8 
 35 3.9 92.7 0 5.1 
 42 2.5 96.2 0.2 2.1 
 
Table 4. 9  Murine Stromal Development:  Mean Absolute Count of the Non-Adherent 
Cell Populations, Identified By Surface Antigen Detection 
The mean absolute count of the different cell populations the non-adherent cells collected weekly for 6 
weeks during stromal layer development is shown.  The different cell populations were identified using 
flow cytometry to identify lineage specific surface antigens. The absolute counts of all four populations 
of cells decrease during the first four weeks and then plateau during the last two weeks of the stromal 
development period.  Additionally, a reduction in erythroid count was noted during the development 
period.  The monocytic/ macrophage cell population was found to be the predominant cell lineage in the 
non-adherent layer.  The granulocyte precursors and progenitor cells were more prominent than 
erythroid precursors.  
4.3.14 Confluent Murine Stromal Layer Inoculated with CD117 Positive Cells 
 
At weekly intervals, murine non- adherent cells were collected, counted and the cell lineage 
determined using flow cytometry.  In all three experiments carried out, the cell count increased 
from the initial inoculation density (mean count of 4.6 x104) to a mean of 1.7x106 by day 70 
(Figure 4.37); the cell counts are provided in table 4.10.  Figure 4.38 shows the cell density in 
the non-adherent compartment throughout the entire culturing period in the murine LTBMC 
described here.  As can be seen the inoculation with fresh pluripotent cells increased the cell 
density by approx. two orders of magnitude. 
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Figure 4. 37 The Non-Adherent Weekly Cell Count from Murine LTBMC After 
Established Stromal Layer was Inoculated With CD117+ Cells 
The total counts of non-adherent cells collected weekly from murine LTBMC after the confluent stromal 
layer was inoculated with fresh CD117 positive cells.  In all three experiments carried out, the cell count 
increased from the initial inoculation density (mean count of 4.6 x104) to a mean of 1.7x106 by day 70. 
Data is from three separate experiments Data shown as Mean +/- SEM 
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Figure 4. 38 The Mean Non-Adherent Cell Count of The Murine LTBMC, Throughout 
The Entire Culturing Period (Day 0-70) 
The absolute count of non-adherent cells collected from murine LTBMC throughout the culturing period 
(stromal cell development and 4 weeks after the confluent stromal layer was inoculated with fresh 
murine CE117 positive cells). During stromal layer development the absolute count declined (day 43).  
Following inoculation with CD117 positive cells the absolute count increased. Data from three separate 
experiments Data shown as Mean +/- SEM.  SEM bars shown for each experiment, however, the bars 
are too small to be shown clearly in figure 
Inoculation with CD117 positive cells  
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Exp. No Culture 
No. 
Cell count of non-adherent Cells in murine LTBMC 
(x103/L) 
  Day 49 Day 56 Day 63 Day 70 
1 1 4.6 11.1 15.2 110 
 2 5.2 12.3 15.7 119 
 3 4.1 9.1 16.5 135 
      
2 1 5.0 10.7 17.1 135 
 2 4.4 14.2 14.7 120 
 3 4.8 10.6 16.9 142 
      
3 1 4.3 14.7 18.1 142 
 2 5.4 12.0 15.6 176 
 3 4.1 9.3 17.3 162 
 
Table 4. 10 The Non-Adherent Weekly Cell Count From Murine LTBMC After 
Established Stromal Layer was Inoculated with CD117+ Cells 
The cell counts of non-adherent cells collected weekly from murine LTBMC after the stromal layer was 
inoculated with fresh CD117 positive cells is shown.  The cell counts increased weekly. Data from three 
separate experiments is shown 
4.3.15 Identification of Non-Adherent Cells, By Cell Surface Antigens 
(Phenotype) after Murine Stromal Layer was Inoculated With CD117 Positive 
Cells 
 
Flow cytometric analysis was conducted on murine non -adherent cells collected weekly, after 
inoculation with CD117 positive cells, in order to identify the populations of cells present.    
Using antibodies to mouse cell lineage specific cell surface antigens of the erythroid, 
granulocytic /monocytic, lineages as well as the primitive pluripotent progenitor cells were 
identified (Figure 4.39). The absolute counts of the cell lineages identified by flow cytometry 
are shown in Table 4.11.  The number of non-adherent cells of monocytic /macrophage, 
progenitor cells and granulocytic precursors was maintained during the first three weeks with a 
slight increase in the fourth week. The numbers of erythroid precursors were maintained at a 
steady level throughout the culturing period.  The monocytic/ macrophage cells and 
granulocytic precursors appeared to be the dominant cell populations of the non -adherent 
cells, with equal amounts of each cell population present.  The progenitor cells and unstained 
cells represented a smaller proportion of the non-adherent layer cell populations and the 
erythroid precursors the smallest population (Figure 4.39).   
 
During stromal development the monocytic/macrophage, granulocytic precursor, erythroid and 
progenitor cells declined dramatically and then plateaued (Figure 4.40). Higher cell counts 
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were noted for all four-cell populations after the inoculation of the cultures with CD117 
positive progenitor cells, (Figure 4.40). 
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Figure 4. 39 Phenotype of Murine Non-Adherent Cells After Stromal Layer Inoculated 
With CD117 Positive Cells 
The cell populations identified by flow cytometry analyses of surface antigen expression of murine non-
adherent cells after the confluent stromal layer was inoculated with fresh murine CD117 positive cells. 
The number of non-adherent cells of monocytic /macrophage, progenitor cells and granulocytic 
precursors was maintained during the first three weeks with a slight increase in the fourth week. The 
numbers of erythroid precursors were maintained at a steady level throughout the culturing period. The 
monocytic/ macrophage cells and granulocytic precursors appeared to be the dominant cell populations 
of the non -adherent cells, with equal amounts of each cell population present.  The progenitor cells and 
unstained cells represented a smaller proportion of the non-adherent layer cell populations and the 
erythroid precursors the smallest population Data from three separate experiments Data shown as 
Mean +/- SEM. SEM bars shown for each experiment, however, the bars are too small to be shown 
clearly in figure 
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Figure 4. 40 Phenotype of Murine Non-Adherent Cells Throughout the Culturing 
Period  
The murine cell lineages identified using lineage specific surface cell antigens throughout the LTBMC 
period (stromal layer development and four weeks following inoculation with murine CD117 cells.   
During stromal development the monocytic/macrophage, granulocytic precursor, erythroid and 
progenitor cells declined dramatically and then plateaued.  Higher cell counts were noted for all four-cell 
populations after the inoculation of the cultures with CD117 positive progenitor cells.  Data from three 
separate experiments Data shown as Mean +/- SEM. SEM bars shown for each experiment, however, 
the bars are too small to be shown clearly in figure 
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Exp No Day of 
collection 
of non-
adherent 
cells 
Progeniter cells 
CD117 
(x103/L) 
Mono/Macro 
(F4/80) 
(x103/L) 
Erythroid 
(ter119) 
(x103/L) 
Granulocyte 
precursor 
(x103/L) 
1 49 4.4 38.2 0.2 32.6 
 54 5.2 42.2 0.2 35.1 
 59 3.7 43.1 0.4 46.6 
 64 6.2 41.2 0.6 42.7 
 69 4.4 38.2 0.2 32.6 
 74 5.2 42.2 0.2 35.1 
      
2 49 8.1 46.3 0.1 31.1 
 54 9.3 42.0 1.1 42.4 
 59 13.7 35.6 0.2 45.7 
 64 9.6 38.0 0.1 46.7 
 69 8.1 46.3 0.1 31.1 
 74 9.3 42.0 1.1 42.4 
      
3 49 11.7 35.6 0.4 36.2 
 54 9.3 40.0 0.6 33.7 
 59 6.3 38.9 0.1 40.1 
 64 9.3 41.4 0.2 37.1 
 69 11.7 35.6 0.4 36.2 
 74 9.3 40.0 0.6 33.7 
 
Table 4. 11 Phenotype of Murine Non-Adherent Cells After Stromal Layer Inoculated 
With CD117 Positive Cells  
The cell populations identified by flow cytometry analyses of surface antigen expression of murine non-
adherent cells after the confluent stromal layer was inoculated with fresh murine CD117 positive cells. 
The number of non-adherent cells of monocytic /macrophage, progenitor cells and granulocytic 
precursors was maintained during the first three weeks with a slight increase in the fourth week. The 
numbers of erythroid precursors were maintained at a steady level throughout the culturing period. The 
monocytic/ macrophage cells and granulocytic precursors appeared to be the dominant cell populations 
of the non -adherent cells, with equal amounts of each cell population present.  The progenitor cells and 
unstained cells represented a smaller proportion of the non-adherent layer cell populations and the 
erythroid precursors the smallest population Data from three separate experiments. 
 
4.3.16 Visualization of Stromal Cell Development of hCB Cell LTBMC 
 
Examination of developing stromal layer of hCB LTBMC, by inverted microscope. 
 
The developing stromal layers were examined weekly, by phase contrast, using an inverted 
microscope. The findings were as follows: 
First week: all the flasks were found to contain islands of cells that appeared as flattened cells.  
Spindle-shaped cells (probably fibroblast-like cells) and flattened cells (probably macrophages) 
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were observed in addition to round cells (probably progenitor cells), which were closely 
associated with the adherent cells.  As noted in the murine LTBMC, small and well-
haemoglobinized clusters of erythroid cells that were loosely attached to adherent cells were 
also seen. However, after the first week in culture, these erythroid clusters were no longer 
found. 
 
End of week two: the number of cells attached to the bottom of the flask increased.  
 
Week 4:  A small number of the spindle-shaped cells began to accumulate small droplets of 
lipid and were located in several regions of the culture flasks.   
 
Week 5: A confluent adherent layer composed of numerous cell types (macrophages, 
fibroblasts fat cells) with islands of small round cells, resembling 'cobble stones', by light 
microscopy.  The stromal layers achieved between 90 to 95% confluency in all cultures 
studied, and areas of active haematopoiesis and fat cells were also found irregularly distributed 
in the culture flasks. Photographs taken at weeks 2, 4 and 5 show the cell types described 
(Figures 4.41 to 4.43). 
 
 
Figure 4. 41 hCB LTBMC 
A phase contrast of human LTBMC stromal layer development 2 weeks after culture 
initiation is shown.  The cells can be seen adhering to the flask bottom. (objective x 
100) 
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Figure 4. 42 hCB LTBMC 
A Hofmann Modulation contrast of human LTBMC stromal layer development 4 weeks 
after culture initiation is shown A small number of the spindle-shaped cells began to 
accumulate small droplets of lipid and were located in several regions. (objective x200) 
 
 
 
Figure 4. 43 hCB LTBMC 
A phase contrast of human LTBMC stromal layer development 5 weeks after culture 
initiation is shown. A confluent adherent layer composed of numerous cell types 
(macrophages, fibroblasts fat cells) with islands of small round cells, resembling 'cobble 
stones are shown. (objective x200) 
 
4.3.17 Characterization of the Non-Adherent Layer during hCB LTBMC Stromal 
Layer Development 
 
The weekly total cell counts of hCB non -adherent cells declined steadily during the stromal 
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layer development phase (Figure 4.44).  The cell counts are provided in Table 4.12. 
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Figure 4. 44 hCB Stromal layer development: Mean total cell counts of non-adherent 
cells  
The total human non-adherent cell count during hCB LTBMC stromal layer development; the weekly 
total cell counts of hCB non -adherent cells declined steadily during the stromal layer development 
phase. Data from three separate experiments Data shown as Mean +/- SEM.  SEM bars shown for 
each experiment, however, the bars are too small to be shown clearly in figure. 
 
Exp. No Culture 
No. Cell count of non-adherent Cells in hCB LTBMC (x103/L) 
  Day 0 Day 7 Day 14 Day 21 Day28 Day35 Day 42 
1 1 500 489 149 11.1 9.7 1.8 0.8 
 2 500 414 208 14.8 10.9 2.5 0.5 
 3 500 399 160 10.7 8.6 3.3 0.7 
         
2 1 500 518 259 14.5 11.2 4.1 0.8 
 2 500 539 148 12.6 10.7 1.9 0.9 
 3 500 489 102 18.9 13.6 2.7 0.9 
         
3 1 500 543 161 11.3 8.2 1.5 0.7 
 2 500 531 170 12.0 9.2 1.4 0.9 
 3 500 510 149 10.7 8.6 1.9 0.9 
Table 4. 12  Total Cell Counts of Non-Adherent Cells hCB during Stromal Layer 
Development  
The total human non-adherent cell count during hCB LTBMC stromal layer development; the weekly 
total cell counts of hCB non -adherent cells declined steadily during the stromal layer development 
phase. 
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4.3.18 Morphological Identification of hCB Non-Adherent Cells during Stromal 
Layer Development 
The hCB non-adherent cells collected, during the stromal layer development, were cyto-spun, 
fixed and then stained with May Grunwald Giemsa, in order to morphologically identify the 
cells.  The cell types identified morphologically (percentage and absolute counts) are shown in 
Tables 4.13 and 4.14. 
 
The steepest decline was observed for the mononuclear cell population.  The 
monocyte/macrophage cell population initially declined (day 7) and the steadily increased 
weekly reaching a peak at day 35 and then declined on day 42.  Erythrocytes were observed at 
day 7 only. The numbers of the remaining cell types (promyelocytes, pro-monocytes, 
metamyelocytes and mono/macrophages) plateaued by day 42 (figure 4.45).  
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Figure 4. 45 hCB Stromal Layer Development: The Absolute Count of Different Cell 
Types Collected in the Non-Adherent Layer, Identified by May Grunwald Giemsa 
Staining Morphology 
The cell types present in the non-adherent cells collected throughout the hCB stromal cell development, 
identified by morphology. The steepest decline was observed for the mononuclear cell population.  The 
monocyte/macrophage cell population initially declined (day 7) and the steadily increased weekly 
reaching a peak at day 35 and then declined on day 42.  Erythrocytes were observed at day 7 only. The 
numbers of the remaining cell types (promyelocytes, pro-monocytes, metamyelocytes and 
mono/macrophages) plateaued by day 42. Data from three separate experiments is show. Data shown 
as Mean +/- SEM.  SEM bars shown for each experiment, however, the bars are too small to be shown 
clearly in figure 
127 
Exp. No Culture day 
non-adherent 
cells collected 
Mononuclear cells 
(%) 
Promyelocytes 
(%) 
Metamyelocytes 
(%) 
Erythrocytes 
(%) 
Promonocytes 
(%) 
Monocytes 
/macrophages 
(%) 
Culture ID  1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
1 0 95 83 95 0 0 0 0 0 0 0 0 0 0 0 0 5 17 5 
2   98 95 91 0 0 0 0 0 0 0 0 0 0 0 0 2 5 9 
3   90 94 93 0 0 0 0 0 0 0 0 0 0 0 0 10 6 7 
                                        
1 7 31 35 38 32 36 41 1 1 1 26 27 15 5 1 3 5 0 2 
2   40 38 28 27 33 33 1 2 0 26 22 28 3 5 7 3 0 4 
3   33 34 27 28 33 43 2 1 1 31 22 24 2 4 3 4 6 2 
                                        
1 14 22 28 27 44 34 46 7 11 15 1 0 0 24 24 10 2 3 2 
2   33 24 25 46 47 40 16 10 12 0 1 0 2 16 22 3 2 1 
3   25 28 24 49 38 42 13 15 19 1 0 0 7 11 15 5 8 0 
                                        
1 21 7 9 5 11 16 9 9 12 11 4 2 2 11 8 21 58 53 52 
2   8 3 6 13 12 19 15 13 16 1 1 2 10 12 8 53 59 49 
3   4 9 4 17 12 11 14 14 13 0 0 3 14 12 18 51 53 51 
                                        
1 28 0 1 1 12 14 9 3 7 4 0 0 0 17 14 18 68 64 68 
2   0 0 0 15 12 10 7 5 6 0 1 0 11 16 12 67 66 72 
3   0 0 0 11 14 15 5 8 8 0 1 0 13 17 16 71 60 61 
                                        
1 35 1 0 0 9 11 14 6 3 6 0 0 0 10 18 13 74 68 67 
2   0 2 0 17 8 15 5 9 4 0 0 0 11 12 16 67 69 65 
3   0 0 0 12 11 13 8 10 8 0 0 0 17 13 14 63 66 65 
                                        
1 42 0 0 2 4 15 16 5 8 6 0 0 0 12 17 16 79 60 60 
2   1 2 1 15 9 11 7 4 9 0 0 0 13 10 11 64 75 68 
3   1 1 0 16 11 14 8 5 5 0 0 0 12 13 13 63 70 68 
Table 4. 13 hCB Stromal Layer Development: The Percentage of Different Cell Types Collected in the Non-Adherent Layer, Identified by May Grunwald Giemsa 
Staining Morphology  The cell types present in the non-adherent cells collected throughout the hCB stromal cell development, identified by morphology. The steepest decline 
was observed for the mononuclear cell population.  The monocyte/macrophage cell population initially declined (day 7) and the steadily increased weekly reaching a peak at day 
35 and then declined on day 42.  Erythrocytes were observed at day 7 only. The numbers of the remaining cell types (promyelocytes, pro-monocytes, metamyelocytes and 
mono/macrophages) plateaued by day 42. Data from three separate experiments is shown. 
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Exp. No Culture day 
non-adherent 
cells 
collected 
Mononuclear 
cells 
(x103/l) 
Promyelocytes  
(x103/l) 
Metamyelocytes  
(x103/l) 
Erythrocytes  
(x103/l) 
Promonocytes  
(x103/l) 
Monocytes 
/macrophages 
(x103/l) 
1 0 75.3 0 0 0 0 22 
2  68.4 0 0 0 0 15 
3  79.4 0 0 0 0 25 
        
1 7 17.3 12.7 0.7 0 1.3 1.8 
2  11.0 11.5 0.4 0 1.7 2.1 
3  15.8 10.3 0.6 0 1.9 2.0 
        
1 14 7.9 19.3 3.2 0 3.2 2.7 
2  8.9 15.0 6.9 0 1.8 3.8 
3  6.3 14.9 5.4 0 2.5 4.1 
        
1 21 5.3 14.8 5.4 0 8.3 6.3 
2  6.6 19.2 7.4 0 7.4 5.6 
3  4.4 14.7 9.3 0 9.4 8.3 
        
1 28 3.6 5.7 3.2 0 6.3 19.5 
2  4.3 9.4 5.4 0 5.1 22.6 
3  7.3 5.7 4.1 0 7.0 21.0 
        
1 35 1.4 4.8 3.6 0 7.4 32.9 
2  1.9 5.1 4.9 0 8.2 24.7 
3  0.6 5.9 4.2 0 8.8 26.7 
        
1 42 0.3 5.3 3.2 0 6.0 17.6 
2  0.6 5.9 3.9 0 5.8 16.1 
3  0.5 5.4 2.3 0 6.7 18.1 
Table 4. 14 hCB Stromal Layer Development: The Absolute Count of Different Cell Types Collected in the Non-Adherent Layer, Identified by May Grunwald Giemsa 
Staining Morphology 
The cell types present in the non-adherent cells collected throughout the hCB stromal cell development, identified by morphology. The steepest decline was observed for the mononuclear 
cell population.  The monocyte/macrophage cell population initially declined (day 7) and the steadily increased weekly reaching a peak at day 35 and then declined on day 42.  
Erythrocytes were observed at day 7 only. The numbers of the remaining cell types (promyelocytes, pro-monocytes, metamyelocytes and mono/macrophages) plateaued by day 42. 
Data from three separate experiments is shown.
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4.3.19 Identification of hCB Non-Adherent Cells, By Cell Surface Antigens 
(Phenotype) Throughout Culturing Period 
 
Flow cytometric analysis was conducted on hCB non -adherent cells collected weekly, 
throughout the culturing period, in order to identify the populations of cells present.   The use 
of human cell lineage -specific cell surface the identification of cells of the erythroid, 
granulocytic /monocytic, lineages as well as the primitive pluripotent progenitor cells (Figure 
4.46). The percentage of the different populations of haematopoietic cells identified in the 
non-adherent layer throughout the hCB LTBMC culturing period is shown in Table 4.15.  The 
monocytic/ macrophage cell population (CD14 expression cells) was found to be the 
predominant cell lineage in the non-adherent layer and represented between 50 and 63% of the 
total non-adherent cell population throughout the culturing period.  The percentage of 
granulocytic/ monocytic cell precursors (CD33 expressing cells) was maintained at the same 
level, between 20 and 28% throughout the culturing period. Additionally, a slight reduction in 
the percentage of granulocytic precursor cells was noted at day 49.  The percentage of 
megakaryocytic precursors (c-mpl expressing cells) decreased from days 7 through to day 35.  
After inoculation with fresh hCB (once stromal layer confluency had been achieved), the 
percentage of c-mpl expressing cells was maintained at 8% of the total non-adherent cell 
population.  The percentage of pluripotent cells (CD34 expressing cells) was maintained at 
levels between 4 and 8% throughout the culturing period.  Erythrocytic precursors (CD35) 
represented less than 1% of the total non-adherent cell population throughout the culturing 
period.  
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Figure 4. 46 Percentage of the Non-Adherent Cell Populations, Identified By Surface 
Antigen Detection per Culture 
The percentage of different cell types present in the non adherent cells during hCB LTBM stromal layer 
development.  Cell types were identified by flow cytometry of lineage specific surface antigen 
expression.  The monocytic/ macrophage cell population (CD14 expression cells) was found to be the 
predominant cell lineage in the non-adherent layer throughout the culturing period.  The percentage of 
granulocytic/ monocytic cell precursors (CD33 expressing cells) was maintained at the same level 
throughout the culturing period. Additionally, a slight reduction in the percentage of granulocytic 
precursor cells was noted at day 49.  The percentage of megakaryocytic precursors (c-mpl expressing 
cells) decreased from days 7 through to day 35.  Data from three separate experiments Data shown as 
Mean +/- SEM.   
    Inoculation with fresh hCB cells  
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Exp No Day of 
collection 
of non-
adherent 
cells 
CD34 
positive (%) 
CD14 
positive (%) 
CD33 
positive (%) 
CDC-mpl 
positive (%) 
erythro 
precursor 
positive (%) 
1 0 98 2 0 0 0 
 7 5.3 49.1 24.3 20.2 0.2 
 14 4.5 51.9 28.5 16.9 0.4 
 21 5.0 50.7 28.1 16.9 0.3 
 28 5.1 60.2 27.0 8.2 0 
 35 4.4 57.6 30.0 8.0 0 
 42 3.3 67.1 19.0 11.1 0.1 
 49 8.3 62.8 18.1 10.3 0 
 56 6.1 59.3 11.4 15.4 0 
 63 7.3 60.4 14.7 9.5 0 
 70 5.4 62.3 7.5 3.3 0 
       
2 0 94 5 1 0 0 
 7 5.2 60.1 19.2 17.4 0.1 
 14 1.0 40.7 33.2 25.0 0.2 
 21 7.1 49.1 30.2 14.0 0 
 28 4.0 66.9 24.7 6.1 0 
 35 7.1 63.6 21.7 8.0 0 
 42 3.6 52.9 31.0 13.0 0 
 49 9.2 66.1 12.7 10.3 0 
 56 5.7 63.1 16.3 9.3 0 
 63 4.7 64.5 9.5 14.0 0 
 70 4.0 66.6 13.8 5.4 0 
       
3 0 99 1 0 0 0 
 7 1.0 40.7 33.2 25.0 0.2 
 14 5.1 51 33.9 10.2 0.4 
 21 5.1 52 27.2 15.7 0.7 
 28 5.6 51.5 33.7 9.2 0.2 
 35 7.0 59.1 27.7 6.5 0 
 42 3.4 59.1 23.0 16.0 3.4 
 49 7.1 64.7 18.5 11.5 0 
 56 6.3 58.3 14.3 6.2 0 
 63 7.5 64.0 10.5 7.4 0 
 70 5.3 68.4 11.2 5.8 0 
 
Table 4. 15 Percentage of the Non-Adherent Cell Populations, Identified By Surface 
Antigen Detection throughout the Culturing Period 
The percentage of different cell types present in the non adherent cells during hCB LTBM stromal layer 
development.  Cell types were identified by flow cytometry of lineage specific surface antigen 
expression.  The monocytic/ macrophage cell population (CD14 expression cells) was found to be the 
predominant cell lineage in the non-adherent layer throughout the culturing period.  The percentage of 
granulocytic/ monocytic cell precursors (CD33 expressing cells) was maintained at the same level 
throughout the culturing period. Additionally, a slight reduction in the percentage of granulocytic 
precursor cells was noted at day 49.  The percentage of megakaryocytic precursors (c-mpl expressing 
cells) decreased from days 7 through to day 35.  Data from three separate experiments are shown.   
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4.3.20 Confluent Stromal Layer Inoculated with hCB Cells 
 
After the confluent layer of stromal cells was inoculated with fresh hCB cells, non- adherent 
cells were collected at weekly intervals, counted and plated into in vitro short- term cultures to 
evaluate differentiation into the myeloid and megakaryocytic cell lineages.  The cell count 
increased from the initial count  of 2.4 x106 cells on day 7 to 6.0 x106 cells (day 49).   Figure 
4.47 shows the cell density in the non-adherent compartment throughout the entire culturing 
period in the hCB LTBMC described here.  As can be seen the inoculation with fresh hCB 
cells increased the cell numbers by approx. two orders of magnitude. 
  
 
Inverted Microscope Examination 
 
Haematopoietic cells actively involved in maturation and differentiation were seen on top of 
the stromal cells and appeared as small round cells with a phase-bright appearance and often 
occurred as large tightly packed foci. 
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Figure 4. 47 Mean Non-Adherent Cell Count of the hCB LTBMC, Throughout The 
Entire Culturing Period  
The mean non-adherent cell count throughout the hCB LTBMC period( stromal cell development and 4 
weeks after the confluent stromal cell was inoculated with fresh CD34 positive cells.  The non adherent 
cell count decreases during stromal layer development, but is then maintained after inoculation with 
fresh CD36 positive cells.  Each concentration was evaluated in triplicate on three separate occasions.  
Data shown are Mean +/- SEM 
 
 
         Inoculation with fresh hCB cells 
 
Figure 4.48 shows the number of colonies of each lineage grown. The cells plated into the 
short -term cultures differentiated into colonies of the erythroid, mono/granulocytic and 
megakaryocytic lineages.  Also the number of each specific colony per well remained 
consistent throughout the 4 weeks.  Table 4.16 shows the individual BFU-E, CFU-GM and 
CFU-Mk colony counts achieved from non-adherent cells collected from the hCB LTBMC. 
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Figure 4. 48 Number Of Burst Forming Units-Erythroid (BFU-E), Colony Forming Units 
– Granulocytic/Monocytic (CFU-GM) And Colony Forming Units –Megakaryocytic (CFU-
Mk) Colonies Per Well Grown From Non-Adherent Cells Collected Weekly; After 
Established Stromal Layer Was Inoculated With hCB Cells 
The mean number of BFU-E, CFU-GM and CFU-Mk colonies grown weekly from non-adherent cells collected 
weekly from hCB LTBMC after inoculation with fresh CD36 positive cells. The number of CFU-GM, BFU-E and 
CFU-Mk colonies was maintained throughout the 4 week period.  Each concentration evaluated in triplicate on 
three separate occasions.  Data shown are Mean +/- SEM. SEM error bars for each cell lineage are shown, 
however, some are too small to been seen clearly in figure 
 
 
Mean No BFU-E 
colonies /well 
Mean No CFU-GM 
colonies /well 
Mean No CFU-Mk 
colonies /well 
Week of 
collection 
Plate No Plate No Plate No 
 1 2 3 1 2 3 1 2 3 
1 188 193 141 66 51 48 67 85 93 
2 201 165 168 74 56 49 66 87 77 
3 195 154 196 77 62 81 73 64 84 
4 173 161 226 83 62 84 91 87 80 
 
Table 4. 16 Number Of Burst Forming Units-Erythroid (BFU-E), Colony Forming Units 
– Granulocytic/Monocytic (CFU-GM) And Colony Forming Units –Megakaryocytic (CFU-
Mk) Colonies Per Well Grown From Non-Adherent Cells Collected Weekly; After 
Established Stromal Layer Was Inoculated With hCB Cells 
The number of BFU-E, CFU-GM and CFU-Mk colonies grown weekly from non-adherent cells collected 
weekly from hCB LTBMC after inoculation with fresh CD36 positive cells. The number of CFU-GM, 
BFU-E and CFU-Mk colonies was maintained throughout the 4 week period.  Each concentration 
evaluated in triplicate on three separate occasions. 
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4.4 Discussion 
 
4.4.1 Murine LTBMC Using Standard and Modified Culture Conditions (Falcon 
Flasks) 
 
The literature describes that in murine LTBMC a confluent stromal layer is developed within 
5-6 weeks of culture, consisting of macrophages /fibroblasts, blanket cells and fat cells 
interspersed with ‘cobblestone’ areas, which are compact groups of primitive haemapoietic 
cells which are beneath blanket cells (Dexter et al 1976). Furthermore Falcon manufactured 
the culture flasks described in the literature. However, this was not seen in this experiment 
series. Only rounded cells of various sizes were observed even after 28 days in culture. The 
absence of macrophages/ fibroblasts in the stromal layer probably hindered the development 
of a confluent adherent layer.  Furthermore both phase contrast and Hofmann Modulation 
Contrast microscopy of the murine LTBMC did not reveal the presence of macrophages or 
fibroblast -like cells. However, macrophages and fibroblasts were easily visible in short-term 
GM/E clonogenic cultures using the same source of bone marrow as in the current 
experiments. Therefore, the inability to establish an adherent layer in the LTBMC was not due 
to the absence of fibroblast- like cells and macrophages in the mononuclear bone marrow cells 
preparation. 
4.4.2 Visualization of Murine LTBMC (Standard Method), Using Nunc Culture 
Flasks 
 
Development Phase of Stromal Layer Of Murine LTBMC 
 
In this series of experiments, stromal layer confluency appears to require five to six weeks 
after culture initiation. The weekly morphological examination of the developing stromal layer 
showed small islands of spindle-like cells - fibroblastic cells and flat cells- macrophages by 
the end of the first week.   Indeed by the end of the development phase, the fibroblastic cells 
and the macrophages are found to be the predominant cell types present within the adherent 
layer.    
The presence of the fat cells was only evident from the fourth week suggesting that these cells 
only appear when the cultures are close to achieving confluency. In fact others have shown 
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that there is a correlation between the long-term survival of stem cells and the presence of fat 
cells in the stromal layer (Dexter, et al 1984). Thus, their presence in cultures seems to provide 
an indication of a successful stromal layer for supporting haematopoiesis.  Also 
haematopoietic foci of small round cells are prominent once the cultures are close to achieving 
confluency.  
 
Well-haemoglobinized clusters of erythroid cells seen loosely attached to adherent cells noted 
in the first few weeks of stromal development only. These are most probably the progeny of 
erythroid progenitors present in the mononuclear cell population added initially to the culture 
flasks.  Erythropoietin required for the development of erythroid precursors to Burst Forming 
Cells -Erythroid is not produced by stromal cells, but by the kidney, therefore the absence of 
these cells in the LTBMC is not surprising.   Also the presence and quick loss of the erythroid 
cells did not appear to inhibit stromal cell development, confirming that they play no role in 
the establishment or maintenance of the stromal layer.  The stromal layer development took 5 
to 6 weeks to reach confluency and is similar to that described by Dexter et al (1984) for 
murine cultures.   
 
Whilst stromal layer was developing the production of murine non -adherent cells declined 
weekly, and then finally reached a plateau at weeks five and six - once stromal cell confluency 
was attained. This is similar to that described by Goliaei  et al (1995). 
Morphology of The Murine Non-Adherent Cells During LTBMC Stromal Layer 
Development  
 
The total murine non-adherent cell count and the cell counts for each cell population identified 
by morphology, decreased during the stromal development period and reached a plateau 
between day 28 and day 42.    
 
The most dramatic change in the cell populations monitored was the proportional increase 
over the first four weeks in the relative numbers of monocytes and macrophages in the non-
adherent cells collected, which by week 6, represented 90% of the non -adherent cell 
population.  Thus the monocytes and macrophages appear to be the most predominant cell 
type in both the adherent (discussed in the previous section) and non-adherent layer.  This 
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concurs with work conducted by Kriegler (1990) where macrophages were shown to play an 
important role in the regulation of haematopoiesis in vitro.  Subsequent work conducted by 
Goliaei et al, (1995) demonstrated that there was a delicate balance between the number of 
macrophages present and the maintenance of progenitor cell proliferation and differentiation.   
When macrophages were added to confluent murine LTBMC a modification of 
haematopoiesis was noted.  In vivo, macrophages have been shown to play a similar role to 
that seen in vitro; an integral component of the microenvironment important in supporting 
haematopoiesis, by the production of cytokines to initiate and drive cell differentiation and 
maturation.   
 
A relative increase in the granulocyte population was noted in the first two weeks, with the 
promyelocytes and the metamyelocytes representing 40% and 18% of the total non-adherent 
population, respectively. The relative proportion of the promyelocytes and metamyelocytes 
continued to decline during the stromal development period and also reached a plateau by the 
sixth week of culturing. Also the erythroblasts (nucleated red blood cells) lineage declined the 
quickest with no cells of that lineage observed after week 2. 
 
Daniel et al (1989) evaluated the proliferative capacity of established LTBMC for producing 
Colony Forming Units- GM (CFC-GM) and Burst forming units - Erythroid (BFU-E), without 
the addition of fresh inoculum of pluripotent stem cells.  The number of both types of colonies 
varied from culture to culture. The BFU-E numbers decline after only three weeks post 
stromal layer confluency.   The CFU-GM colony numbers declined after 6-8 weeks.  The 
complete removal of non- adherent cells from a confluent stromal layer produces an in vitro 
culture system with growth -promoting potential.  Therefore, the growth and differentiation of 
the freshly inoculated pluripotent progenitor cells is evaluated and not that of any pre- existing 
progenitor cells (Reimann and Burger, 1979) 
Inoculated Murine LTBMC with Confluent Stromal Layer 
 
After the murine stromal layer reached confluency and freshly isolated mouse bone marrow 
mononuclear cells were re -inoculated, there was a continuous production of non-adherent 
cells throughout the four-week period that the cultures were maintained.  Also, the cell count 
of the murine non-adherent layer was maintained despite the total removal of non-adherent 
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cells at the weekly cell collections.  This suggests that an active murine LTBMC system had 
been established enabling the continuous proliferation and differentiation of haematopoietic 
progenitors.   
 
Murine Clonogenic Cultures Of Non- Adherent Cells After Inoculation With CD117 
Positive Cells 
 
Cells present within the murine non-adherent cell population harvested at weekly intervals 
from the CD117 inoculated cultures were able to proliferate and differentiate into colonies of 
the erythroid, granulocytic/ monocytic and megakaryocytic cell lineages.  Also colony 
numbers for all cell lineages were maintained throughout the four-week period over which the 
cells were collected.  Although a slight drop in megakaryocytic colony numbers was seen in 
some cultures at week three, a return to previous levels was noted by week four.  As this was 
only seen in one study of three, it may imply some experimental error at week 3 in that study. 
Proliferation of freshly aspirated bone marrow in established murine LTBMC has been 
described by Reimann et al (1979) and Talts et al (1998), respectively.  Reimann et al (1979) 
reported total Colony Forming Units C (total colony numbers) not distinguishing between 
CFU-GM or BFU-E's, whereas Talts et al (1998) counted the CFU-GM colonies only.  
Megakaryocytes have been observed in LTBMC culture and quantified by counting the 
number present in the LTBMC cultures by Briddel et al (1992).  
 
4.4.3 Murine Stromal Layer Development in T25 Flasks from Different 
Manufacturers 
 
 
In the studies described here, the ability to establish confluent murine stromal layers was 
examined using T25 flasks from three different manufacturers.  As seen in the previous study 
a confluent stromal layer developed after five to six weeks using Nunc flasks.  Indeed by the 
end of the development phase, the fibroblastic cells and the macrophages were found to be the 
predominant cell types present within the adherent layer.  Furthermore, fat cells were evident 
as well as islands of small round cells, resembling 'cobble stones', in association with adherent 
cells.   
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Only 65% confluency was achieved using Costar flasks and less than 40% confluency using 
Falcon flasks.  This suggests that properties in the plastic used in the manufacture of the flask 
influence directly the ability of the cells to adhere. Furthermore, differences in the ability of 
macrophage/fibroblast like cells to adhere to plastic have previously noted (Gordon, 1993) 
where adherence of some fibroblasts was restricted by the properties of the plastic used.  Also 
changes to the procedures employed to sterilize the flasks may alter the properties of the 
plastic.  This may help explain the difference in stromal layer development found by Dexter 
(1976) and this study.  Regrettably no information on the differences in the flasks is available 
due to the reluctance of the manufacturers to discuss their respective plastic formulation or 
sterilization procedures.  
 
The ability to grow the stromal layer on Thermanox coverslips will enable further 
characterisation of the stromal layer using immunohistochemistry and electron microscopy. 
For example, immunohistochemistry could be used to identify the different cell populations in 
the stromal layer using cell specific surface markers and electron microscopy could be used to 
elucidate the intricate stromal structure.  
 
4.4.4 Murine non-adherent cell counts (Nunc flasks only) 
 
The total cell counts of murine non-adherent cells throughout the culturing period (stromal 
development and after inoculation with CD117 positive cells) was similar to that reported 
earlier.  Also the rapid decline in non-adherent cell numbers during stromal development and 
the maintenance of non-adherent cell numbers, after inoculation with CD117 positive cells the 
same as noted previously and at the same time points.  These findings substantiate the 
robustness of the LTBMC developed.   
 
4.4.5 Development Phase of Stromal Layer of hCB LTBMC 
 
In the work described here, hCB stromal layer confluency appears to require five weeks after 
culture initiation. The weekly morphological examination of the developing stromal layer 
showed small islands of spindle-like cells (fibroblastic cells) and flat cells (macrophages) by 
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the end of the first week.   By the end of the development phase, the fibroblastic cells and the 
macrophages were found to be the predominant cell types present within the adherent layer.    
 
The presence of the fat cells was only evident from the fourth week suggesting that these cells 
only appear when the cultures are close to achieving confluency. In fact others have shown 
that there is a correlation between the long-term survival of stem cells and the presence of fat 
cells in the stromal layer (Allen and Dexter, 1984). Thus, their presence in cultures seems to 
provide an indication of a successful stromal layer for supporting haemapoiesis.  Also 
haemapoietic foci of small round cells are prominent once the cultures are close to achieving 
confluency.  
 
Well-haemoglobinized clusters of erythroid cells seen loosely attached to adherent cells were 
noted in the first week of stromal development only. These are most probably the progeny of 
erythroid progenitors present in the mononuclear cell population added initially to the culture 
flasks.  Erythropoietin required for the development of erythroid precursors to Burst Forming 
Cells -Erythroid is not produced by stromal cells, but by the kidney, therefore the absence of 
these cells in the LTBMC is not surprising.   Also the presence and quick loss of the erythroid 
cells did not appear to inhibit stromal cell development, confirming that they play no role in 
the establishment or maintenance of the stromal layer.  The stromal layer development took 5 
weeks to reach confluency and is similar to that described by Dexter et al (1976) for human 
bone marrow cultures. Whilst the stromal layer was developing the number of non -adherent 
cells remained consistent.  
 
4.4.6 Characterization of the hCB Non-Adherent Cells during LTBMC Stromal 
Layer Development 
 
The total hCB non-adherent cell count and the cell counts for each cell population identified 
by morphology remained slightly increased, when compared to the number of cells initially 
added to the cultures, during the stromal development period. 
 
The greatest change in the cell populations monitored was the proportional increase over the 
first five weeks in the relative numbers of monocytes, pro-monocytes and macrophages in the 
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non-adherent cells collected, which by week 6, represented 80% of the non -adherent cell 
population.  Thus the monocytes, its precursors and macrophages appear to be the most 
predominant cell type in both the adherent (discussed in the previous section) and non-
adherent layer. In vivo, macrophages have been shown to play a similar role to that seen in 
vitro; an integral component of the microenvironment important in supporting haematopoiesis, 
by the production of cytokines to initiate and drive cell differentiation and maturation.   
 
A relative increase in the granulocyte population was noted in the first three weeks, with the 
promyelocytes and the metamyelocytes representing 40% and 18% of the total non-adherent 
population, respectively. The relative proportion of the promyelocytes and metamyelocytes 
continued to decline during the stromal development period and also reached a plateau by the 
fifth week of culturing.  
Also the erythroblasts (nucleated red blood cells) lineage declined the quickest with no cells of 
that lineage observed after week 1. 
 
4.4.7 Inoculated LTBMC with Confluent Stromal Layer 
 
There was a continuous production of non-adherent cells throughout the four-week period that 
the cultures were maintained.  Also, the cell count of the non-adherent layer was maintained 
despite the nearly total depletion of non-adherent cells at weekly intervals.  This suggests that 
an active LTBMC system had been established enabling the continuous proliferation and 
differentiation of haemapoietic progenitors.   
 
4.4.8 Clonogenic Cultures of Non Adherent Cells after Inoculation with Fresh 
hCB Cells 
 
Cells present within the hCB non-adherent cell population harvested at weekly intervals from 
the inoculated cultures were able to proliferate and differentiate into colonies of the erythroid, 
granulocytic/ monocytic and megakaryocytic cell lineages.  Also colony numbers for all cell 
lineages were maintained at constant levels throughout the four-week period that the cells 
were collected. 
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4.4.9 Identification of Cell Lineages within the Murine and hCB Non-Adherent 
Cells, Using Flow Cytometry 
 
The morphological identification by light microscopy, of the cell lineage of some of the cells 
was difficult, and cells that could not be identified were classified as mononuclear cells.  Cell 
lineage identification was easier using lineage specific markers.  Also a larger number of cells 
could be analysed; 10, 000 cells by flow cytometry as opposed to 100 cells by light 
microscopy, improving the accuracy of the analysis. Additionally comparisons of the cell 
lineages identified by morphology and flow cytometry demonstrated similarities in the 
proportions of the different cell lineages (analysed in the stromal development phase only).  
For example, the mono/macro precursors and the granulocytic precursors are the predominant 
precursor cell lineages, as determined by flow cytometry and cell morphology.  Additionally, 
both methods of lineage identification identified similar proportions of progenitor cells and 
erythroid cells.  The use of flow cytometry and light microscopy for the identification of cell 
populations, have both advantages and disadvantages.  Flow cytometric analysis enables large 
numbers of cells to be analyzed, and identifies cells that are difficult to distinguish 
morphologically, whereas light microscopy can aid visualization of different developmental 
stages of cells that are not accompanied with a change in surface markers.  The utility of both 
flow cytometry and morphology in combination was demonstrated by this work. In order to 
confirm the cell populations identified by flow cytometry, immunohistochemical staining 
techniques could have been employed on cytospins of the non adherent cells.  This additional 
confirmation step was not carried out in this work.  Both flow cytometry and 
immunohistochemistry are recognized as diagnostic tools in the diagnosis of leukemia, 
lymphomas and a number of other tumors (Solomon and Kossev, 2002).  Therefore the 
additional confirmation of the flow cytometric analysis, by immunohistochemistry could be 
considered unnecessary. 
4.4.10 Comparison of Murine LTBMC with hCB LTBMC 
 
The development of the hCB stromal layer morphologically appears to be similar to that 
described for murine stromal layer development.  hCB stromal layers appear to reach 
confluency by the end of 5 weeks whereas the murine stromal layers appear to require 6 
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weeks. 
 
Comparison of the hCB non-adherent cells with murine non-adherent cells identified using 
flow cytometry shows similarities.  For example, the monocytic and granulocytic cell 
populations were the most prominent cell lineage identified in both human and murine 
cultures.  Additionally, for both species a fast decline of erythrocytic precursors was seen. 
Both murine and hCB LTBMC were able to proliferate and differentiate into colonies of the 
erythroid, granulocytic/ monocytic and megakaryocytic cell lineages.  Also colony numbers 
for all cell lineages were maintained throughout the four-week period that the cells were 
collected. 
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Chapter 5 
5.1 Experimental Part 3: Elucidation of mechanism of action of 
Anagrelide Hydrochloride 
5.1.1 Anagrelide Hydrochloride (AN) 
 
Anagrelide (6-7- dichloro-1, 5 dihydroimidazo (2, 1-b)-quinazoline-2 (H3) –one 
monohydrochloride monohydrate), is currently licensed for the treatment of Essential 
Thrombocythemia (ET).  However, AN was originally developed by Roberts laboratories Inc 
(Eatontown, USA) as a potential anti-thrombotic therapy.  The anti-thrombotic pharmacology 
of AN results from the inhibition of platelet aggregation.  Single dose administration up to and 
including a dose of 25mg, resulted in the desired anti-thrombotic activity with no reduction in 
peripheral blood platelet count during the two week follow- up period. However, initial repeat 
dose studies in healthy volunteers highlighted the ability of anagrelide to reduce platelet 
counts.   Doses greater than or equal to 1mg were noted to cause a reduction in peripheral 
blood platelet count (SBA. 1997).   A detailed review of the structure, pharmacology, 
preclinical data on AN is provided in Chapter 1. 
 
Bone marrow aspirates from patients with ET pre and post treatment with anagrelide 
demonstrated no alteration in the number of megakaryocytes (SBA, 1997). Additionally, doses 
that resulted in the reduction of platelet counts in the pre-clinical toxicology studies caused no 
significant reduction in megakaryocytes.  Therefore the reduction in circulating platelets was 
not a direct result of a reduction in the number of megakaryocytes within the bone marrow. No 
reduction in erythrocytic or granulocytic or monocytic cell counts was noted, highlighting the 
specificity of anagrelide (AN) to the megakaryocytic lineage alone.  The mechanism (s) 
involved in this unique megakaryocytic lineage specific inhibition is currently unknown.  
Several hypotheses of the potential mechanism have been put forward by a number of 
researchers; the current understanding of the potential mechanism is discussed on Chapter 1.   
AN has been in clinical use for the treatment of ET (second line treatment) for at least 8 years 
and although it has been shown to reduce platelet counts effectively in ET patients, there is 
some concern that it may cause myelofibrosis. 
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Mazur et al (1992) demonstrated that AN at concentrations of 32 μM to 161μM, resulted in an 
increase (65%) in the percentage of megakaryocytes in developmental stages I and II when 
compared with concurrent controls (41.5% in developmental stages I and II).  This shift in the 
developmental stage of cultured human megakaryocyte is a morphological change only, and in 
terms of megakaryocyte function is unclear.  
 
Lane et al, (2001) hypothesized that all in vitro and in vivo studies carried out with AN’s 
thrombocytopenic effects have been complicated, for a number of reasons. Firstly, the water-
insoluble nature of AN (solubility of AN in water was 2μg/mL) has hindered in vitro studies, 
secondly, AN only decreases platelet levels in human subjects. This obstacle has hindered 
studies related to pharmacokinetics and toxicity in monkeys, dogs, and mice. Finally, the 
extensive biotransformation of AN has suggested that the anti-platelet aggregation and 
thrombocytopenia effects may not be directly mediated by intact AN, but rather through active 
metabolite AM.  Lane et al (2001) proposed that biotransformation of AN into active 
metabolite was essential for its thrombocytopenic effect in mice.  On the basis that only the 
human liver has the capacity to generate the active metabolite, AN compound can only induce 
thrombocytopenia in humans.  
 
Erusalimsky et al (2002) and Wang et al (2005) showed that all animal species investigated 
(rats, dogs, and rabbits) produce significant amounts of AM. For example, in rats given AN at 
5 mg/kg per day (dietary dosing), Cmax of AM was 38.6 nM and for AN 45nM.   
Another explanation for the species difference in the activity of AN comes from the work of 
McCarty et al (2006).  These investigators suggest that AN has greater affinity towards the 
human c-mpl (TPO) receptor than the murine c-mpl (TPO) receptor.  Clearly the debate on the 
mechanism of action of AN resulting in platelet count reduction is unresolved.  
5.1.2 Taxol 
 
As previously discussed, taxol is a known anti-microtubule agent that promotes the assembly 
of microtubules from tubulin dimers and stabilizes microtubules by preventing 
depolymerization (Needleman et al, 2005). This stability results in the inhibition of the normal 
dynamic reorganization of the microtubule network that is essential for vital interphase and 
mitotic cellular functions.   Bone marrow suppression is the major dose-limiting toxicity noted 
with Taxol. Neutropenia is the most common finding in clinical trials with Taxol with up to 
146 
30% decrease in neutrophil counts (Breton et al, 2001).  Thrombocytopenia has been noted in 
20% of the patients (platelet counts <100,000 cells/mm3) (White and de Alarcon, 2002.  In 
this work taxol was used as a positive control (compound known to cause tubulin changes in 
megakaryocytes) for tubulin flow cytometry analyses. 
5.1.3  Human Cord Blood Haematopoietic Stem Cells 
 
Over the last decade, a series of studies have revealed human cord blood as an abundant 
source of haematopoietic stem cells (Broxmeyer et al, 1989; Hofmeister et al, 2007).  
However, it is only in the last few years that human cord blood derived haematopoietic stems 
cells have become commercially available for in vitro use.  
Cord blood contains high concentrations of haematopoietic stem cells, higher than that found 
in adult bone marrow (Broxmeyer et al, 1992; Hofmeister et al, 2007).  In vitro assays 
conducted with human cord blood derived haematopoietic stem cells give rise to all the cell 
lineages, when exposed to the appropriate cytokine cocktails3. Comparison of cord blood and 
bone marrow in vitro cell lineages demonstrated that most colonies were 
monocyte/macrophage colonies (60.0 +/- 4.6%), whereas those from bone marrow were 
largely granulocyte colonies (88.3 +/- 6.2%). The differences of growth curve, colony size, 
and turnover state of CFUc between cord blood and bone marrow seemed, in part, to result 
from the dominancy of monocyte/macrophage colony-forming cells in cord blood. The cell 
cycling rate of CFUc in cord blood was remarkably lower than that in bone marrow. From 
these results, it seems clear that CFUc in cord blood may differ in some aspects from those of 
bone marrow derived haemopoietic cells (Hofmeister et al, 2007).   
 
5.1.4   Aims 
 
The work described here aims to investigate the mechanism(s) of the inhibition of 
megakaryocytic maturation, in vitro, by an agent used in the treatment of ET, AN.   
Although several advances to define the action of AN have been reported the elucidation of 
the mechanism(s) of megakaryocytic inhibition is currently unclear. AN appears to be 
selectively suppress megakaryocytes. Although a similar inhibition of murine megakaryocytes 
has been demonstrated both in vivo and in vitro, human megakaryocytes clearly appear to be 
more sensitive to the action of AN (chapter 3).  Therefore in order to elucidate the mechanism 
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of the inhibition of megakaryopoiesis human cord blood cells will be used as a source of 
human haematopoietic stem cells.   
To elucidate the mechanism of the selective inhibition of human Mk progenitors a number of 
approaches were used: 
 
1. Characterization of the effect of AN on cell cycling of hCB derived pluripotent stem cells 
in LTBMC.  This enables the evaluation of the effects of AN on the early haemapoietic 
precursors (pluripotent and multipotent stem cells.  In addition, the ability of the AN 
treated pluripotent and multipotent stem cells to give rise to lineage specific progenitors of 
the erythroid, monocytic/granulocytic and megakaryocytic cell lineages was evaluated. 
2. Establishment of the AN concentration at which 50 percent of the CFU-E, GM-CFU and 
Mk colonies growth inhibition is achieved (IC50) using hCB derived stem cells in 
clonogenic cultures 
3. Characterization of the effect of AN on cell cycling and megakaryocytic ploidy using 
hCB derived stem cells in clonogenic cultures. 
4. Determination of the effects of AN on the expression of megakaryocytic cell surface 
antigens using hCB derived stem cells in clonogenic cultures. 
Characterization of the effect of AN on Mk-CFU colony microtubule organisation using hCB 
derived stem cells in clonogenic cultures.  In this work taxol was used as a positive control 
(compound known to cause tubulin changes in megakaryocytes) for tubulin flow cytometry 
analyses. 
 
5.2 Methods 
 
5.2.1 Procedure for Thawing Cryoperserved Mononuclear hCB 
The method employed is described in Appendix A 
5.2.2     Viability Count 
 
Cord cell viability was determined using the method described in Chapter 2 (section 2.2.8).  
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5.2.3   Human LTBMC Medium 
 
Human cord blood cultures were utilized as described in chapter 2 (section 2.2.5). 
 
5.2.4   Inoculation of Confluent Stromal Layer with Fresh hCB Stem Cells (CD34 
positive cells)  
 
The method employed is described in chapter 2 (section 2.2.12).  Within 1 hour of the fresh 
hCB stem cells being added to the established stromal layers, AN was added to the culture 
systems.  Concentrations of AN evaluated ranged from 0.01 to 10μM.  Each concentration was 
evaluated on 5 separate occasions, in triplicate on each occasion.  The preparation of the AN 
was carried out as described in section Chapter 2 (section 2.2.18) 
5.2.7   hCB Clonogenic Cultures 
 
Non-Adherent Cells Collected From hCB LTBMC Treated with AN  
 
For the assessment of non-adherent cells collected from the hCB LTBMC, 0.1mL of non-
adherent cells (1x105cells/mL) were added to the clonogenic culture media as described in 
Chapter 2 (sections 2.2.7 and 2.2.8).  Cell count was determined using an automated cell 
counter (Advia 120, Bayer, USA).    
Assessment of Affects of AN on Cell Lineages  
 
hCB clonogenic cultures as described in Chapter 2 were utilized in these experiments (sections 
2.2.7 and 2.2.8).  0.1ml of viable hCB cells (1x105cells/mL) were added to the cultures. Cell 
count was determined using an automated cell counter (Advia 120, Bayer, USA).    
Concentrations of AN evaluated ranged from 0.01 to 10μM.  Each concentration was 
evaluated on 3 separate occasions, in triplicate on each occasion.  The preparation of the AN 
was carried out as described in section Chapter 2 (section 2.2.11). 
5.2.6   Collection of CFU-Mk Colonies 
The method employed is described in chapter 4 (section 4.2.14) 
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5.2.7  Cell Cycle Analysis 
Cell cycle analysis as described in chapter 2, section 2.2.9 was employed.  
 
5.2.8  Flow cytometry of Cell Surface Receptors  
 
Cell preparation and flow cytometry analyses previously described in Chapter 2 (section 2.2.6) 
were employed.  Table 5.1 details the specific cell surface target for each antibody employed.  
 
Antibody Tube Concentration of 
Antibody 
(μg/mL) 
Expression/Target 
CD34/FITC 1 ,2 and 3 5 Stem cell 
CD61/PE 1, 2 and 4 5 Mk Glycoprotein IIIb Part of GPIIa/IIIb 
complex 
CD42/FITC 4  5 GP1 receptor 
CD42/PE 3 5 GP1 receptor 
 
Table 5. 1 Antibodies for receptor expression 
The human CFU-Mk lineage specific antibodies used in this investigation are shown, together with their 
respective antigen target, volume and concentration used as well as the tube combination employed. 
  
5.2.9  Intracellular Staining 
 
Intracellular staining technique as described in Chapter 2, (section 2.2.6) was employed. 10μL 
of anti-Tubulin α or anti-Tubulin –β was added to the cells.  Table 5.2 details the specific cell 
surface target for each antibody employed.  
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Antibody Tube Concentration of 
Antibody 
(μg/mL) 
Expression/Target 
Mouse Anti-
Human Tubulin α 
1  5 Tubulin α 
Mouse Anti-
Human Tubulin β 
2 5 Tubulin –β 
 
Table 5. 2 Antibodies for Intracellular staining  
The anti- human tubulin-α and tubulin –β antibodies used are shown  
5.3 Results 
5.3.1 Evaluation of the Effect of AN on Cell Cycling of hCB Derived Pluripotent 
Stem Cells in LTBMC  
Effects of AN on Cell Cycling 
 
Cell cycle analyses were carried out on vehicle and AN treated hCB LTBMC.  Non-adherent 
cells were collected at weekly intervals and cell cycle analysis performed using flow 
cytometry.  Figures 5.1 to 5.3 show the percentage of non-adherent haemopoietic cells in 
G0/G1, G2/M (mitotic) and synthesis phase (S).  Non adherent cells from each AN treated 
culture was collected and pooled prior to analyses. Mean data from 3 separate occasions are 
shown.  In addition, table 5.3 shows the cell cycle analyses from each culture.   
 
151 
0
10
20
30
40
50
60
70
80
90
-1 1 2 3
Week
Pe
rc
en
ta
ge
 o
f C
el
ls
 in
 G
0/
G
1 
(%
) 
Vehicle control 0.01 μM AN 0.1 μM AN 1 μM AN 10 μM AN
 
Figure 5. 1Cell Cycle Analyses: Percentage of Non-Adherent cells Collected from hCB 
LTBMC in G0/G1   
The mean percentage of Mk culture cells in the G0/G1 of cell cycling is provided.  Vehicle control and 
AN at concentrations from 0.1 to 10μM were evaluated in triplicate on 3 separate occasions. No 
change in the percentage of cells in G0/G1 was noted in vehicle control or any AN treated cultures.   T- 
test and Dunnetts test performed comparing  AN treated cultures concurrent weekly vehicle control.  
No statistical difference in the percentage of cells in G0/G1 was noted in vehicle control or any AN 
treated cultures. 
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Figure 5. 2 Cell Cycle Analyses: Percentage of Non-Adherent cells Collected from 
hCB LTBMC in S Phase   
The mean percentage of Mk culture cells in the S phase of cell cycling is provided.  Vehicle and AN at 
concentrations from 0.1 to 10μM were evaluated in triplicate on 3 separate occasions. No change in 
the percentage of cells in S phase was noted in vehicle control or any AN treated cultures.   T- test and 
Dunnetts test performed comparing  AN treated cultures with concurrent weekly vehicle control.  No statistical 
difference in the percentage of cells in S phase was noted in vehicle control or any AN treated cultures. 
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Figure 5. 3 Cell Cycle Analyses: Percentage of Non-Adherent cells Collected from 
hCB LTBMC in G2/M  
The mean percentage of Mk culture cells in the G2/M of cell cycling is provided.  Vehicle and  AN at 
concentrations from 0.1 to 10μM were evaluated in triplicate on 3 separate occasions. No change in 
the percentage of cells in G2/M was noted in vehicle control or any AN treated cultures.   T- test and 
Dunnetts test performed comparing  AN treated cultures with concurrent weekly vehicle control. No statistical 
difference in the percentage of cells in G2/M was noted in vehicle control or any AN treated cultures. 
  
 
The  cell cycle analyses carried out weekly on vehicle control treated cutlures (Figure 5.1 to 
5.3 ) shows no alteration in cell cycling, with 70% of the cells in G0/G1, 8% in S and 22% in 
G2/M phase.  No statistically significant changes in the percentage of G0/G1, S or G2/M were 
noted in the weekly analyses. 
Cell cycle analyses carried out on cultures treated with AN at concentrations ranging from 
0.01 to 10 μM  (Figure 5.1 to 5.3).  No statistically significant alteration in cell cycling when 
compared with vehicle control.  At 0.1 μM AN concentration, all three weekly experiments 
show the same slight numerical (statistically insignificant) increase in the percentage of cells 
in G2/M phase when compared with vehicle control levels (for each corresponding weekly 
cvehicle control), but not when compared with pre-treatment levels.  A similar numerical 
(statistically insignificant) increase in the percentage G2/M cells was noted at 10 μM AN 
concentration in weeks 2 and 3 when compared with pre-treatment and vehicle control levels. 
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Treatment Sampling Occasion Percentage of 
colonies in G0/G1 
(%) 
Percentage of 
colonies in S 
(%) 
Percentage of 
colonies in G2/M 
(%) 
 EXP. No 1 2 3 1 2 3 1 2 3 
Vehicle Pre-Dose 73 70 71 10 7 11 17 23 18 
 Post Dose Week 1 71 68 73 7 11 9 22 21 18 
 Post Dose Week 2 81 70 64 4 8 8 15 22 28 
 Post Dose Week 3 84 73 70 6 3 6 10 24 24 
 Post Dose Week 4 68 70 61 4 8 10 28 22 29 
                    
0.01μM AN Pre-Dose 67 72 66 5 9 7 28 19 27 
 Post Dose Week 1 64 78 70 11 7 8 25 15 22 
 Post Dose Week 2 69 73 67 4 10 7 27 17 26 
 Post Dose Week 3 61 70 66 13 4 10 26 26 24 
 Post Dose Week 4 74 70 74 3 9 8 23 21 18 
                    
0.1μM AN Pre-Dose  70 64   61  5  6  9 24   30  30 
 Post Dose Week 1 68 75 80 4 4 2 28 21 18 
 Post Dose Week 2 78 74 71 4 4 4 18 22 25 
 Post Dose Week 3 77 72 70 7 9 9 16 19 21 
 Post Dose Week 4 70 74 74 4 4 8 26 22 18 
                    
1μM AN Pre-Dose 72 74 77 12 1 5 16 25 18 
 Post Dose Week 1 66 73 81 6 9 4 28 18 15 
 Post Dose Week 2 77 70 72 9 12 6 14 18 22 
 Post Dose Week 3 73 75 77 8 6 8 19 19 15 
 Post Dose Week 4 74 71 77 10 4 5 16 25 18 
                    
10μM AN Pre-Dose 71 74 69 13 6 4 16 20 27 
 Post Dose Week 1 69 74 70 12 11 5 19 15 25 
 Post Dose Week 2 71 73 74 16 4 5 13 23 21 
 Post Dose Week 3 75 73 79 12 8 4 13 19 17 
 Post Dose Week 4 72 74 78 3 9 6 25 17 16 
 
Table 5. 3  Cell Cycle Analyses of hCB Derived LTBMC Treated with Vehicle or AN 
Weekly for 4 Weeks  
The percentage of non-adherent cells, collected from hCB LTBMC, in the G0/G1, S and G2/M of cell 
cycling is shown.  Vehicle and AN at concentrations of 0.01 to 10μM were evaluated in triplicate on five 
separate occasions. No change in the percentage of colonies in G0/G1, S and G2/M was noted in 
vehicle control or any AN treated cultures. 
 
5.3.2 Ability of AN Treated LTBMC Non-Adherent Cells to Differentiate into 
Lineage Specific Progenitors 
 
Non adherent cells were collected at weekly intervals from hCB LTBMC treated weekly with 
either vehicle or AN for 3 weeks were collected, washed and added to hCB clonogenic cell 
cultures. The mean colony counts per well for the granulocyte/ monocyte; erythrocyte and 
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megakaryocyte cell lineages are shown in Figures 5.4 to 5.6, respectively and the granulocyte/ 
monocyte; erythrocyte and megakaryocyte colony counts are shown in table 5.4. No 
statistically significant change in colony counts per well was noted irrespective of AN 
concentration evaluated in the erythroid or granulocytic/monocytic or megakaryocytic cell 
lineages. 
 
Treatment Sampling Occasion Colony Counts /Well 
  CFU-GM  BFU-E CFU-Mk 
Exp. No 1 2 3 1 2 3 1 2 3 
Vehicle Post Dose Week 1 70 68 72 184 198 180 85 88 72 
 Post Dose Week 2 64 62 77 179 178 190 81 79 81 
 Post Dose Week 3 72 64 71 191 181 188 77 70 79 
           
0.01μM AN Post Dose Week 1 66 61 68 177 168 167 72 75 78 
 Post Dose Week 2 62 63 64 164 184 181 74 71 77 
 Post Dose Week 3 70 62 62 170 172 190 69 70 82 
           
0.1μM AN Post Dose Week 1 58 61 60 178 182 181 72 76 71 
 Post Dose Week 2 70 55 57 181 174 183 71 68 77 
 Post Dose Week 3 68 60 61 180 167 185 77 72 70 
           
1μM AN Post Dose Week 1 60 78 66 175 190 181 70 73 77 
 Post Dose Week 2 66 64 62 170 181 188 68 74 72 
 Post Dose Week 3 64 70 61 190 173 184 77 79 73 
           
10μM AN Post Dose Week 1 66 73 79 189 195 178 63 77 68 
 Post Dose Week 2 61 65 61 179 193 176 80 71 65 
 Post Dose Week 3 63 69 60 181 190 180 72 76 74 
Table 5. 4 The Mean CFU-GM, BFU-E and CFU-Mk Colony Counts Following 
Treatment with Vehicle or AN in hCB LTBMC 
The mean number of colonies per well after treatment with AN treatment (0.01 to 10μM), weekly for 4 
weeks.  No statistically significant change in BFU-E, CFU-GM or CFU-Mk colony counts per well was 
noted irrespective of AN concentrations evaluated. 
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Figure 5. 4 Change in Erythroid Colony Number after Treatment with AN in hCB 
LTBMC 
The mean number of colonies per well after treatment with AN treatment (at concentrations from 0.1 to 
10μM), weekly for 4 weeks. No statistically significant change in BFU-E colony counts per well was 
noted at any of the AN concentrations evaluated. Each concentration evaluated in triplicate on three 
separate occasions. Mean vehicle control BFU-E colony count 188 (+/- 28).  
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Figure 5. 5 Change in Granulocytic/Monocytic Colony Number after Treatment with 
AN in hCB LTBMC 
Figure shows the mean number of colonies per well after treatment with AN at concentrations from 0.1 
to 10μM. No statistically significant change in CFU-GM colony counts per well was noted at any of the 
AN concentrations evaluated. Each concentration evaluated in triplicate on three separate occasions.  
Mean vehicle control CFU-GM colony count 69 (+/- 15).  
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Figure 5. 6 Change in Megakaryocytic Colony Number after Treatment with AN in 
hCB LTBMC 
Figure shows the mean number of colonies per well after treatment with AN concentrations from 0.01 to 10μM. No 
statistically significant change in CFU-Mk colony counts per well was noted irrespective of AN 
concentration evaluated. Each concentration evaluated in triplicate on three separate occasions.  Mean 
vehicle control CFU-Mk colony count 85 (+/- 11).   
 
5.3.3 Establishment of the AN IC50 Concentration for the CFU-E, CFU-GM and 
Mk Colonies, using hCB Derived Stem Cells in Clonogenic Cultures 
 
The effect of AN on granulocyte/ monocyte, erythrocyte and megakaryocyte maturation was 
assessed in short-term cultures, and data was expressed as IC50 values (the concentrations at 
which in vitro colony growth was inhibited by 50%).  The change in colony counts per well 
for the granulocyte/ monocyte, erythrocyte and megakaryocyte cell lineages are shown in 
Figures 5.7 to 5.9, respectively. The individual colony counts are shown in Table 5.5.  Figure 
5.10 shows the mean number of colonies per well for the granulocyte/ monocyte, erythrocyte 
and megakaryocyte cell lineages (of three experiments).  
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A reduction in the colony counts per well with an increase in AN concentration was noted in 
the megakaryocytic cell lineage only. The IC50 concentration of AN for the megakaryocytic 
cell lineage was 1.92μM.  No biologically relevant decrease in colony number was noted in 
either the granulocytic/monocytic lineage or the erythrocytic cell lineage.  Consequently the 
IC50 concentrations of AN for the granulocytic/monocytic lineage or the erythrocytic cell 
lineages could not be determined. 
 
Treatment Exp. No Colony Counts /Well 
  CFU-GM  BFU-E CFU-Mk 
 Replicate No. 1 2 3 1 2 3 1 2 3 
Vehicle 1 54 73 79 192 173 205 80 83 80 
 2 77 81 80 161 164 169 82 86 86 
 3 72 71 81 166 151 116 83 84 83 
           
0.01μM AN 1 83 74 70 193 160 206 73 74 77 
 2 73 63 83 145 188 164 86 79 81 
 3 68 56 59 160 186 185 69 65 71 
           
0.1μM AN 1 75 54 76 215 196 188 61 66 60 
 2 68 70 70 189 153 204 77 68 76 
 3 59 73 76 139 154 172 61 62 63 
           
1μM AN 1 59 73 76 215 196 188 52 57 49 
 2 68 70 70 189 153 204 61 57 65 
 3 75 54 76 157 181 169 55 55 52 
           
10μM AN 1 61 69 61 139 154 172 47 42 44 
 2 81 83 71 165 164 182 52 41 43 
 3 63 75 77 206 200 216 46 41 46 
           
100μM AN 1 41 68 77 185 196 159 40 38 32 
 2 67 69 73 193 173 149 44 30 33 
 3 84 93 72 165 183 176 38 35 32 
Table 5. 5 Change in CF-GM, BFU-E and CFU-Mk Colony Number after Treatment 
with AN in hCB Clonogenic Cultures 
 
The number of colonies per well after treatment with AN at concentrations of 0.01 to 10μM is shown. 
Each concentration evaluated in triplicate on three separate occasions.  No biologically or statistically 
relevant decrease in colony number was noted in the CFU-GM or BFU-E colony numbers at any AN 
concentration evaluated.  The IC50 concentrations of AN for the CFU-GM could not be determined.  A 
reduction in the CFU-Mk colony counts per well with an increase in AN concentration was noted. The 
IC50 concentration of AN for the CFU-Mk was 1.92μM. 
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Figure 5. 7 Change in Erythroid Colony Number after Treatment with AN in hCB 
Clonogenic Cultures 
The mean number of colonies per well after treatment with AN at concentrations from 0.01 to 100μM is shown. No 
biologically or statistically significant decrease in colony number was noted in the BFU-E colony numbers at any 
AN concentration evaluated.  The IC50 concentrations of AN for the BFU-E could not be determined. Each 
concentration evaluated in triplicate on three separate occasions. Mean vehicle control colony count 188 /well (+/- 
17 BFU-E colonies).  
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Figure 5. 8 Change in Granulocytic/Monocytic Colony Number after Treatment with 
AN in hCB Clonogenic Cultures 
The mean number of CFU-GM colonies per well after treatment with AN at concentrations from 0.01 to 
100μM is shown. No biologically or statistically relevant decrease in colony number was noted in the CFU-GM 
colony numbers at any AN concentration evaluated.  The IC50 concentrations of AN for the CFU-GM could not be 
determined.  Each concentration evaluated in triplicate on three separate occasions.  Mean vehicle 
control colony count 83 colonies /well (+/- 24 CFU-GM colonies).  
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Figure 5. 9 Change in Megakaryocytic Colony Number after Treatment with AN In 
hCB Clonogenic Cultures 
The mean number of colonies per plate after treatment with AN at concentrations from 0.01 to 100μM is shown. A 
reduction in the CFU-Mk colony counts per well with an increase in AN concentration was. The IC50 concentration 
of AN for the CFU-Mk was 1.92μM.  Each concentration evaluated in triplicate on three separate occasions. Mean 
vehicle control colony count 76 colonies /well (+/- 31 CFU-Mk colonies). * P<0.05 compared AN treated cultures 
with concurrent no AN treatment control 
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Figure 5. 10 Mean Change in Colony Number after Treatment with AN in hCB 
Clonogenic Cultures 
The mean number of colonies per well after treatment with AN at concentrations from 0.01 to 100μM is shown. No 
biologically / statistically relevant decrease in colony number was noted in the CFU-GM or BFU-E colony numbers 
at any AN concentration evaluated.  The IC50 concentrations of AN for the CFU-GM could not be determined.  A 
reduction in the CFU-Mk colony counts per well with an increase in AN concentration was noted. The IC50 
concentration of AN for the CFU-Mk was 1.92μM. Each concentration evaluated in triplicate on three separate 
occasions. Data shown are Mean +/- SEM. *  P<0.05 compared AN treated cultures with concurrent no AN 
treatment control. Mean vehicle control BFU-E colony count 188 (+/- 17 BFU-E colonies). Mean vehicle 
control colony count 83 colonies /well (+/- 24 CFU-GM colonies). Mean vehicle control colony count 76 
colonies /well (+/- 31 CFU-Mk colonies). 
 
5.3.4 Evaluation of the effect of AN on cell cycling and megakaryocytic ploidy 
using hCB derived stem cells in clonogenic cultures 
 
Cell Cycle Analyses 
 
The previous cell cycle analysis was carried out on non-adherent cells collected from hCB 
LTBMC.  In this series of experiments cell cycle analyses were carried out on vehicle and 
anagrelide treated cells in triplicate Mk-CFU clonogenic cultures on three separate occasions. 
Table 5.6 shows the cell cycle analyses.   Figure 5.11 shows the percentage of cells in G0/G1, 
synthetic (S) and G2/mitotic phase (G2+M). 
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Figure 5. 11 Cell cycle analyses of AN Treated hCB Clonogenic Cultures  
The mean percentage of Mk cells at different phases of cell cycling after treatment with vehicle or AN (0.01 to 
10μM) shows a AN treatment related increase in CFU-Mk colonies in Go/G1 at concentrations of 1 and 10μM.  A 
corresponding decrease in CFU-Mk colonies S and G2/M is also noted. Vehicle control or AN was evaluated in 
triplicate on three separate occasions.  Data shown are Mean data from three separate experiments.  Data shown 
are mean +/- SEM. *P<0.05 compared AN treated cultures with concurrent no AN treatment control. 
 
The cell cycle analyses carried on vehicle control treated cutlures (Figure 5.11) shows no 
alteration in cell cycling, with 60% of the cells in Go/G1, 11% in S and 29% in G2/M phase.   
 
Cell cycle analyses were carried out on Mk-CFU colonies collected from clonogenic cultures 
treated with AN at concentrations ranging from 0.01 to 10 μM (Figure 5.11). No treatment 
related change in the percentage of G0/G1, S and G2/M populations was noted at 
concentrations of 0.01 or 0.1μM AN. A treatment related increase in the precentage of 
colonies in G0/G1 and corresponding decrease in the percentage of colonies in S phase was 
noted at 1 and 10 μM AN.  In addition at 10 μM AN concentration a decrease on the 
percentage of colonies in G2/M was also noted.  
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Treatment Exp. No Cell Cycle Data 
  Colonies in G0/G1 
(%) 
Colonies in S 
(%) 
Colonies in G2/M 
(%) 
 Replicate No. 1 2 3 1 2 3 1 2 3 
Vehicle 1 58 61 63 14 17 12 28 22 25 
 2 57 60 62 15 14 11 28 26 27 
 3 55 67 63 15 6 12 30 27 25 
           
0.01μM AN 1 66 64 53 3 7 15 31 29 32 
 2 57 63 62 10 4 13 33 33 25 
 3 63 56 66 6 14 4 31 30 30 
           
0.1μM AN 1 62 63 60 5 11 3 33 26 27 
 2 64 62 61 6 10 13 30 28 26 
 3 60 64 62 9 10 5 31 26 33 
           
1μM AN 1 77 75 76 6 7 3 17 18 21 
 2 70 79 77 11 3 3 19 18 20 
 3 71 70 68 6 8 7 23 22 25 
           
10μM AN 1 80 84 78 4 3 3 16 13 19 
 2 81 83 77 1 3 7 18 14 16 
 3 83 80 76 1 5 7 16 15 17 
Table 5. 6 Cell cycle analyses of AN Treated hCB Clonogenic Cultures 
 
The percentage of Mk colonies in G0/G1, G2/M and S phase, after treatment with vehicle or AN shows 
a AN treatment related increase in CFU-Mk colonies in Go/G1 at concentrations of 1 and 10μM.  A 
corresponding decrease in CFU-Mk colonies S and G2/M is also noted. Vehicle or AN was evaluated 
in triplicate on three separate occasions. 
 
 
The ploidy number of CFU-Mk colonies was determined of colonies collected from the 
cultures (Figure 5.12 and Table 5.7).  The majority of colonies have a DNA content of 2N 
(60%), 25% 4N with 8N, 16N, 32N and 64N each representing <5% of the total CFU-Mk 
colony population.  A statistically significant increase in the number of 2N colonies and a 
statistically significant decrease 4N and 8N ploidy were noted in CFU-Mk colonies treated 
with 1 and 10 μM AN, respectively.  No changes were noted in the number of CFU-Mk 
colonies with DNA content > 8N.    
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Figure 5. 12 Ploidy Determination of hCB CFU-Mk Colonies following AN Treatment 
The mean percentage of Mk colonies with different ploidy levels after treatment with vehicle control or AN (0.01 to 
10μM) shows an increase in the percentage of colonies with 2N DNA content at AN concentrations of 1 and 10μM.  
A decease in colonies with 4N and 8N DNA content is also noted at 1 and 10μM.  Each concentration was 
evaluated in triplicate on three separate occasions.  Data shown are mean +/- SEM.  *P<0.05 compared AN 
treated cultures with concurrent no AN treatment control. 
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Treatment Exp. No Ploidy (N Number )Data 
  2N 4N 8N 16N 32N 64N 
Vehicle 1 55 20 15 3 3 4 
 2 60 22 11 5 3 1 
 3 55 26 10 3 3 3 
        
0.01μM AN 1 61 15 16 5 2 1 
 2 66 12 8 6 3 5 
 3 53 17 11 8 4 7 
        
0.1μM AN 1 55 24 12 6 3 3 
 2 61 17 16 4 2 0 
 3 56 24 7 6 4 3 
        
1μM AN 1 80 7 2 5 3 0 
 2 80 9 4 3 3 1 
 3 81 11 2 2 1 3 
        
10μM AN 1 84 5 7 2 1 1 
 2 82 7 5 2 4 0 
 3 80 8 4 4 4 0 
 
Table 5. 7 Ploidy Determination of hCB CFU-Mk Colonies following AN Treatment 
The mean percentage of Mk colonies with different ploidy levels after treatment with vehicle control or 
AN (0.01 to 10μM) shows an increase in the percentage of colonies with 2N DNA content at AN 
concentrations of 1 and 10μM.  A decease in colonies with 4N and 8N DNA content is also noted at 1 
and 10μM.  Vehicle or AN was evaluated in triplicate on three separate occasions. 
 
5.3.5 Determination of the Effects of AN on the Expression of Megakaryocytic 
Cell Surface Antigens Using hCB Derived Stem Cells in Clonogenic Cultures 
 
Treatment with AN resulted in a numerical decrease in the percentage of CD34 positive /CD 
61 negative colonies and, although not statistically significant, at 1 and 10 μM anagrelide 
(Figure 5.13). Table 5.8 shows the percentage of cells with each of the surface antigen 
expression evaluated.  The percentage of CD34 negative /CD61 positive colonies show a 
statistically significant decrease at 1 and 10 μM AN concentrations. The percentage of CD34 
positive/CD61 negative, CD34 / CD61 dual positive and CD61 / CD42 dual positive colonies 
demonstrated no statistically significant changes at all AN concentrations evaluated.  
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Figure 5. 13 Surface Receptor Expression Determination of CFU-Mk Colonies Treated 
with AN 
The mean percentage of Mk colonies expressing lineage specific surface receptors after treatment with AN at 
concentrations from 0.01 to 10μM is shown.  Treatment with AN resulted in a numerical decrease in the 
percentage of CD34 positive /CD 61 negative colonies and, although not statistically significant, at 1 and 10 μM 
AN. The percentage of CD34 negative /CD61 positive colonies show a statistically significant decrease at 1 and 10 
μM AN concentrations. The percentage of CD34 positive/CD61 negative, CD34 / CD61 dual positive and CD61 / 
CD42 dual positive colonies demonstrated no statistically significant changes at all AN concentrations evaluated  
Each concentration was evaluated in triplicate on three separate occasions.  Data shown are Mean +/- SEM. * 
P<0.05 compared AN treated cultures with concurrent no AN treatment control 
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Treatment Exp. No Percentage of Surface Antigen Expression (%) 
  CD34 positive/ 
CD61 negative 
CD34 Positive 
/CD61 positive 
CD34 Negative/ 
CD61positive 
CD61 Positive 
/CD42 positive 
 Replicate No. 1 2 3 1 2 3 1 2 3 1 2 3 
Vehicle 1 18 15 14 33 35 39 36 37 30 13 13 17 
 2 14 16 17 27 33 30 33 35 36 26 16 17 
 3 17 16 15 34 27 29 35 34 35 14 23 21 
              
0.01μM AN 1 15 13 15 22 31 34 33 30 35 30 26 16 
 2 15 16 14 34 33 30 34 27 31 17 24 25 
 3 14 18 12 24 23 25 34 30 29 28 29 34 
              
0.1μM AN 1 13 18 15 34 26 33 34 39 33 19 17 19 
 2 14 11 16 31 28 35 34 37 31 21 24 18 
 3 16 11 19 33 34 31 33 30 32 18 25 18 
              
1μM AN 1 23 25 22 33 35 39 12 15 18 32 25 21 
 2 21 19 27 41 30 35 18 18 12 20 33 26 
 3 23 24 22 36 38 37 17 16 17 24 22 24 
              
10μM AN 1 26 24 25 34 30 28 12 18 17 28 28 30 
 2 28 22 29 27 35 31 15 16 14 30 27 26 
 3 25 24 23 33 29 30 14 17 15 30 30 32 
 
Table 5. 8 Surface Receptor Expression Determination of CFU-Mk Colonies Treated 
with AN 
The percentage of Mk colonies expressing lineage specific surface receptors after treatment with AN is 
shown.  Treatment with AN resulted in a numerical decrease in the percentage of CD34 positive /CD 
61 negative colonies and, although not statistically significant, at 1 and 10 μM AN. The percentage of 
CD34 negative /CD61 positive colonies show a statistically significant decrease at 1 and 10 μM AN 
concentrations. The percentage of CD34 positive/CD61 negative, CD34 / CD61 dual positive and 
CD61 / CD42 dual positive colonies demonstrated no statistically significant changes at all AN 
concentrations evaluated   
 
5.3.6 Evaluation of the Effect of AN on Mk-CFU Colony Microtubule 
Organization using hCB Derived Stem Colonies in Clonogenic Cultures 
 
Two AN concentrations (1 and 10 μM) that have previously been shown to cause alteration in 
Mk precursor ploidy, cell cycling, Mk precursor cell surface receptor alteration and inhibit Mk 
–CFU colony growth were selected.  Taxol was selected as a positive control compound.  The 
defined pharmacology of taxol is as a microtubule disrupter, as well as clinical data 
demonstrating the ability of taxol to induce thrombocytopenia in 20% of patients.  The 
concentration of Taxol used in this experiment (1μM) was selected based upon hCB cell 
viability (concentration at which 75 to 81% cell viability was achieved), Figure 5.14.  The 
hCB viability percentages are shown in Table 5.8. 
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The percentage of tubulin –α and tubulin-β1 in Mk colonies after treatment with AN (1 and 10 
μM) or Taxol (1μM) was determined, using intracellular flow cytometric staining techniques.   
Figure 5.15 shows the mean percentage of tubulin –α and tubulin-β1 in Mk colonies post 
anagrelide and Taxol treatment.  Table 5.10 shows the percentage of tubulin –α and tubulin-β1 
in Mk colonies post anagrelide and Taxol treatment.  Although the number of tubulin –α and 
tubulin-β1 positive colonies tended to be lower, no statistically significant decrease in the 
expression levels of either tubulin –α and tubulin-β1 was noted.  
 
The mean fluorescence intensity of the tubulin –α and tubulin-β1 staining of Mk colonies 
treated with AN or Taxol was compared with the mean fluorescence intensity of the untreated 
Mk colonies (Table 5.11).  A statistically significant decrease in the mean fluorescence 
intensity was noted with tubulin-β1 staining (Figure 5.16) of Mk colonies treated with AN at a 
concentration of 10 μM and with Taxol at a concentration of 1 μM.  No statistically significant 
change in mean fluorescence intensity was noted in tubulin –α staining of Mk colonies treated 
with AN or Taxol.    
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Figure 5. 14 Mean Percentage of Viable hCB after Treatment with Taxol. 
The percentage of viable colonies (determined using Annexin V/ PI staining) is shown, following 
incubation with vehicle control and Taxol at concentrations from 0.1 and 100μM.  The percentage of 
viable colonies decreases with Taxol concentration.  Minimal cell viability is lost at Taxol concentrations 
of 0.1 and 1 μM.  Each concentration evaluated in triplicate on three separate occasions.  Data shown 
are Mean +/- SEM 
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Figure 5. 15 Mean Percentage of Alpha and Beta Tubulin in Mk Colonies after 
Treatment with AN or Taxol. 
The mean percentage of tubulin –α and tubulin-β1 expression in Mk colonies after treatment with AN (1 and 10 
μM) or Taxol (1μM) is shown.   The number of tubulin –α and tubulin-β1 positive colonies tended to be lower 
(compared with concurrent control) no statistically significant decrease in the expression levels of either tubulin –α 
and tubulin-β1 was noted. Each concentration evaluated in triplicate on three separate occasions.  Data shown 
with +/- SEM  
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Treatment Exp. No Viability Counts (%) 
 Replicate No. 1 2 3 
Vehicle 1 88 80 74 
 2 81 84 85 
 3 78 73 76 
     
0.1μM Taxol 1 80 87 94 
 2 88 75 89 
 3 83 89 88 
     
1μM Taxol 1 70 78 79 
 2 67 71 89 
 3 71 85 72 
     
10μM Taxol 1 65 61 51 
 2 58 68 50 
 3 51 68 56 
     
100μM Taxol 1 46 42 38 
 2 40 41 45 
 3 39 49 38 
 
Table 5. 9 Percentage of Viable Mk-CFU Colonies after Treatment with Taxol 
The percentage of viable colonies (determined using Annexin V/ PI staining) is shown, following 
incubation with vehicle control and Taxol at concentrations from 0.1 and 100μM.  The percentage of 
viable colonies decreases with Taxol concentration.  Minimal cell viability is lost at Taxol concentrations 
of 0.1 and 1 μM.  Each concentration evaluated in triplicate on three separate occasions. 
 
 
Treatment Tubulin Percentage of Tubulin expression (%) 
 Exp. No 1 2 3 
 Replicate No. 1 2 3 1 2 3 1 2 3 
Vehicle Tubulin-Alpha 80 79 73 80 83 78 77 80 84 
 Tubulin-Beta 85 87 75 78 74 87 83 81 80 
           
1μM AN Tubulin-Alpha 75 77 80 79 81 76 79 80 77 
 Tubulin-Beta 76 73 84 76 77 79 74 75 78 
           
10μM AN Tubulin-Alpha 63 67 63 64 68 61 60 63 61 
 Tubulin-Beta 65 67 68 63 67 64 58 67 57 
           
10μM AN Tubulin-Alpha 63 60 63 57 59 64 61 60 59 
 Tubulin-Beta 58 63 64 66 65 63 61 60 63 
 
Table 5. 10 Percentage of Alpha and Beta Tubulin in Mk Colonies after Treatment 
with AN or Taxol 
The percentage of tubulin –α and tubulin-β1 expression in Mk colonies after treatment with AN (1 and 
10 μM) or Taxol (1μM) is shown.   The number of tubulin –α and tubulin-β1 positive colonies tended to 
be lower (compared with concurrent control) no decrease in the expression levels of either tubulin –α 
and tubulin-β1 was noted. Each concentration evaluated in triplicate on three separate occasions. 
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Figure 5. 16 Mean Fluorescence Intensity of Alpha and Beta Tubulin Staining in Mk 
Colonies After Treatment with AN or Taxol. 
The mean fluorescence intensity of the tubulin –α and tubulin-β1 staining of Mk colonies treated with 
AN or Taxol was compared with the mean fluorescence intensity of the untreated Mk colonies.   A 
statistically significant decrease in the mean fluorescence intensity was noted with tubulin-β1 staining 
of Mk colonies treated with AN at a concentration of 10 μM and with Taxol at a concentration of 1 μM.  
No statistically significant change in mean fluorescence intensity was noted in tubulin –α staining of Mk 
colonies treated with AN or Taxol. Each concentration evaluated in triplicate on three separate 
occasions.  Data shown with +/- SEM * p< 0.01 compared AN treated cultures with no AN treatment 
group 
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Treatment Tubulin Mean Fluorescence Intensity Value 
 Exp. No 1 2 3 
 Replicate No. 1 2 3 1 2 3 1 2 3 
Vehicle Tubulin-Alpha 63 55 52 53 55 58 54 49 59 
 Tubulin-Beta 80 83 87 84 88 86 79 86 74 
           
1μM AN Tubulin-Alpha 43 40 41 45 43 43 46 43 47 
 Tubulin-Beta 73 70 75 71 77 74 70 70 71 
           
10μM AN Tubulin-Alpha 33 37 38 31 33 36 38 32 38 
 Tubulin-Beta 74 75 78 71 73 71 72 70 75 
           
10μM AN Tubulin-Alpha 21 24 25 20 19 28 22 26 24 
 Tubulin-Beta 54 51 50 53 57 63 64 61 57 
Table 5. 11 Fluorescence Intensity of Alpha and Beta Tubulin Staining in Mk 
Colonies after Treatment with AN or Taxol 
The fluorescence intensity of the tubulin –α and tubulin-β1 staining of Mk colonies treated with AN or 
Taxol was compared with the mean fluorescence intensity of the untreated Mk colonies.   A statistically 
significant decrease in the mean fluorescence intensity was noted with tubulin-β1 staining of Mk 
colonies treated with AN at a concentration of 10 μM and with Taxol at a concentration of 1 μM.  No 
statistically significant change in mean fluorescence intensity was noted in tubulin –α staining of Mk 
colonies treated with AN or Taxol. Each concentration evaluated in triplicate on three separate 
occasions.   
 
5.4. Discussion 
 
5.4.1 Evaluation of the Effect of AN on Cell Cycling of hCB Derived Pluripotent 
Stem Cells in LTBMC.   
 
LTBMC enable the evaluation of the very early maturation and differentiation events of 
pluripotent haematopoietic stem cells (HSC) within a supporting microenviroment (stromal 
layer).  The microenviroment layer is considered to be similar to that found in vivo (Dexter et 
al,1984).  The microenviroment not only provides the cell to cell interactions that are essential 
for HSC differentiation and maturation but also the cytokines such as IL-3 and stem cell factor 
required to drive the initial maturation events.  The concentrations of AN used were the same 
as those used in the clonogenic cultures where a reduction in megakaryocytic colony counts  
per well was noted.  In addition the concentration range utilised encompasses the plasma 
concentration 23.6nM (734 ng/mL) of AN at the therapeutic human dose 2.0mg daily.  AN 
was added to the LTBMC at weekly intervals for a total of three weeks.  
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No alteration in cell cycling or colony counts of the erythroid, granulocytic/monocytic or 
megakaryocytic cell lineages was observed. AN, at the concentrations evaluated, did not affect 
cell cycling of HSC. Additionally, the microenviroment was maintained enabling 
haemapoietic stem cells to maintain their ability to differentiate and mature further to give rise 
to multipotent precursors (non adherent cells) that were still capable of giving rise to 
erythroid, granulocytic/monocytic or megakaryocytic colonies, after repeated administration 
of AN.  Finally, the number of colonies of each cell lineage was comparable to vehicle control 
levels demonstrating that the lineage specific precursors can differentiate.  The evaluation of 
AN in hCB LTBMC suggests that the reduction in platelet counts noted after in vivo dosing in 
humans does not result from action of AN on the most primative haematopoietic cells that are 
found in the LTBMC.   
 
5.4.2 Establishment of the AN IC50 Concentration for the CFU-E, GM-CFU and 
Mk Colonies, Using hCB Derived Stem Cells in Clonogenic Cultures 
 
Clonogenic cultures enabled the evaluation of the haematotoxicity of AN towards the 
multipotent and lineage specific granulocytic/monocytic, erythroid and megakaryocytic 
precursors, events further down stream from those in the LTBMC.  The findings from the 
clonogenic cultures demonstrated that the culture conditions respond in a lineage specific way 
to AN, replicating clinical responses.  The IC50 established using hCB derived haematopoietic 
cells was 1.92μM.  In vitro clonogenic cultures using human bone marrow-derived stem cells 
showed that concentrations between 0.32nM - 161μM inhibited megakaryocytic colony 
formation with an IC50 concentration of 32 μM (SBA, 1997).  The 16 fold greater sensitivity 
noted with the bone marrow derived may be due to differences in the experimental procedures 
employed.  The bone marrow derived stem cells were pre-incubated in AN for 6 hours washed 
and then added to culture media.  The additional washing process employed to remove AN 
following pre-treatment may have damaged the haematopoietic cells prior to culturing.  
Alternatively, incubation with AN may have caused indirect cell toxicity.  The procedure 
employed for this work ensured that the haematopoietic cells were exposed to AN throughout 
the culturing period by adding the cells to the culture media containing AN.   
Recently, Wang et al, (2005) using hCB derived cells in clonogenic cultures similar to those 
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employed in this work, reported an IC50 concentration for AN of 0.26μM a concentration 123 
and 7 fold higher than that reported by the manufacturer’s of AN and reported herein, 
respectively.  Most likely the difference in IC50 concentrations reflects differences in the 
culturing techniques, the genetic differences in the donors and the source of the bone marrow 
of the haematopoietic cells (Ortel MD, 1998).   
5.4.3 The Effect of AN on Cell Cycling and Megakaryocytic Ploidy Using hCB 
Derived Stem Cells in Clonogenic Cultures 
 
In contrast to the cell cycle analyses data from non-adherent cells collected from AN treated 
hCB LTBMC, a statistically significant decrease in the percentage of G2/M phase and a 
statistically significant increase in the percentage of G0/G1 phase cells was noted at AN 
concentrations of 1 and 10 μM, respectively.  These data is indicative of cell cycle arrest at 
G0/G1.  The development and maturation of the committed megakaryocytic stem cells is 
unique in that they develop a highly polyploid DNA content, associated with giant multi-lobed 
nuclei (Matsumura and Kanakura, 2002).   
 
The majority of cells in the vehicle treated cultures had 2N (60%) DNA content, 25% with 4N 
DNA content and 8N, 16N, 32N and 64N each representing less than 5% of the total CFU-Mk 
colony population.  These findings are similar to published data of Minamiguchi et al (2001), 
where 70% of the cord blood derived CFU-Mk colonies were shown to have 2N DNA content, 
using a similar method for cell cycling analyses.   
 
A statistically significant increase in 2N CFU-Mk colonies was noted in CFU-Mk colonies 
treated with 1 and 10 μM AN.  In addition, a statistically significant decrease, in the number of 
CFU-Mk colonies with DNA content at 4N and 8N was also noted.  The cell cycle and ploidy 
data when considered together is suggestive that AN treatment resulted in cell cycle arrest 
predominantly of cells at the 2N ploidy stage of development, preventing the maturation of 
Mk cells of 4N ploidy and greater.  Mk cells of greater than 4N are considered to 
predominantly release platelets into circulation.  These findings concur with those of Mazur et 
al (1992), where concentrations of 32μM to 161μM, resulted in an increase (65%) in the 
percentage of megakaryocytes in developmental stages I and II (Chapter 3) when compared 
with concurrent controls (41.5% in developmental stages I and II).  In addition, these data also 
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concur with the findings of Wang et al (2005) where AN and its metabolite AM were shown 
to inhibit the ploidy of Mk cells.  
5.4.4 The Effects of AN on the Expression of Megakaryocytic Cell Surface 
Antigens using hCB Derived Stem Cells in Clonogenic Cultures 
 
The expression of different receptors on the surface of haematopoietic progenitors permits the 
interaction with various regulatory elements present in their environment, which includes 
stromal cells, extracellular matrix molecules (EMM) and soluble regulatory factors (cytokines 
and growth/differentiation factors). The expression of these surface antigens is known to 
change during the maturation event (Civin and Locken, 1987).  As the totipotent 
haematopoietic cells mature the surface antigen specific for the totipotent potential of the cells 
is lost, and instead lineage specific surface antigens develop.   
 
Megakaryocytes progressively express lineage restricted surface antigens, some of which play 
essential roles in platelet physiology (Erickson et al, 1993; Wang et al 2005; Hong et al 2006).  
Two such antigens are CD61, part of a complex receptor GPIIb/ GPIIIa, and CD42 part of the 
GPIb –V-IX complex.  The expression of these two antigens occurs at different stages of 
maturation.  CD61 is expressed early in megakaryocytic development.  In contrast CD42 was 
expressed later in megakaryocytic development.  Only the CD34 negative /CD61 positive 
population demonstrated a statistically significant decreases at the two highest AN 
concentrations evaluated.  
 
The loss / inhibition of cells expressing CD34 negative /CD61 positive receptor profile was 
indicative of an alteration of maturation and differential events that lead to the reduction in Mk 
cells and ultimately reduce the number of circulating platelets.  Alteration in the maturation 
and differentiation events is further supported by the statistically significant reduction in the 
G2/M cell population again at AN concentrations of 1 and 10 μM.  Recently, a statistically 
significant reduction in CD61 expression has been reported following treatment of hCB 
clonogenic cultures with AN at a concentration of 1μM (Wang et al, 2005).  The reduction in 
the CD61 receptor expression was noted at the same concentration at which a reduction in 
CD34 negative/CD61 positive receptor expression was noted in this work.  Interestingly, 
Wang et al (2005) evaluated only CD61 expression and not the combination of receptor 
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expressions as carried out in this thesis.  Therefore this work may have identified a specific 
sub population of Mk cells affected by AN treatment.   
 
5.4.5 The Effect of AN on Mk-CFU Colony Microtubule Organisation using hCB 
Derived Stem Cells in Clonogenic Cultures 
 
Treatment with AN concentrations of 1 and 10 μM resulted in no changes in the percentage of 
cells expressing tubulin –α and tubulin-β1 levels.  However, the decrease in mean fluorescence 
intensity noted with tubulin-β1 staining of Mk cells treated Taxol suggests that AN treatment 
results in the reduction tubulin - β1 levels per cell that in turn results in the inhibition of the 
normal reorganization of the microtubule network.   
 
5.4.6 Drug- induced Immune thrombocytopenia  
 
 
Neither Clonogenic culture nor LTBMC can be utilized to evaluate the potential of therapeutic 
agents to promote drug induced thrombocytopenia.  Although the LTBMC contain antigen 
presenting cells (macrophages), no B-cells are present within the cultures to produce 
immunoglobulins.  Plasma samples from patients treated with AN as well as anti-platelet 
antibody assays would be required to determine if an immunological mechanism may be 
involved in the reduction of platelets.  No antibodies have been detected in 26 healthy 
volunteers treated with AN in phase I clinical studies or 48 ET patient samples (SBA, 1997).  
Therefore it is unlikely that the platelet count reduction noted in essential thrombocythemia 
patients is due to a drug induced immunological response.   
 
5.4.7 Hypothesis of the action of AN on Mk-CFU colonies 
 
 
Megakaryopoiesis results in the production and release of platelets. As with the other lineages 
it is a multistage process of cellular differentiation and maturation regulated by a variety of 
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cytokines.  Mk cells originate from pluripotent stem cell.  In fact the development and 
maturation of the committed megakaryocytic stem cells is unique in that they develop a highly 
polyploidy DNA content which is associated with giant multi-lobed nuclei.  The formation of 
platelets results from the projection of megakaryocytic cytoplasm through the sinusoidal 
endothelium of the megakaryocytes (Figure 5.19).  
 
Mk progenitors express the CD34 antigen, the earliest surface antigen identifying pluripotent 
stem cells, but mature Mk cells have lost the CD34 receptor (Erickson et al, 1993). 
Additionally the precise stage along the Mk differentiation at which the CD34 is lost is not 
known. By flow cytometry, CD34+ cells bearing platelet glycoproteins (GP) could be 
detected, but at a low frequency (less than 2% of the marrow CD34 positive (+) cells.  These 
cells gave rise within another 4 days in culture to numerous Mk (up to 50%), showing that 
these CD34+ cells were greatly enriched in Mk precursors. Erickson et al, (1993) confirmed 
the presence of typical megakaryoblasts, by ultra-structural studies. Megakaryoblasts are large 
cells with a small nucleus and a vast cytoplasm.  In some cells the cytoplasm is divided into 
smaller areas by microtubules.  By flow cytometry, three populations of small cell size can be 
defined: CD34+ CD61-, CD34+ CD61+, and CD34- CD61+ cells (Chapter 3). The two 
CD61+ populations are almost pure immature Mk. Alpha-Granules, organelles containing 
alkaline phosphotase, are rare in the CD34+ / CD61+ cells, whereas they are more developed 
in the CD34- / CD61+ cells, which also exhibited demarcation membranes (Erickson et al, 
1993).  
 
In vitro data, reported in this thesis, has demonstrated the effects of AN on ploidy, cell cycle 
and receptor expression indicate that the action of AN may be at a late stage in Mk colony 
development.  Alterations in ploidy and CD61 receptor expression following in vitro treatment 
of hCB clonogenic cultures with AN have also been reported recently by Wang et al (2005), 
corroborating the findings reported herein. The results from the experiments on tubulin –α and 
tubulin-β1 has identified another potential mechanism by which AN reduces platelet counts in 
patients with ET, via disruption of the microtubule organization.  It is currently unclear 
whether an alteration in cell cycling or the inability to organize the microtubule network is the 
primary mechanism of AN mode of action. Two alternative therapies used in the treatment ET, 
vinblastine and vincristine, are know to inhibit cell mitosis by binding to the protein tubulin in 
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the mitotic spindle and preventing polymerization into the MTs (Islam et al, 2004). This mode 
of action is also shared with other natural agents such as colchicine and podophyllotoxin 
(Islam et al, 2004). 
 
Table 5.3 shows the concentrations at which each of the changes in colony growth, ploidy, 
receptor expression, cell cycling and tubulin levels occurred.  Based on the lowest 
concentration at which the changes were noted the inability to organize the microtubules 
appears to be secondary to alteration in cell cycling, surface receptor expression and inhibition 
in achieving high (greater than 8N) ploidy number.  However, identification of the primary 
mechanism based solely on concentration appears to be very crude and most probably reflects 
a limitation of in vitro systems.  Most likely a combination of mechanisms including inhibition 
of cell cycling and the inability to organize the microtubules contributes to the reduction in 
platelet release.  
 
Clinical trial data demonstrated that AN doses ranging between 1-3mg given every 8 hours for 
6 to 9 days caused a profound reduction in platelet count with a nadir of 20 x10 9/ L occurring 
within 10 and 12 days of commencement of treatment (SBA, 1997).   The mean Cmax at 
2mg/kg (once daily) was 23.6nM (734ng/mL), 10 fold below the lowest in vitro AN 
concentration at which alterations in cell cycle, ploidy, cell surface receptor expression and 
tubulin- β1 were noted.  It is important to note that in vivo AN concentrations in the bone 
marrow are not known and may be lower than the plasma concentrations.  Furthermore the 
distinction between in vivo and in vitro inhibitory concentrations may reflect genetic 
variability in humans, but most likely reflects differences between clonogenic cultures and in 
vivo bone marrow.   
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Statistically Significant Effect of AN Noted Lowest Concentration 
of AN  change noted 
(μM) 
Colony growth inhibition 1 
DNA cell cycle 1  
 Cell Ploidy 1  
Surface receptors 1  
Change in MFI of Tubulin -β1 expression 10  
 
Table 5. 12 Alterations in Mk-CFU Cell Growth Noted following AN Treatment 
Throughout the Culturing Period (12 Days) 
The lowest concentration at which a statistically significant change in hCB derived CFU-Mk clonogenic 
cultures of colony growth inhibition, cell cycling, cell ploidy and surface receptor expression was 1μM.  
A reduction in the MFI of tubulin –β1 expression was noted at 10 μM.  However, each effect is possibly 
interrelated so it is difficult to distinguish a single mechanism of AN action.   
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6.0  General Discussion 
 
6.1 Haematotoxicity 
Dose limiting haematotoxicity has been associated with a range of therapeutic agents used for 
the treatment of a number of different conditions are known to block cell cycling (Botta et al, 
1999).  As a consequence of the blockade of cell cycling, haematopoietic cell differentiation 
and maturation is disrupted, resulting in clinically significant decrease in the number of mature 
cells released into blood circulation.  Also self- renewal of the totipotent stem cells can be 
disrupted (Botta et al, 1999). 
 
The potential for haematotoxicity is typically assessed as part of the preclinical toxicology 
studies in experimental animals where changes in peripheral blood cell numbers and bone 
marrow cellularity are determined usually at the end of the study; blood samples are routinely 
collected prior to the start of dosing, during dosing and at the end of the study.   However, 
information on the potential mechanism of the haematotoxicity is rarely revealed.  The 
identification of the mechanism (s) of the haematotoxicity may provide in sight whether 
haematotoxicity is likely to be specific to that toxicology species or likely to be of clinical 
relevance.  For example, reductions in red cell counts, haemoglobin and heamatocrit were 
noted in rodents with p38 kinase inhibitors at doses evaluate including the predicted clinical 
therapeutic dose range (Tamura et al, 2000).  However, no reduction in red cell parameters has 
been noted in clinical trails which strongly suggest that the changes are specific to rodents. In 
addition, information on the potential mechanism (s) of the toxicities noted in preclinical 
toxicology studies is required to enable the progression of the development of the new 
therapeutic agent, for regulatory submissions and eventual drug registration. The information 
is in turn used by the medicines approval agencies to review the risk: benefit of the product. 
Finally, the mechanism (s) elucidated may identify specific biomarkers of the toxicity noted 
that can be incorporated into the clinical protocols for safety monitoring. In vitro bone marrow 
cultures could be utilized in two different approaches: 
Data from in vitro bone marrow screens into the discovery optimisation process could 
facilitate early detection of potential haematotoxicity and identify the most sensitive cell 
lineage.  Compounds for a given therapeutic target could be ranked according to their 
haematotoxicity and those compounds with the desired haematotoxicity profile would be 
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progressed.  However, the necessity to identify the different haemopoietic cell lineages by 
morphology (particularly in the case of clonogenic cultures) is time consuming and therefore 
not suitable for use as a high throughput screen.  Interestingly, a multifunctional 
Biocheminescence Colony Forming Assay has recently been described that utilizes a 96 well 
format (Rich and Hall, 2005).  The biocheminescence system may negate the need for manual 
colony identification stream lining the screening significantly.   
 
Secondly, the results from in vitro assays can provide a means of elucidating the potential 
mechanism (s) for the haematotoxicity noted in vivo.  These assays require small quantities of 
the therapeutic molecule to investigate the haematotoxicity and often only small quantities are 
available during the early phase of drug development.    In vivo mechanistic studies can take 
significant time to conduct and clinical trails may be halted until the potential mechanism has 
been identified.  Delays in the development process are costly. 
 
6.2 Megakaryocytic Lineage Specific Haematotoxicity 
 
Anti-cancer and anti-viral therapies are known to cause myelotoxicity, however the first cell 
lineage most often affected in vivo is the megakaryocytopoietic.  The availability of 
recombinant thrombopoietin, has now made it possible to evaluate this lineage easily in vitro.  
In these studies, the murine CFU-Mk clonogenic assay was established and optimised and the 
murine GM/E and Mk clonogenic haematopoietic cultures were used to evaluate the lineage 
specific haematotoxicity of compounds used in the treatment of ET (Chapter 3).  The IC50 
data and the ranking order demonstrated that some of the ET compounds evaluated had shown 
selective toxicity towards specific cell lineages.  Anagrelide was most toxic towards the 
murine megakaryocytic lineage and the least towards the murine granulocytic/monocytic, 
erythroid (myeloid) cell lineage. Vincristine sulfate also demonstrated a specificity towards 
the megakaryocytic lineage, whereas vinblastine and hydroxyurea showed specificity towards 
the granulocytic /monocytic and erythroid cell lineages, respectively (Chapter 3). The 
difference in the lineage sensitivity may reflect differences in the uptake and consequently 
intracellular concentrations of the compounds by the different lineage progenitors and is 
particularly demonstrated by AN.  AN was developed as an anti-thrombotic agent targeting 
megakaryocytes, therefore higher intracellular uptake of AN by megakaryocytic progenitors 
184 
would not be surprising.  However, high concentrations of all the compounds evaluated 
produced haematotoxicity in all cell lineages, it was most likely due to non-specific toxicity 
such as direct cytotoxicity. 
To fully validate the murine CFU-Mk clonogenic assay it would have been of value to include 
compounds that are not used in the treatment of ET, such as 3C-azido-3C-deoxythymidine 
(AZT), that have been shown in vivo to cause reduction in platelet counts as well as 
compounds that are generally known not to cause haematotoxicity.  A further validation of the 
CFU-Mk clonogenic cultures was completed using methotrexate, chloramphenicol succinate, 
vincristine sulfate and diazepam (data shown in Chapter 2).  These studies demonstrated that 
chloramphenicol succinate and diazepam were the least specific towards the megakaryocytic 
lineage.  Vincristine sulfate once again demonstrated the greatest toxicity towards the 
megakaryocytic lineage.  Methotrexate demonstrated toxicity to the myeloid/monocytic and 
megakaryocytic cell lineages and chloramphenicol succinate was the most toxic towards the 
erythrocytic cell lineage.  Methotrexate and chloramphenicol succinate block cell cycling, in 
the case of chloramphenicol succinate an accumulation of CFU-E colonies in G2M phase was 
noted (Chen, 2005).  Interestingly, both methotrexate and chloramphenicol succinate also 
effect the bone marrow microenvironment.   In contrast, vincristine sulphate inhibits the 
formation of microtubules.  No haematotoxicity has been reported for diazepam in clinical use 
and demonstrated the haematotoxicity in vitro only at high concentrations. 
Based on limited in vitro GM/E and MK clonogenic human culture data on compounds used 
for the treatment of ET, a similar lineage specificity to that demonstrated in the in vitro short -
term murine haematopoietic cultures was found, although the culture conditions and 
compound exposure times varied (Oertel 1998).   
It is important to note that the IC50 concentrations were determined following single in vitro 
exposures to the ET compounds, whereas the haematotoxicity in vivo is often noted after 
repeated administration.  This raises a potential uncertainty of whether the mechanism of 
haematotoxicity in vitro and in vivo is the same.  Interestingly, the IC50 concentrations for AN 
were noted to be markedly different when the murine IC50 concentration 88.6μM (Chapter 3) 
was compared with hCB IC50 concentration 1.92μM (Chapter 5).  This 46 fold disparity may 
be indicative of differences in species sensitivity or may be indicative of AN having a greater 
affinity towards the human c-mpl (TPO) receptor than the murine c-mpl (TPO) receptor as 
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suggested by McCarty et al (2006). The sequence homology between mouse and human c-mpl 
(TPO) receptor is approximately 64%, which suggests that the difference in mouse and human 
AN megakaryocytic lineage toxicity is due to species sensitivity (Jandrot-Perrus et al, 2000).  
The clonogenic cultures may be capable of some metabolism primarily through the action of 
macrophages, however, their number would be very low following positive selection for 
pluripotent stem cells prior to addition to clonogenic cultures. However, media from the 
treated cultures were not collected for the determination of concentration of the ET reference 
compounds at the end culturing period.  Therefore a clear understanding of the dynamics of 
the test compound in the cultures is not known.   It is important to note that the semi-solid 
methyl cellulose based media used in the clonogenic cultures would also make treatment 
concentration checks at the end of the culturing period difficult and serve to prevent 
equilibration of the concentration in the culture media of any metabolites of the test compound 
if produced. 
6.3 Hypothesis of Mechanism of Action of Anagrelide (AN) 
 
Using hCB derived haematopoietic stem cells, in both clonogenic and LTBMC the potential 
mechanism (s) of Mk –CFU reduction was assessed in this study (chapter 5).  In hCB LTBMC 
repeated weekly exposure to a range of AN concentrations for a total of 3 weeks showed no 
significant changes in cell cycling, or in the number of non adherent cells produced by the 
cultures, suggesting that the reduction in platelet counts following repeated dosing in humans 
may not result from alterations to these parameters of multipotent stem cells (chapter 5).  The 
action of AN did not result in an alteration of the morphology or confluency of the stromal 
layer.  In addition, the action of AN did not inhibit the ability of the multipotent stem cells to 
differentiate into cells of the erythroid, granulocytic, monocytic or megakaryocytic cell 
lineages, again following repeated adminsitration (chapter 5).   
 
Consequently, the investigation of the potential mechanism of action of AN was focused 
directly on Mk CFU cells, using hCB clonogenic cultures.  In vitro hCB clonogenic indicate 
that the action of AN may be during Mk development (Chapter 5).  Interestingly, these data 
also concur with the findings of Wang et al (2005) where AN was shown to inhibit the ploidy 
of Mk cells and result in a reduction in the expression of CD61 receptors on Mk cells collected 
from hCB clonogenic cultures. Wang et al (2005) evaluated only CD61 expression and not the 
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combination of receptor expressions as carried out in this thesis.  Therefore this work may 
have identified a specific sub population of Mk cells affected by AN treatment (chapter 5).  
The decrease CD34 negative / CD 61 positive sub population of Mk cells most likely reflects 
the cell maturation arrest that leads to reduced/ inhibition of  CD 42 receptor.   
 
The results from the experiments on tubulin –α and tubulin-β1 identified another potential 
mechanism by which AN might reduce platelet counts in patients with ET, via disruption of 
the microtubule organization (chapter 5).  It is, however, unclear whether an alteration in cell 
cycling or the inability to organize the microtubule network is the primary mechanism of AN’s 
mode of action.  Based on the lowest concentration at which changes were noted (Chapter 5), 
the inability to organize the microtubules (10μM) appears to be secondary to alteration in cell 
cycling, surface receptor expression and inhibition of increase in ploidy (1μM). This work 
suggests that the action of AN on CFU-Mk colonies is most likely a result of a combination of 
mechanisms 1) inhibition of cell cycling, 2) a disruption in the expression of cell surface 
receptor expression and 3) inhibition in the ability of the cells to increase in ploidy number 
associated with the inability to organize the microtubules leading to a reduction in platelet 
release (Figure 6.1).   AN prevented the CFU-Mk cells achieving greater than 2N ploidy.  This 
is particularly significant as only Mk cells with greater than 4N ploidy can form proplatelets 
and release platelets.  Furthermore, cell cycling and tubulin activity in Mk progenitors is 
different from that in other haemopoietic cells; M phase is normally incomplete and Tubulin-β 
is pivotal in platelet production. Tubulin-β1 KO mice have been found to produce up to 60% 
less platelets when compared with wild type (Levin et al 1993).  These differences may render 
the Mk lineage more sensitive to compounds that inhibit cell cycle and microtubulin 
formation. 
 
Other therapies are known to cause platelet count reduction.  For example, nucleoside reverse 
transcriptase inhibitors such as 3'-azido-2', 3'-dideoxythymidine (Gynn et al, 1972) and folate 
antagonists such as methotrexate (Storb et al, 1986) by cell cycle disruption.  Interestingly, the 
mechanism of action of two other therapies used in the treatment of ET, Vinblastine and 
Vincristine is via inhibition of the formation of microtubules: predominatly resulting in cell 
cycle arrest at metaphase (chapter 3). These compounds inhibit mitosis by binding to the 
protein tubulin in the mitotic spindle, thereby preventing polymerization into the microtubules 
(Islam et al 2004). Therefore it would not be surprising that the mechanism of action of AN is 
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similar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 1 Hypothesised  Mechanism of Action of AN on Megakaryopoiesis.  
AN does not effect primitive multipotent stem cells in hCB LTBMC (stromal cell confluency, cell cycling, 
or ability of the non adherent derived stem cells to differentiate into BFU-E, CFU-GM or CFU-Mk 
colonies).  AN effect on CFU-Mk colonies are the result of a combination of mechanisms: inhibition of 
cell cycling, disruption of the expression of cell surface receptors and inhibition in the ability of the cells 
to increase in ploidy - associated with the inability to organize microtubules -ultimately leading to a 
reduction in platelet release.  No effect on CFU-GM or BFU-E colonies noted. 
 
Clinical trial data demonstrate that AN can cause profound platelet count reduction (nadir of 
20 x109 /L) at a mean systemic exposure level (Cmax) of 23.6nM which is 81 fold below the 
lowest in vitro AN concentration at which alterations in cell cycle, ploidy, cell surface receptor 
expression and tubulin- β1 were noted, in the studies reported herein.  It is important to note 
that in vivo AN concentrations in the bone marrow are not known and may be lower or higher 
than the plasma concentrations.  There is currently no data to demonstrate a direct causality 
between effects on cell cycle inhibition, alteration in cell surface receptor expression, 
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inhibition in the ability of cells to increase in ploidy number and the inability to organize the 
microtubules leading consequently to a reduction in circulating platelets. Recently, however, 
Wang et al (2005) reported similar changes in ploidy and CD61 receptor expression following 
in vitro treatment of hCB cultures.  It is also recognized, that synchronicity between nuclear 
and surface receptor expression and high ploidy are required for platelet release (Petrides, 
2006).  Therefore the direct comparison of the in vitro changes in Mk-CFU and in vivo platelet 
count reduction may be appropriate.   
 
Although the concentration of AN added to the cultures is known, supernatants from LTBMC 
and clonogenic cultures were not collected and evaluated to confirm the concentrations of AN 
during the culture period.  In vivo AN is rapidly cleared from plasma with a terminal half life 
of 2.3 hours +/-0.26 hrs. In the absence of clearance, in vitro, it is likely that some AN was 
present throughout the culturing period of 7 (LTBMC) to 10 (clonogenic cultures) days.   
6.4 Source of Haematopoietic Cells 
 
The Balb/C mouse has been shown to be a good source of bone marrow for use in the in vitro 
haematopoietic cultures.  The quantity, quality and consistency in stem cell numbers collected, 
does make it an ideal source for bone marrow to facilitate haematotoxicity evaluations. 
Furthermore, in vitro murine haematopoietic cultures have been shown to be predictive for 
human haematotoxicity associated with anti- cancer and anti-viral therapeutics (Scheding et al 
1994). However, the CD1 mouse rather than the Balb/C mouse is routinely used for in vivo 
toxicology studies. The difference in strain utilised in the in vitro verses in vivo studies may 
contribute to the different sensitivities to the haematotoxicity noted.   Differences, however, in 
species sensitivity to haematotoxicity have been described (Van De Heuvel et al, 1999, 
Masubuchi N et al 2004, and Anderson et al 2000).  Unfortunately obtaining human bone 
marrow for haematotoxicity assessments within the UK was very limited.  Human cord blood 
has been shown to be the next best source of human haematopoietic stem cells (Chapter 5).  
Although it was possible to obtain human cord blood derived stem cells from commercial 
sources, the supply was often haphazard (often delivery hCB cells was unreliable) as well as 
costly (over £460  for 1x 1018 cells).  Moreover, the supply limitations together with the 
regulatory restrictions on the use of human cells in research make it unlikely that human cord 
blood or bone marrow can be used routinely for haematotoxicity evaluations.  In the future, 
non-human primates, such as the cynomolgus monkey (Macaca fascicularis), could be 
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explored as a potential source of bone marrow and cord blood cells.  The cynomolgus monkey 
is sometimes used as an alternative toxicology species to the dog and background 
haematology data in this species demonstrates similarities to human haematopoiesis.  For 
example, red cell lifespan is the same as in man - 120 days.  The cynomolgus monkeys used in 
toxicology studies are bred at specialised breeding farms rather than wild caught; therefore 
cord blood collections from the breeding colonies may be possible. 
6.5  LTBMC  
 
The unique feature of LTBMC cultures is that sustained haematopoiesis occurs in the absence 
of added growth factors but is absolutely dependent upon the establishment of an adherent 
layer of bone marrow derived stromal cells. The latter provide the appropriate environment to 
promote the survival, self-renewal, proliferation, and differentiation of the haematopoietic 
progenitor cells (Daniel et al, 1989).  LTBMC provide a unique system with which to 
investigate effects on several aspects of haematopoiesis that can not be achieved by simply 
using clonogenic assays.  For example, cell adhesion interactions that bind progenitor cells 
and their progeny to specific stromal elements as well as the synthesis, secretion, and 
presentation of growth-stimulatory and growth-inhibitory factors by stromal cells can be 
studied. 
 
In addition, the effects on haematopoiesis following repeated administration of test 
compounds on the stromal layer and on the early stem cell maturation can be evaluated, 
potentially mimicking in vivo haematotoxicity.    
Whilst establishing and optimizing the LTBMC the importance of the type of culture flasks 
was highlighted; and the ability to establish confluent stromal layers was examined using T25 
flasks from three different manufacturers.  The properties of the plastic used in the 
manufacture of the flask are known to affect the surface charge of the plates which in turn can 
alter the ability of the cells to adhere. In addition, an alteration in the sterilization process can 
result in a change in the charge.  A change in the plastic used in the manufacture of the flask 
was found to influence directly the ability of the cells to adhere (Chapter 4). Furthermore, 
differences in the ability of macrophage/fibroblast like cells to adhere to plastic have 
previously noted (Gordon, 1993) where adherence of some fibroblasts was restricted by the 
properties (charge) of the plastic used.  Unfortunately no information on the differences in the 
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flasks is available due to the reluctance of the manufacturers to discuss their respective plastic 
formulation or sterilization procedures. It is most likely that a change in polycarbonates used 
possibly resulted in a change in the flask charge.  Furthermore, the ability to grow confluent 
stromal layers in Nunc rather than Falcon flasks using the same batch of culture media and 
murine bone marrow confirmed that the inability to achieve confluent stromal layers in the 
Falcon flasks was not due to issues with the reagents, bone marrow collection or due to 
operator differences.  Without clear communication between suppliers and their customers on 
changes made in their materials, not only time consuming but misleading data could be 
generated.   The inability to establish confluent stromal layer in LTBMC resulted in a 4 month 
delay and was only resolved after collaborating with Addenbrookes Hospital Haematology 
department. 
 
The combination of cell identification techniques flow cytometry and light microscopy 
enabled a more detailed understanding of the different cell populations within the non-
adherent layer (Chapter 4). Each technique had its own advantages when compared to the 
other; flow cytometric analysis enabled the identification of cells that were difficult to 
distinguish morphologically whereas, light microscopy identified the later stages of cell 
development (past committed lineage specific progenitor) for which no specific antibodies 
were available.   
 
The time taken to achieve confluent stromal layers was similar irrespective of whether human 
or mouse was the source of the haematopoietic stem cells.  In addition similar numbers of non-
adherent cells were generated. 
 
There are, however, limitations to the LTBMC, irrespective of the source of haematopoietic 
stem cells.  Cytokines that drive the differentiation to give rise to erythrocytic and 
megakaryocytic cell lineages (Epo and Tpo) are not present within the cultures; Epo (Eckardt 
et al, 2005) and Tpo (Wolber et al, 2002) are produced by the kidney and liver respectively.  
Indeed, the presence of erythroid cells within LTBMC can result in the demise of the cultures. 
Thus, effects on stem cell differentiation and maturation relating to Epo or Tpo production can 
not be evaluated in LTBMC; a limitation of the culture system.  Finally, effects on the 
development and differentiation of lymphocytic cell lineage are not possible in LTBMC.  
The assessment of any potential toxicity for a new chemical entity can not be made solely 
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using a series of in vitro cultures, each representing a potential target organ.  When used in 
isolation no information on the potential interrelationships between toxicities can be 
elucidated.  In vitro assays provide a means of elucidating the potential mechanism (s) for the 
toxicity noted in vivo.  In addition the in vitro assays provide a means of ranking compounds 
for the same therapeutic target for which the primary toxicity or toxicity of concern is known. 
6.6 Additional Avenues of Investigation 
 
As mentioned earlier, the biocheminescence system may negate the need for manual colony 
identification stream lining the screening significantly.  The preliminary validation report of 
eleven reference compound (Rich and Hall, 2005) suggests that this system may have potential 
as a screening tool.  Future work could include the assessment of the biocheminescence 
system, using known haematotoxic compounds as well as compounds not reported to cause 
haematotoxicity. 
 
Alterations in gene expression and transcriptional effects would be expected to occur as a 
consequence of drug therapy. Therefore, future work to elucidate the mechanism of AN’s 
mechanism of megakaryocytic specific haematotoxicity could include a comparison of 
selected gene expression using quantitative reverse polymerase chain reaction (PCR), with and 
without anagrelide treatment.  The genes proposed would include: 
• Genes involved in DNA cell cycle, the Cyclins and the CDKs.  The principal CDKs 
responsible for G1 progression and entrance into S phase CDK2, CDK3, CDK4, and 
CDK6.  
• The D-type cyclins (D1, D2, and D3); the regulatory subunits for CDK4/6.  
• Cyclin E, which activates CDK2 and possibly CDK3 and is expressed in late G1 and 
early S phase. Cyclin A which can also activate CDK2, but essential later, at the G1/S 
boundary and throughout S phase (Ewen, 2000). 
• Tubulin- α and tubulin β genes 
• c-mpl, JAK2 and  TYK2 genes 
The analysis of the data would provide an insight in to which signaling pathways are affected 
and their lineage sensitivity.  Time course studies would need to be carried out to ensure that 
changes in gene expression were monitored throughout the culturing period.  Concentrations 
of AN that would be evaluated would include IC10 as well as IC50 concentrations, as changes 
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in gene expression levels can be noted at concentrations lower than those associated with the 
observed toxicity. Haematotoxicity may occur at the transcriptional level therefore analysis of 
proteins such as GATA-1, FOG-1, TAL-1 that have recently been identified to play a role in 
the regulation of megakaryopoiesis would be a further avenue of investigation. 
6.7 Summary 
 
These studies have evaluated the utility of both clonogenic and LTBMC culture systems as a 
tool for assessing the lineage sensitivity to VC, VB, H and AN and the mechanisms of the 
megakaryocytic specific haematotoxicity of AN.   Murine and human Mk-CFU clonogenic 
cultures and LTBMC were established and characterized  
 
Compounds commonly used in the treatment of ET, a disease state resulting in an over 
production and release of platelets, were evaluated in murine and hCB clonogenic cultures.  
By ranking the ET compounds according to the lineage specific IC50 concentrations, 
anagrelide was most toxic towards the murine megakaryocytic lineage and the least towards 
the murine granulocytic/monocytic, erythroid (myeloid) cell lineage.   Although the lineage 
specificity between human and murine cultures was the same, megakaryocytic, the IC50 
concentrations differed. This species difference might be related to a difference in the uptake 
of the compounds by the haemopoietic progenitors.  The most marked difference was noted 
with AN, indicative of differences in species sensitivity and /or is indicative of AN having a 
greater affinity towards the human c-mpl (TPO) receptor than the murine c-mpl (TPO) 
receptor as suggested by McCarty et al (2006).   
 
Using hCB derived haematopoietic stem cells, in both clonogenic and LTBMC the potential 
mechanism (s) of Mk –CFU reduction was assessed. The action of AN did not inhibit the 
ability of the multipotent stem cells in hCB LTBMC to differentiate into cells of the erythroid, 
granulocytic, monocytic or megakaryocytic cell lineages.  Focussing on the Mk committed 
progenitor cells revealed that AN treatment specifically caused an inhibition of cell cycling, 
disrupted the expression of cell surface receptors, inhibited an increase in cell ploidy and a 
disrupted microtubule organisation.  AN was shown to prevent the CFU-Mk cells achieving 
greater than 2N ploidy.  This is particularly significant as only Mk cells with greater than 4N 
ploidy have been shown to form proplatelets and release platelets.  Furthermore, cell cycling 
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and tubulin activity during cell cycling in Mk progenitors is different from that compared with 
other haemopoietic cells; M phase is normally incomplete and Tubulin-β is more concentrated 
in mature Mk cells.  These differences may render this lineage particularly sensitive to cell 
cycle and tubulin acting agents. This work confirms the potential utility of in vitro bone 
marrow cultures as a tool for evaluating compounds for their lineage specificity and as a tool 
to assess mechanism (s) of haematotoxicity as demonstrated herein providing an insight to 
mechanism of platelet count reduction by AN.    
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7.   APPENDIX A 
 
Materials 
 
Murine selection and purification 
The reagents used for the selection and purification of murine stem cells are shown below. 
 
Antibodies for selection of murine 
haematopoietic cells 
Supplier Catalogue 
Number 
Anti-C kit antibody coated Dynabeads Dynal (UK) Ltd 113-35D 
Dynabeads M-450 Sheep Anti-Rat (IgG) 
coated beads 
Dynal (UK) Ltd 140-11 
Rat -Anti mouse Ckit (CD117) monoclonal 
antibody (IgG) 
Serotec, UK 073403 
 
 
Murine bone marrow aspiration and 
Purification 
Supplier Catalogue 
Number 
Murine bone marrow Purification Life Technologies, UK 647881 
LymphoprepR Robbins Scientific 
Corporation, West 
Midlands, UK 
442151 
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Murine Clonogenic Culture Reagents 
Details of the murine clonogenic culture media, including their source employed in this project 
are provided below 
Murine Clonogenic assay 
Supplier Catalogue 
Number 
Granulocytic /Monocytic and Erythroid clonogenic 
assay Methocult GF M3434 
Metachem Diagnostics, 
Northampton, UK 
14425 
Megakaryocytic clonogenic assay media HCC-4900 
media 
Metachem Diagnostics, 
Northampton, UK 
23514 
Recombinant Mouse (rm) IL-6 for CFU-MK cultures Metachem Diagnostics, 
Northampton, UK 
25547 
Collagen for CFU-MK cultures StemCell Technologies Inc 4902 
 
hCB Clonogenic Culture Reagents 
Details of the murine clonogenic culture media, including their source employed in this project 
are provided below 
hCB Clonogenic assay 
Supplier Catalogue Number 
MegaCultTM –C StemCell Technologies Inc, UK 132248 
MethoCultTM –GF StemCell Technologies Inc, UK 128862 
Murine LTBMC  
Details of the manufacturer of the murine LTBMC media provided below 
 
Murine LTBMC –Standard Mathod 
Supplier Catalogue Number 
MyeloCult M StemCell 
Technologies, 
UK 
17753 
 
 
Murine LTBMC –Modified method
Supplier Catalogue Number 
MyeloCult M StemCell Technologies, UK 17753 
IL-6 (5ng/ml)  StemCell Technologies, UK 84226 
196 
SCF (25ng/ml) StemCell Technologies, UK 54719 
hCB LTBMC  
Details of the manufacturer of the hCB LTBMC media provided below 
 
Human cord blood LTBMC  
Supplier Catalogue Number 
MyeloCult H5100 StemCell 
Technologies, 
UK 
65543 
Megakaryocytic Culture Plates 
Details of the type and manufacturer of the plates used for the human and murine 
megakaryocytic culture clonogenic cultures is provided below  
 
 
Culture plates  
Supplier Catalogue 
Number 
Double Chamber Slides StemCell Technologies Inc 4813 
6 –well plates Becton Dickinson, UK 351146 
Double Chamber Slides StemCell Technologies Inc 4813 
Plates Used For Murine And Human Granulocytic/Monocytic And Erythroid Clonogenic Assays 
Details of the plates employed for the clonogenic (murine and hCB) cultures is provided 
below 
 
Culture plates  
Supplier Catalogue 
Number 
6 –well plates Becton Dickinson, UK 351146 
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Flasks Used For Murine And Hcb LTBMC 
Details of the plates employed for the LTBMC (murine and hCB) is provided below 
 
Flasks  
Supplier Catalogue 
Number 
T25 flasks (Costar) Costar, UK 7543A 
T25 flasks (Falcon) Falcon, Becton Dickinson, 
UK 
1134-1664 
T25 flasks (Nunc) StemCell Technologies Inc 166865 
CFU-Mk: Identification of murine CFU-Mk Colonies 
Reagents employed for the identification of murine CFU-Mk colonies are provided below 
 
APAP staining antibodies and APAP 
staining reagents 
Supplier Catalogue Number 
APAAP Rat monoclonal  Dako, UK D0651 
Rabbit Anti-Rat immunoglobulins  Dako, UK M0737 
Rat -Anti mouse Ckit (CD117) monoclonal 
antibody (IgG) 
Serotec, UK LS301 
Rat Anti-Mouse CD41 (GpIIIb/IIa)  Dako, UK M7088 
200 ml Acetone optimal Sigma, UK 323969 
Filter cards Metachem 
Diagnostics, 
Northampton, UK 
62138 
Polypropylene separators Metachem 
Diagnostics, UK 
384125 
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Flow Cytometry Reagents 
 
The source of the flow cytometry reagents employed for the surface cell receptor 
identification, cell cycle analysis, cell viability and intracellular markers are provided below  
 
Flow cytometry Reagents  
Supplier Catalogue 
Number 
FACSFlow Becton Dickinson, UK 342003 
CellFix Becton Dickinson, UK 258102 
Cell cycle Test-plus Becton Dickinson, UK 855312 
Via-Probe (7-amin-actinomycin D) PharMingen San Diego 
USA 
764992 
Intracellular staining Kit Becton Dickinson, UK 548319 
 
LTBMC: Morphological Identification of Non-Adherent Cells 
 
Reagents employed for the morphological identification of non-adherent cells from hCB and 
murine LTBMC is provided below 
 
May Grunwald-Giemsa staining 
Supplier Catalogue 
Number 
May-Grunwald stain  Dako, UK AR164 
pH 6.4 buffered water - - 
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General Methods 
Murine Bone Marrow Source and Aspiration Procedure 
 
Bone Marrow was harvested from male Balb/C mice from Charles River Laboratories Inc. 
(age: 4 - 6 weeks).  The animals were killed by inhalation of carbon dioxide and cervical 
dislocation.  The femora were dissected and the bone marrow aspirated into 1mL of Iscoves 
modified Dulbecco’s culture medium IMDM (Life Technologies, UK), using a syringe with a 
20-gauge needle. 
Pre-Selection of Murine Mononuclear Bone Marrow Cell Population 
 
Pluripotent stem cells, found in the mononuclear bone marrow cell population, were separated 
from the red blood cells using LymphoprepR (Robbins Scientific Corporation, West Midlands, 
UK).  0.5-ml peripheral blood was added to 6 ml of LymphoprepR.  This preparation was 
centrifuged at 400g for 30 minutes at room temperature.  The mononuclear cells were 
aspirated from the LymphoprepR interface and resuspended in IMDM.  The cell count of the 
suspension was determined using an automated cell counter (Advia 120, Bayer, USA)   and 
adjusted to 105cells /ml with IMDM. 
 
Isolation of Murine Pluripotent Progenitor Cells (Ckit Positive Cells) 
 
25μl of M-450 sheep Anti-Rat (IgG) coated Dynabeads (concentration of antibody 5μg/mL) 
were washed prior to use in IMDM.  The tubes containing the beads were placed in a particle 
collector (MPC) to magnetically hold the beads to facilitate aspiration of the media the media. 
The washing procedure was repeated once more before the Dynabeads were re-suspended in 
10µl of IMDM. 
 
The magnetic beads were coated with 0.2mL of Anti-mouse CKit antibody ( at a concentration 
of 5μg/mL) prior to positive selection.  20 μL of washed Anti-C kit antibody coated 
Dynabeads were added to 0.5 mL of 105 mononuclear cells.  The tube was incubated for 20 
minutes at 4o C for 20 minutes.  At the end of the incubation time the cells were gently mixed 
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and placed in a Dynal MPC for two minutes. Before removing the tube from the Dynal MPC, 
the media and cells were aspirated off. The tube was removed from the Dynal MPC and the 
Dynabeads / C kit positive cells were re-suspended in 0.5 mL of IMDM. This procedure is 
termed positive selection. 
Murine Granulocytic /Monocytic and Erythroid Clonogenic Assay (GM/E) - 
Standard Culture Conditions  
Composition Methocult GF M3434 was as follows: 
0.9%  Methylcellulose in Iscoves MDM 
15%   Fetal calf serum. 
10-4    2-mercaptoethanol 
2 nM   L- glutamine 
1%   Bovine serum albumin 
10 μg/mL  Bovine pancreatic Insulin 
200 μg/mL  Human transferrin 
10 ng/mL  rm IL-3 
10 ng/mL  rh IL-6 
50 ng/mL   rm SCF 
3 units /mL  rm Erythropoietin 
hCB Megakaryocytic (Mk) Clonogenic Cultures  
Composition MegaCult-C media was as follows: 
1.1mg/mL Collagen 
1%  Bovine Serum Albumin 
10μg/mL Bovine Pancreatic Insulin 
200 /mL Human Transferrin (Iron Saturated) 
10-4M  2-Mercaptoethanol 
2mM  L-glutamine 
1% Methylcellulose in Iscove's Modified Dulbecco's Medium (IMDM) 
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Murine Clonogenic Colonies. a) BFU-E Colony; b) CFU-GM Colony; c) CFU-Mk Colony 
Murine BFU-E colonies with a globular appearance and a red hue- objective x 200; Murine 
CFU-GM colonies that are clear (no staining) star shaped colonies- objective x100; Murine 
CFU-Mk colony stained with Giemsa stain (objective x 20) 
 
 
 
hCB Clonogenic Colonies. a) BFU-E Colony and CFU-GM Colony; b) CFU -Mk Colony 
a)hCB derived CFU-GM and BFU-E colonies grown in methylcellulose clonogenic cultures b) Giemsa 
stained CFU-Mk colonies.( Objective x 20 for all colonies shown) 
a b 
c
a 
b 
BFU-E 
colony 
CFU-GM 
colonies 
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Procedure for thawing cryoperserved mononuclear hCB 
Original vial of cells 
The cells (supplied at a concentration ranging from 1 x1012 to 1 x 1014 cells per vial) were 
thawed in a water bath at 35oC by dipping and gently swirling intermittently and were aliquot 
into three equal sterile flow tubes once in the liquid state.  This was done with extreme 
swiftness (within 20 seconds), so that the cells were in cryopreservative agents for as little 
time as possible.  
 
Procedure for thawing hCB Cells (35oC standard temperature) 
 
IMDM was warmed containing 10% FBS (Sigma, UK), and 1mL of PBS (Phosphate Buffered 
Saline) was added to the powdered DNase I (2,000units/mL).  Then 1mL of stock DNase I 
was added to 100 mL of conditioned medium to give a 20 U/mL of DNase I.  DNase I was 
added to prevent the cells from clumping resulting from the release of DNA from any cells 
lysed following the freeze/ thaw process.  Finally, 1 mL of Penicillin / Streptomycin (added to 
prevent bacterial growth) was added to the conditioned media.  The vials of frozen cells were 
quickly thawed in a 35oC water-bath by swirling in the water.  The outside of the vial was 
wiped with 70% ethanol when thawed and the mononuclear cell suspension aseptically 
transferred to a 50ml conical tube.  The vial containing the hCB was rinsed with 1mL of 
medium with the rinse added drop-wise to the cells while gently swirling the tube.  4mL of 
medium was slowly added, drop-wise, to the cells while gently swirling after each addition of 
several drops of medium.  Before resting, the cells were gently mixed by pipetting up and 
down to ensure an even suspension.  The cells were then rested for 10 minutes at 35oC and 5% 
CO2.  2.5mL of cells in media were placed into two 15mL tubes.  Subsequently, the tube 
containing the cells was rinsed with 2mL of media and distributed evenly between the two 
tubes.  The total volume of each tube was then made up to 10mL using the media.  Before 
resting again, the cells were gently mixed to ensure an even suspension.  The cells were then 
rested for 10 minutes at 35oC and 5% CO2.  The tubes were then centrifuged at 400g at 35oC 
for 15 minutes.  After centrifugation, 8.5 mL of media was removed and discarded from both 
tubes.  The cells were then gently re-suspended in the remaining media and pooled together.  
The cells were rested again for one hour at 35oC and 5% CO2.  The cells were centrifuged for 
5 min at 400g after this resting period.  2mL of media was removed and discarded, and the 
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remaining cells re-suspended in the remaining 1mL of media by gently pipetting up and down. 
Flow Cytometry 
 
 
 
Four Sub-Populations of Fluorescence Intensity Two- Dimensional Dot Plots (FITDDP) 
Two dimensional dot plots (TDDP) were used to distinguish the different cell phenotypes as well as the 
relative size and relative complexity of the cells. The fluorescence intensity two dimensional dot plots 
(FITDDP), positively stained ‘events’ were expressed as percentages of the total population counted.  An 
‘event’ is the fluorescence signal produced by one cell. Four sub populations are described on FITDDP. 
These are green fluorescence and orange fluorescence negative (LL), green fluorescence negative/PE 
positive (UL), green fluorescence positive/ orange fluorescence negative (LR), and both green 
fluorescence / orange fluorescence positive (UR).  The bracketed letters indicate the representation of 
events as quadrants for each population on a TDDP.   
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